var title_f15_11_15536="Thin blood smear 3 with answer";
var content_f15_11_15536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Babesia microti",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This thin peripheral blood smear (Giemsa stain; x1000) shows Babesia microti. Several erythrocytes contain multiple parasites, including a diagnostic tetrad form (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15536=[""].join("\n");
var outline_f15_11_15536=null;
var title_f15_11_15537="HLA II expression in Graves";
var content_f15_11_15537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HLA class II expression in Graves' disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thyroid tissue from a patient with Graves' hyperthyroidism. The brown staining indicates the presence of HLA class II (DR) molecules which are not expressed in normal thyroid tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Terry F Davies, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15537=[""].join("\n");
var outline_f15_11_15537=null;
var title_f15_11_15538="Airway resistance child";
var content_f15_11_15538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comparison of airway resistance in a pediatric versus adult airway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 729px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of airway narrowing. Resistance to gas flow is inversely proportional to the fourth power of the radius of the airway lumen, meaning that small decreases in luminal diameter result in large increases in airway resistance. Because infants and children have smaller airways than adults at comparable levels, the same amount of airway narrowing (eg, 1 mm) results in a disproportionate increase in resistance for these patients. This problem is compounded by the fact that the immature respiratory musculature of a pediatric patient is less efficient and therefore more prone to fatigue than that of an adult.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King, C, Rappaport, LD. Emergent Endotracheal Intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King, C, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15538=[""].join("\n");
var outline_f15_11_15538=null;
var title_f15_11_15539="Rectal cancer node EUS";
var content_f15_11_15539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal cancer seen on endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 273px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAERAXYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKWkooAcuNwz0zUij7uSFzyM/zqNfvDnHPX0qwXVli/dgADJ2jk896AAMAjGTDZ745FQsh27s8H16mplDGQnYVVjjGO1OGxTI5VTxhcc7f8TQBBCBu6r7lulWGBMe05aXcAue30qL5nJ2LlemAOn+TVm0UJI/mKZXBwoz8pY/1oAFj3Z28ueyHt9aHhlhuAibWcDJKjp7Cp/s0jwmT7kj5AwcDA64HoPWpbCxlnizbuTHnruxtXvn+tAFK2Ba6O07pM/KB1H49KtyRwOd7sfMPAjhXJJ/3j/OmXBEERgQQuWbGY/vOPr2FMjs5ZHkBRtiABiG+Rfb3PtQBBfBzy6ooHC85P4nuaqNuydxIz61vzx2dpbIWZ1bGNikGQ/X+6KxLgbn3AHBPGaAIaOp96XBOQB054FOYrhcFiehJ9KAI6XtSgAg4HT1NGM9Bz6CgBPpSgZAx9OtHXnH1pBjv0oAXackcZHuKUIc9VH40DBzg7e+KMA425z6UAJtPcHFGD6HPWnFCoBOR3BxxTPU9KADHNKDxg5x6Z705ZWXGMce3WrEd2pOJ4IpVJ5z8rf99CgCqoPUA474pPWr5hsp2/0eZoH/uzcr/30P6io7yxntVDuu+I9JUO5D9CKAICyYU7ecYI/rSFcDKnIPT1pg60uQDkZFAFmzIWULhG3YwG4P4EdDVyRECEPM2x/mGB8w+vrisuNS52gDJ9alclW+XcpXr3FAE0lvLbuEIikAwww2QRSPLFiPckZGMNtGCKnsmWLzFPlyJwWVxgH8D0P0ou4IFQyQsPIkPyHGdh9D7UAVY2zOn73bxgNj+dBLzMUUFmBzu9venlc5hlABB4YDp+PpSOHyQgO9ejqcbv8aAGMFwuBhwcHHINJMFDZUgBlyVHTNBY5yV2nsAMZpFD7XZh93g88igD0K55/Z6gOeP+EpkwP+3OOitzx7qWh6r8E7G48MeHj4esV8RSRyWv2+S8Ekn2ZT5m6QArwQMD0ooA8aooooAKKKKACiiigAooooAKKKKAHJjeuc4zzirduEAYSdDznP3fT+tUxjIz0qaQlGO0BNwHA7UAPMfzkZOWOAOv51btLP8Aew4/eB2zlhhdvrUul2ImWJpGYyyHESY4Hqze1W7tUsgWD+dNKD82Og6Z9vagDOdPLu5SoUleAQeAfUU6zkUJJINqMoI8wjIjH+yO7H1qEoUfAwCoyBn5QPUmm/KzCCEMwHcfrigC1BG98x+8beLDSSyjp7df0pZLhynlO5FrywiHG5R646CmJcebCIfljt4V3YycBs/qTS29sby8jigZ53nP3F4/OgB8MbrAbqGDaz/KhAJI9do/rWnGZ44WWXdEAoCRjlgPp0HuanMF28otLNSHjO0uGBzjqB6D3qxa6df3RnW3jZo4jkvsJVm75b+I/pQBj2lrDdxMit5KBtpIG+SQ96oXSRyPMoKokR2gjksP6VvDTbqY+U8GFXOdzBcerOw6eyjmqEtipkNusWHBJ/uqR6k9h6CgDBCMFOR8vqTgH/GmlGD7SvI61rvAltd/6QjTcYGGyD/h9Kzpyo+ZE2oWPyk8n8PSgCAj0H+FP2hVO6TDY6AZ/Whg3yqrL856KeBU1tC8rSIHjRepDHH5CgCoBn6VIGZUKbvlY9O1AXG7JUY75qSCJSpLgZxwGJUfnQAqmOIFsgtjAKLkf+Pd6ktoYZfkVyZDwPkyPr/kVFMVWNQqBJAefmJPt7U2LKyAvHu56HIzQBoX9lLHErb0KY27VBU/981lqq5IYkY9qvGIsQ7ulsCOFGQfy71B5cfnquXlycYAxn6HNAEKIHOA2D6ngfnTmR4wu4Ha3IPr9K0nURyIqZWJlAMbjLH2NV72IplBHOAvOHPC57g+lAFHOVA9Papba5ltnLRMVJGDjoR7iosDBOfwptAGg01tOo+0IUbH+shQDn3Hf9KiuLN4kSQYeF+kqnK/Q+h9jVYAngZNWrK7e2n3/LkjDA9D7Ed6AKrgq5DDBFKo3cDGfritSSC1vyzaephnA3NbueD6lG/oayyhVirAqQcYPY0ASqGkG0YZl9ev4VJazBXfg7CD8meCO4qtkDAKgj8jUwkRgocZz95s9D2NAEsjRJBjYxLDKN7ehpixCNFlZtynkBeop64j3oQH2nerKMdOv1qNXwhC7VDHvyD/AIGgCRSrSv8Adk47jGR/Q/41Eu0PGQu9ehJ7+1KVYvvjBIUDKsOg9PpTW271LlvLIwB3A9KAPQLpSn7PlsvBH/CUykH/ALc4qKdeEN+z5AVYuD4pcAkY6WcdFAHmtFLSUAFFFFABRRRQAUUUUAFFFFAD4iVlQrjcDxmrSRB40fqudpx1YmqY6jHJrRsGWKKWRzhgCqZGeT1P1x/OgC4LhrOB2Qq8soK/J2XjIHt/OqV0CSzTOTISCffPb6Cnb9qBwNqsQqoRyw9ailjLyFVYSIuWODwOOfpQA+3C7wwAbyweo+XPYn1pFjiy6/aNsROC23G7/PpTG3oolwhVeFweM57etNldWOQckL1x1J6mgC1HOIoCYogTNJheMcDgVoJ5VtMmZM3O0qwT72W65PYCs5JPK8x4I+BtClzyOMcD1q3YW4jeKFxIEkHmTSIMkY/hX/69AHoehw2tjZQxPAu1gAULYaTPQHHRR6Vb8X6/FJpzaVZyxQqMK8wJ2p6oijkn3NcFcTpPdK8UiwdVVM/LFGo5Zj/Ee341oWFvaDbKBJ8w+V2AyPZV9/U0APnM0sKWFtm3toUyZyOuR/CPXuTVVrKxECGJjtj482bj/ebHc1sJaraS3BaV/tl1g+UkfmEDsCc4WqUlqr6innW0Ee37wcEgY6s3qfQCgDBuLe1ntwdOjkG1jgSN80mf4j/h71lG1hEfzyojAYJJzzXc3UxlaQBvKBBUbVxx6FsVzt7YxW1wIYW3TRDHEfyk+57mgDHt44vMj2DHzcSOT834AcVYV7hHKiAPLICvqVHtntT7yzIffcl7csdxBO7cfYCnyKgmiBgNvE2BkHlhnqSeefSgBlnbHyPNaYxqDtUKFO76N2/KoZE8tR8iSP8AxNs38+x6Gr2n28ZvpUWUAodwEhyWA7AD+VaFvZhIZ5p8OTyV8hw+0d9pPH0oAxfK2BHjRMuQWjcbWA9QOgHv1rVsLaK4mWN5laXONjHeqnrye9StpU9+8DXUyrFIu1ZmCvIR6FVPAq/ZJhmsmNuYVOwSxxEMq46qc8H86AMTW7N7G62qxLlMtvjOwD61kW0UkdwkpT+LI2MFP4E8V3uq2ytZt5d1M0YTZ5cW6QsR1zVTQtNkVkt9qCIqXQTx71Pt1HNAGPPJJLGXg86aMj549wB/+vWVdQSRJE4lkmgb7qNkEE8YIrqNbggjEsFwQj53BIxuU+uBjKn8a5K6SOIkqXKEfI4cN+BFAFKQqWOwEL2z1plKadGhdsKMnGcZxQA3tQBmnyFSFATawGDz1ohjaR9qqW7kDrigBqllIZcgg8EetaiTrfMVnaOOcjCy9n9m/wAaoSI8DlQTjqM9CPpSCJggOOSSpB4x3oAkEbxOyuoUhtpDc49j/jUkKOYnILBVwGxzj6j096jeYuFUbmCjAyecen0/lRDcSxbDGSCpyOOo7g+1ACPt3uCDgngqOMd+KsfZljYbZAyspyCvXFakQsJlCXkPlvnbG8bYHs359RVKPNuZ1kRisbbW2HcAf8DQBDaqZld3Y/KNmfbrULrmNQhJOShUc+4NTuscREqFhCw4UH7p9/Wo0dhFubBV/wB3Jxj6GgDublt37PkGWDEeKHzg/wDTnH/h+horb8c+JtY8W/BC01DxBeRXl3F4kkgWWOCOEbPsqN0jVQTknkjNFAGlomm6ZqXw68F6Hc6ZpNumr2Gp3NxqyWKG9je3llePEvUg7Fjx3DYB6V00fh8aN4n0mTVPAmmWFvF4itfDFubuxSSLUbGRnHmujDDTr5IPnrjd5p4wAK5rwp4qs7X4K20o1TTba/0G5iEa/wBhyPcvK1xLdQwG5E4/ds0GThBtwOpAJo2MlzHrU02iXmmSXbRweOpoXsnhCXUCyTfY4wZPnjVJmbIOSBxgg0Adda3MVz4EXXItM+Fen3X2y+E0WsadFAZ1iCBFtUAO7HORnO4jnmvnKzCT6jAJo5HjklUPHAo3MCeQo6Z9BX0xaNpngPwdo9r45u/DMs15LPdx22o+GH1FrSR9hmiD+eoXaxCkYBDKc5wDXzRarLNqcSWTFZnmAhKnZhi3y4545x34oA0PGltaWfivVbfTbG/0+yjuHWG0v023EK54WQZOGH1Ney2dnZWHha8sJvDuhFdN8PWPiGyubiwBurhz9nkdnkP+thMkssRQjG1doI28+OeN7LVdO8X6vZ+Ibg3Orw3LpdTGQyeZIDy248nNex2V5c6/8K4vDmn+INEm1210yEXU/wBkdJodPe4jPkyX5l2+XH5yb49mF2sv8JJAOe+I1tc+IdG8GwaR4f0afVtUimvs+G9LWOPGxf8ARgYyTJJGFZ5FYZQuAOOT03wv0fRx4P0ay1bRdPuoPEOm37xzvYpJdvdI1yreVM3Maxx28R+UNh5hx82RrwXmo634t8Haj8OJdFlsY7u9it7Ww09tHtmvY7XeTLEXk37oyqkjaSuU3JncPPvCXjHxBoXwevJYoNMe0tr57HTby5hd7u1e4hYz/ZZRIPKChVY4XlpRnrQBqfF/RIpNMsrfT9O8PS3h1FLSxj8Owr9ohV1YeRqAUf8AHyxWPYvPKT+lWPgrpltZabZPrmhabPbXGtS2F+dS09J59yi2WK2g342ys08hYZB2RuwGUwa9xqmveIbb4e6pJpulabNqevBbePTITaS6jLE8ai5nmJfc4eSRQxUkFpDznFafws186ffarpWvajocWpX2vt9lsrnSW1FoL0EKZYiJk8nLOqq5znYcH5TQB5lr8Ojf8IL4Zk0O3mExnmS+ublFEktzsiLIu0nEKArtJOWLOSF4zzcVrPJexQRkNIRn2XPWvUPEsWnXnwostI0278NzanoqW+pXpsdNKThJdkZzdiRllYPPCrqFXlevyc8BpySWHmXTncUTeY24Jb+EH2xzQAzUrRLZczOzSkbUUDkju+O3PAqGEJFbeWE5kwZXXnaPQe+KWSc3Mkt1PIxZzk54yg9PbPSqdyyvEpjYBPTuPwoALmYTzkRoBCihF9lFSwQOZVLHyznIiHB+gFRW8hV41RFHl/N83c+p/wAK0RbTvFNJHtkmLDdKDjHHTNAEcKrApZgwKZZ1X5iCeBz24qwPPeaOG33xmUHH+woHU/WrttZSzaJFIqosSuW24P7w55f1OOw6VXNvPdy/LvSJVBLHAz3Jb047UAJ9jFrIFGPLT7zE5BPoPxrYiupLaOMSFTfTPlYQPuoO5JqtZTxRuwM0UzpmYgDODjCqo7nnJo8uW6lkuLhzG0fys7LmQnrgDt9aAOk09nt3eeWTcxP3c/KW7kgcnFUZoEl1ESEysJSf30xKNJ7Key1Vs4LqOJ3iEqooBQlcBm579WNaFldSJa/apjGQg2fOTjJPLD1Pt0oAfbSxQtItsDwuyFyN/PcKDx9WNYOoxK++ZoQJMYI3dBj7xPQHP9a6iUrPcW42MxkLbEK7UUDu2Dn8O9WbjQrKC0WbWLmWZnPmCJowFk/4B1A96AOAtZUtmWcRqjSR8iU9B67vSrlxpoe3Eh3u2AQsIBIX2HWukuNKjnDstg1sm8GJYIdj5zySW69sYFa+p6EksFusLyPK/Lh23SP7A8CgDz2IpLNAFspImD5VnbY2fUkdR7VqS3cloIbdsQxshGwxbRz0I3HP/wBatO7spxFGmJUCnYIwRz7DHQ/XmpYrS6EDs8FrYIQC/nRgscDHqT7dKAKOlW9rPNFCqJCDlyhh2sTxg46MK2001wou7yGRHDGNYwULMPUJjFUdLtl+3MII545UxLJufKKRzkZAIHt0FdZ+/leQQyRzWUowwZS3mNjBwykjigDlNXWOKD7LI0ttvAP2jbsf2yBxVDSrM+cPIuGlePhZSu/aOpJHX8q6vWtBjuJo2iR5DEhR9kg2R+gcHnI9O1M1DTJFgS6W2+zuIwirkESgH72VyeP1FAHKXul3LXP2qVpJUUBJpQ2FUE8cdjXMa3ZfYbmeMGPYrEFPO3D2IHY13GsTOYHuI3Q3a43EksZP9kqQDj0ribsG+vLiVnMMh5kdhkOe/B9/rQBkRWhluFhjZSWOODmrF9apYBomaOSUfLIjdVPqK0Y7W2sILa5hvf8ASScPGv3lz6AjOKm1C3Mqfb5na4jlQJ9oCj5PqOze9AHMhAysV6g9DTc46dfWtdtPSZysb+TJkBCw+Rz6bux+vWqZtp7efbcW/wA2SrKwxk/40APsYzdPsuCzRDk4b5h9PetKzt4trW8iBWbaW3tsBGeoPOD7GoNPiVJDJbufNGdm8Y8zj7jZ4pywBkMplkSFjj5hkx45x7YPrQBSubae3uQPKkiVzmMuuMjOM1YttPk2OY0cSJ2JBVh7VqC7/tS1VblPlTJinAO5GH3uPQ8ZFPt/tFpI01wF8h1G1gOnqR/OgCmlrCVPmB/s/wB7GfnhbHp3FU3EsUnEqMZFLKVbKt6j/wCtVvUriC9jWeItBcW/ysy5IkGeo9Kq2NuZI2lDcJIDuA49jj+dAFSdGjn8sM0iDBBA6jqKkbzUt85+U/eBORjPB/Ct28tY/sQeBkS4TA2se3sfSsNo5ZpHUjlv4V6Z7jHrQB292qr+z3b7Rx/wlUvXr/x5x8frRS3Ydf2erZZFII8Uyg54P/HnFxiigDlbLULWPwBrOmvLi9uNTsbiKPafmjjiu1c5xgYMsfBOTu46HHWDX9J0nVLTUdL1pZ7tPD9sY3Fo6fZb+LytsWGBDlWhVt+Npzjtz5nRQB9K6H4/0SX4aaPokHxL/wCEWnFtJFqcA0KS9NyzqATv2/IQNw+U+9fOELRRXaNKnnwI4LJkp5ig8jPUZFQ0tAGh4iu7G+1y+utJsP7O0+WVngtPNMnkoTwu48mvXYr3wb/wr7RdCX4gvb6RLLZXGq6JHo0nmvMzx/aZDdFSCUUvtCrt2xIMM2WbxGigD2z4ieLNAvfFmhaxrPiVPiHYwLPDLpiabJpKwRlTsUP1YbmznlvkGSc1x3hmHw5L8NvEMep+KI9O1iWdJbfTm06aUziGNigEqnam9pGXkcbcng5HCUUAeq+KPGXg/V7DSJ4dG1ES22qQvPp1xfB42sooIohErrGuMrGFByWGCSTuGNz4U+KPD+k+Hdd+xeM08DahqOouXT+yZdSc2YT91Gr/AHVAMkuTjedqnIA58OooA9o8a6z4av8A4V6NpOieMlW30+K1uI/DP9ky7muyMTu923BbMsx4wmAAB0NeVy3EjK63C5ErDO04A981nQnbKjEZwwOPWtKRwPLAlRnJLscZ28cD6CgCvcSosGxMsHPU8YA7CoTHudViBIY8DufehuPL3j93jjHU/wD6zVviEJj+FdzqTzz0FAD4Id9izsqsznARTliB1NaduZINNiSFT9odmd06lUPT+VZlmrM4dOAoLkDjJHQewre0+JrdUDRot1IoySflUGgCaL7bPpMiTWoMciFYhu2jr1PpVcSSmzbTIoS8OAJ7pTnAzk4/lV+aeLyEsoJftgDmSWQnhmz8vPoPSp9NdrZRYMR57cysy/Kmect6cdBQBR0mO3stWaXynZBwZWXq3ZVFdDZ20R1RTqWY4W3SSY4Jbsg/TNMkihsrU33mM9vGNlvGV3GRsj58dSetPglkvpm/tC6+zRwAEMPvNuPO3jr29qALepxxwRrc4WFm3ApKp+VfYDvWPK1wdO8q4hkhjmYNtCbs54VRgde9a5ukvS8fkl7cyEI8jfKFH95j37mtnRdMlnlLTXEUMhGBIi71gT2X+8egoAXw9ZrYq15M0tvaYCrJLEC0rgfdB9c+lJf3D3EzT3UrSX28+VDAPmVcdD6nPp6VbhWZmmLs1tbWwKxzls7Uzj5QeN2Tz1OauWtjY6VYG7ntPtmrMzLFBECBEp67s/xH0oAzoLG/mdJ7gz5QnzDI3Eecc/X6VoyaTG4AlS4t2djGpdyxUepAHUjtVq+1MXsdvBaxvHewKsW2OEFCfQL7epNdDpnh6cxtJqt5HZED5YlZnZmPqRnH0OKAOIi8GO3+i2F1O0cSl2eZ8bTnOWA6dKhuvD39kTGbU4TuTDxyI7bWY9MnHTr1r0uaOyMQhsJVdmYeZtGxIto7+uT+lUZowbi4eKWOd/ljmURthGz2Uk5OOmPagDymzsYbyWWF188Kw/1Z2h88lRzz2roV0i1SKB2NzZKrBxCi4XcDxn61Y8RQ6dYYuhALa9jYw8qz+YMk5IA+U9f0FZen+KrrzGhv9PkKIOPLkOGOcYU9AM9M0AdALV5YmkmnDSBx8skoU4PUFsDP061m3r3SLCtlH5kKnHlkfNG3tjqKqah4n8+7WGdY5FiUYUkA/XPXr3qpFqdoUF3bz+RcIS+JFZCG7465GKAKury290udUE8cyyAjaVVQc42k9cVl67aWxjlzbT+TDGGcBkZkz7jkg+orRk1UvBJdQLYSsUG1hICzEHhgD1985rd8OaK3iOcw/aliEwCKkUeC5IBYRk428jOOaAPJrmzhkmWUhxDt2Jlt2Ezx8x6f/XqZ1uJNLjt7SNivIIZgSwHt3r2efwBaWkcslvK7XafIQ6hsjOOVA6ZwM1Gvhq2gdo5rGaO+j+VoBIMFTzuXuDzxnjFAHinl/wCqRoJIzgB3jGS/+8D3HqKuwrZXkzwX8E7W5G5poDkxntIB6eor0a+8LR3K+bZLHMtvMUlTzdr7OnA4wQeq1y8ltbx309pZIySKxbuAyHsM9DQBlyaDKipDNEVtGfMV7HgidcdR7jqe9Wb7Qv7Jgs7rUEbyZ2xKytuSYdDj26H2qtYan5O5NTX/AIlkrbZInIDJIv8AEh6A47d60bS31CS3n0e7uPOsZsz6fcjkZHcehxgFaAOf1OwhsHeGwInhnk8yDa/Ix90j+RFUXnkjwkiqJG3KFf7pBxwPQ5rTvdNcJp5s2YXIBEcZIw7g/Oo988gU3VLZbkRSNbkksRLgEEemR2NAFy0srZtOjldYopirb1LfKR64/Q1iyWDW1hJcQYMLH5o93y/gev0rV0qG6uI992hxbyeXJvGPkbv9Kh8SudJf7DahZLSdNyKR9xhng+4/rQBTkgEcLCKT7RAYsnJ5KEdfqKz72RZLbzbZkyhAfB5PH3hVaK4eJE8mUAKpbaece30otHRGnjVVaKZMHPGDjj8jQB6V4t07VtK+BdpBr+mXum3kniaSVYru3aF3T7JGu4KwBIyvX1zRVbW7m7vPgJBNqF3cXdyviiRC88zSMB9kjIGSfc0UAa2h+E7D/hAPDupXvgiGfS9TdLSbxGdTkEkUslw8ZK26yAZQDA+UglQTnJFdlqXwvs4tfktR8NLeO8825XTdNGuSldThUczNIZD5Zj/dfLld/nEY+XjzbSNEvPs3hvxTb3Ohtc6TbJejRzfFb25ht5HkeTbswvyIzY3E7VyAeBXbXFlqFncatJ4m8F6f4htQL7UXt7fWBDJpluHWW4s5HVQSUeeCTA6F22/fkAAKMXhTwzDqmi6fqvg/7PqHiLWJtIkto9Rmb+x/KMUZaJgzCViZTIS5ZeAMYrxAwQpqht5pStus3ltJtyQu7BbH05xX034Kv59PtbK+svDGl6bZTEyeFrGbxJJFNIJo4xcwwsEJmZ2VRmUrsdlCngEeKeIvBN74alS7bXtBl1eO6RG0y3vDNd28xOdrjZtLIw2thiM+tAHOeL7PTdP8U6rZ6Fcy3WlwXLx208ow7oDgE8Dn8B9BXcxy+Bb/AMA6xKvh0WF1Y2FrBDqBup2uLrUHCb8RbzEI/knJPULtwMnA4rxudabxfq//AAlWf7d+0uL3IQfvc/N9z5f++ePSnaLJdapp8PhfT7Tzr3UdSgaA+YF3SYaNU5wBkyDkkYx+QB0PwntfDNzNqn/CTx6RLIsaG2TVr64tIcZO8hoFLM4+TC9CCxzkCvSR8MfCza5piarbf2VLFFftf6bFcyOs5WW9Fv5DN85CratvY7QQIsDLtWdo3go3fjzVZ7PwnofjfRdUa6urey0bVxbQ2bpKhKCbYjfu0nQbAArCRTyUwq2et+LPEOup8RoPCkt1YaBDqNteFbuNAN7TyNn5QQY1vF/hO7YT/ewAM1/4b/8ACv4tZ1PxN4JGoW1zrUdjo1tJqLYeJxOwx5L7yw2RD5sZye9ec/FU6CnjG4tfC2mQafY2aLbSLBcy3Ecs6/611eQliu7KqeMqqnAJIroPCXxM0zRtf1zUdU8Krqcd/qi6rBCL9rc2kqmXYQ6pklfObB4wecZwRyPjbVdC1fVYrjwx4d/4R6zWEI9r9uku98m5iZN7gEZBUY6fLnvQBgJ99cHBz19KmBQI/lAnjlj2HpUUYLSKByScCpt4WCRB8hO3jHLevNADWCkgRZbOAM+tWIz5yyAr8+BliOnb+VQQAyzRIuVzwSPTuas4LTkWzMqk+WmfbvQBpRm3iMVtE27aDvI6sx6da0boKiSu6tM0AVriVu/oo+gqvpkcUqwrENw3+bPMRztHQf4VsXDW8yvDKvk2odXcAZ+XqfqTxQBnxO8tk01upWQsHXjG1B0wK1omS4uow8q+U6xyXJAxuOOP8KrXd6HheRYTGLlhEkZX7sfRc/XBNW9Et2aFrhgExKoSXrkDoVH6CgDSEX9qatNtVgA4jRCdgWMcfgTV+40y3N95LL5kZTzHRW+b0Cjvk1geTcRSOEdpW3AvubksT90+/T6Vu2FxOklxcEAMibYn8sbSemGPUn2oAn02KTzmtlit1jjhZoINu7yxnqa1Ibi4tQ01jHM8s0nmzOjDfI+Og4+VRSafcSJpjpYOY57oK1zOcZWIdUT0yea0bCCOcW9tcSBEkJcyoSfLhHYerGgCjHY3s5a91CZTYW7CPayg7M9BGBxvJ+ta+nWjSXUzs8qq5Dss2CMnjj39cVrXDtc6hFiBoraM4t4Fxnbt4cD1I65rUg0yK30157y4d90QRSDzEnP4jJP1yKAG6Xb2tk6yWSQwSqpeUr8xY9TnPTFJYSRfY5TqEcoaXd5fIDbv7uQcsT16Yqxp9ve3q2kkIeJGiBZjOERM/wATZ45HOB+VY3jLxnYaHGWs7i4vL7YQZXHlux7EZ+6vI5+nSgDTabTtPtlk1dzbQzfeDuEaQdTlev8A+uuV1Xx9LOsY8J6dAHjVlS4BOHJOeG6E4A59uKydI0nVPE11Ff8AiDzJY1kCJbGTKKuckt3bp0/OtyS/0HSY1HkT6hPCrCOOzhYJGeoBPAXmgDndOj8SaleTST3kUMc0hZ4okDs5PTJ/vE4HH41fm8O+K3RoZ7ycbpNrobNQ4BIAY47jjj61keIPHXilpjLpFkbBgihCI0L578+pHBrldS8X+OWia9nlvETdkzCMmNDn++Oh/WgDuL7wJrrO3my/a8HMRNmpkUEdDjnGecVz8/hvVY7nyr6d0UsFwsO1CV6ZJ/lmuSfx/wCLlaWZNYucPjcyyhuR6n/GtvSPjFrUUQg1ox30IADJPECZB/QjrkUAdL/wibNaJNJfiSDlTG1vtRiOQocfdye3tTtP8PwBYpV1e8ju0ZmCDAjDHGCpPrjHFa+i+MfCXigCzglOi3tzH8yc+S0g6EKMgHA7/WquuaT4g0QxpMovtNfa0EsZ3R4Iw3T5jzz7dqANDS9b1nSJTcPcQXqOzrPbXChGZeQQh6HpnbXbJcaRqunJLfQGIzQ/vAXxLEu7Ji8zAz7Z6V5xBOL22tUjjicOfmSfO444PfJx1/Cuh0q1vrvXltvNtyb5A8JUfLKVHKtnjcQPagC3qeiJa39xJprGa1Zv3N2TlTnHD/7WOMn0ritfjtoXEmrpHcTRPhdgMbKp6OMdcetdXNf3HhqK9nmL2zurQSRnLKxzkIV6ZGODXkOvzXt3fW8sF00qSBmRQ2B15Ge30oAw/GF9BJfPCkSyQb/M8wEZkyD8wIpui62PLGnXlxItsWEkEgADW8nc569O3IrOv7OQqsahmhRyu3oqO3v68fSqd3ExX93CwwuST97g4JPtQB0F1qs1vM1hqNqkbtMJ/MX5dkvd1+oxW1Z3n26G9liMLyhs8jbvX+IEdiDg5rJ1cxa34XtdUt4k+02W23vDjlRt+RsdwcEZ9qxNMuJkvEnhfABAkBHXPBwPpQB19lfvcWdzA6L5sqCGRc8ke4H6Gud1e5DCOArseKLALHIYgnBHtirT2FxpmoM8kkge3KMpU7gyE8fUUmvW9vKxmhULA+ZUYcruzhhjsDQBzUio5DRkKEX51Y88H9aaU/eERHeF5GD0Gc/1rX1u0jEkahVj/h3dDyPlz7dqx0jeOTaRh8EAe9AHoF2Q37Pluyg4PimXknJ/4846KbcqV/Z7t1PBHiqXj0/0SP8Az/ngoA3fA/ibT7V9DsB/YNpex6cCuszqxmizMxmhcmQJgwGZQNoY7lUHcQa6G98X+FrSw8a3nhqGCx1KPW2nH2vUEu01BTHdoTGhUfu2WR1ONxxKMPnBrO8EPe6p4Xi8KLqMMehHS/7Su9K+wNJLdKHkaaSOZELJIgjRk3sFZ/LXBBKnrL3S7iz8a+GdQlutBddK8VWfh/TodMuI7gwWEhlBgnGCcqE+Ut8+ZJScnbtAI4rrwL4ltvCdtNqXh2Hw9pMMqXdrq08nm26XKxSrHAFkRpXQqYjJn5SSxXjFcj8X7exM02qWM3gNbJdTWSKbRNRaXUpIcsFLoXZc7dpbCj5gD0zXU+EdNtfEg8Fm5ht59fu/Fl3qQuGjRfOihmRrmM4AByrK6jH8DDjgH56ZUn8RlfK81JLvHlghNwL/AHc8AZ6dqAND4h6ha6t4513ULC8uL60ubySWO5uFCySqWzuICqBn0CjHpWRpOoXWkarZalp8vk3tnMlxBJtDbJEYMpwQQcEDggitv4l2UGn/ABB8Q2dpYHTreG9lSO0Lq3kqGOFyCR+RNZfhufT7XxFpdxrdu9zpUV1E93BH96WEOC6jkclcjqOvUUAe5eJY9M1nwlD4CtNR8DaXfC9Ouz3VhqBj00AI0AiEsjuWmIKvtG0be2QSWeAda0Gwt/BSvrVggtYp45HmlWNkXdq20uuTtJEsRwT/AMtF65Gcf403ra34E8P6xqGvWniPUJNQuoIdTisjZM1uqRHy/LKIXAkLneAQCxGc5FeLUAFFLSUAOQ7XVh1BzTlDSFj1xljmmDrTlYqDtPXg/SgBASCNp59qnikJdSMhVyze3rUcWDIgIyCwyPWpfOPnE7hs3cjHGM0AbdpepCl1GImAYBFCjk57VrKs7/2hDL5aNHFGFfqAzsOvqdtYVtGZ9QjSMpmbdsGc/MRjn2AqN7+ZvKhlkYrvIkI/j28L+VAHR3UiyA+SH2vn5On7pVIH48ZzWvpjhpEtbSQRzD5FJ6bcc4+lc2148VxOkcQeAKI1cDrnG4fTrWzY3cSKJYisbPK6RvjBJPOR7YGKANRINkrxO8jsu6TahwWfPXPvWxbTA6QYSI8PIFlOd2Tj7gPb3NYFpPHbSI7GWSSOIM0Z4JY88/nXeafFAul21xNbBpfux26AfI7ck+lAEkYtbyyhiECsseBIIgBz/dDHrgCr32WPS590hZp43DbtgcYPKgEDFU9OsJHuJWa6i2HcyR7yvzdxkdeeK0JryeK40tb7zTBvaHGdpjYf3SPT096ANvSbICZ7uUl7l+Y3CAmM88r6g5/CrIhlvtYUPKUhtgpndgTl8fcGPve3v6VDayyQLbi2kSZlGwO7AmJTzjvk546VV8W6ymg6WLOymWXULpsTqTnY2Mk5PUqOmKAMf4h+LorUw6ZYIwcsZHC7cM5+6Sc449O9Y3hbwx9tE+q68Zblg+GcnO0jk7R0Aqp4T8N3Gt3azTiNklJZJXyTGo5JI/rV74p+IbhHg0XQf3MQj3O38HlnjnHJbPQUAZ/jr4i3drM2neFUiiVFCsXiHyfQ54P0rzH7V4i8QSmI6lNMc4Zd4Ujv0HPrXp2leBdO0Z4T4stbu4ubiMNBpVtJuuZ/QzvnESnjgc4zXcaRpF7Zrt0+y0Tw5EefJsYBNL06tI4JJ/GgD5+uPDOqIFjm81Xl5XfJk59eBzRa6b4h0lxAtxMkAcSGOOfADdmKtwfyr6RS+1O0Q/8AFUaoUiOCFhiIB+pGaiv7HU9URZrwWGrxleYr+FYpCOvBAxn3BoA+br7UXupJDq8EcroMG4gRY5AM8EqMA/iKil0OC+0uW602dJ2jOWP3SB6Mp6fUcV69qvhDS9dupIdKtm0vW4o/msLtiyygd4Ze/f5WryTWA+k6nIbaFraZFKMVBRsjhlZelAHORtc6ZfI4LwzxkMCpwR9DXs/wx+KtxoyQaD4vd7zQ7jLMoQNhW53Kw+YHPpx1rgdas7XVdDj1HTo2RUCoyu2SjZ5ye4PX2rlpbifyBaTZKxMdmRyh7gH0PpQB9JeLvC6aKkWsaKRfeHr8s0Dq+7AYY4B6EepxmoLO9uI7S1vEUOIVQoI8YLDgMCpyCMYrK/Z/8bpqVt/wg3iGR5bO5GLP5QTFL/CQfT156V0r6Sug6lf6bfQytAkkkRETHA+gzjGcEYoA6vxIul6tDby3tp5kd5Ar+cGywlxjdj2OfrXlviHw+unRfaZ4iN0vziL5lYgffUjpnrivRba8F14DsYZoTmyleFnVCkjEA4JH0pkaWV7o4he0KEZE7glgI+MH8z196APCW8KSnTIr7z/MS6O+QowIwDwfryPcVFqmgyrYyXpjWRY8KSrHOP4ie+egr0abTH0uzu5LO3RLWPcssAbaCQ2dy++OT61zWtSC3uHKsyWNwpm8rPAwRuII6gigDjfDs9vpniCfTp8/2de/6PdRkHBU/dYfRqztUthZ6tJazoVuISV3p0cgnBx9K29V0pDBcrE/+lRZJBXDrjG056kcjmjxlCk8Frq4lEovbUCTbwRMmFY/jQBSvDLfiyvImJRgYJApIwR060+3uvtdrK7xEqpKSRg8qWG04HpnBqbw3Os2iCN48SQXKvu243gjB/lVLS53g1Qs0TGBm/eRuMNtzyw+maAM64UedaRXDtMiMoL42koemR2IqpKJDJMsoLTJhlYDBzn0q7q0Ziv7lJNxWPKHaeCc8VWujKxlliZjtVN3qMr3/KgD0/x5oR8PfBO2tW1PRtTMviR5hNpN4LqJc2qAqWAGGyM4/wDrUVi3uf8Ahnu33ZJ/4SqQ5/7c46KANzwTqc+meFNP0uz8RyWPi3WEMOmrHYwmOO3eTaIp7gxGUeYwfaqEop2FivJXfGk7dQ1y48D63qb6ppmpzXF4uq2Ns32rVIYriSN4FVHUAKl23zbcHy8fNgjz/QvE/hm103QNTvrK8l8R6Erxx268QXnzFoJGk3DyjEWJ2hGD7Bk/McaureOtAtbTxENCu9XlutZ1E6usr2625sp18wxqpWRixDTFt/ylTGpCknKgHR6FqOiWdlZ6lrHiHxdBrGjW/wDwkKnSrW0jhhN3JArrGCRnLSpuQgJt3DGOG8MgElzqsYgl2TSzDZKx2bWLcMcdOeeOldjrnjGz1W48Q3TwypcarotrZEKoCC4SW1eRgAcKh8mQgAADcAABXFWUqQXkE0sQmjjkV2jOMOAckcg9enQ0Aavjaw1HSvF2r2GuXgvtUtrl4rm5ErS+bIDhm3t8x57nmsm0iSe6hilnito5HVGmlDFIwTgswUFsDqcAn0B6Vf8AFOpW2s+I9R1Gx06HTLW6naWKyhxsgUnhFwAMD2A+lR+HJNOh8Q6XLrsMk+kJdRNeRRkhpIQ48xRgg5K5HUfUUAehfF9LfU9C0TXdIutUGjrLNp8NlqVrb2bQuAszNFDbqIwjCVSWAyWzntXlldh8RdYg16+ivz4p1vxDeOziQ6lZi3EK53ARgTSALkt8oCgdhXH0AFFFFABTiRkY/M0gwCMjI9KUc9uetACCpIuoHVSefegISr8EY+YCnhGBYNlcKSfqRwKALCzPbXAkib97GMDHZcfzwabK4aTdKSh28KoqOPckMzFMZwvSkKF2yx2oBtz1wBQBu2jj/hHTscG58xVQH0B3H8DkflV1Lq0llfyCfOlbbubhU/2B+I7VzNrJPGwaI7Q3ALHjIGKliEqBir84+bbxt4yMHse1AHZ314RNbyx5jcxjeyLuO4sPlHqPf611Gn30jWkcDqjDeZ40LHeAOMk9Mk56GuE0e+SN7dZd8iALH5KgHgDJx68itG1vZ9UaSG1JJR9yoxwFXdnC4GST2oA9M0K8H2mS+hnRFEPypuwD3IGffvU+nagr65ZpeFP9EsXuZYnAYbmPUL369+a5a3lkXS5TLcNcea4jUNhmU90wOmPan2VzbQXusXDTSA/JHCORsVcZ2EAgn68fWgD0DwxeRi71DV9WjkZTH+7cuCc9dobtzg9OK4i6lfWLxYLoiZRGzM247gCeevQc9Tg07U/FcUmhfZrUXC3KPtaXy8DDHDHnjJ7mqel3kT3t3LD8sckJt8LJ0xjJ/Pvk5oA9L0Ew6J4YvZdqK2fIjYEq20AM4XPucehrl/BNrAlrN4jvLVby/upmi0i3dcqZAeZmU8YUkYHqDWvqtyLnwXp8VvK0coEnmouDgsQB17V0aafbxzxTLEkUWj20dvAHG0lmyWcA8HPqKAH6JoEstx9ntLnzdQlYte3ztukY9/mPQepHAq5PqeiaFp8zxJDqSxHM99duYraJvbJG/v8AWl165Ph/wnGHbyn1CGS6u5FPzR2yDJX8Rk4ry+GXSH8P/wDCefEWJn0UyiDRNCiIcycZ5U/KCQQzO2cDAGSVFAG6/wAYdDW6MbXHhYhjsIGmykc/7fl4x712Nnqug6xpQZoo7KOZikV/p0vn2oP91wD8vfPSvDpPjqq3+218BeFo9H3j/Rnikaby+Ny+aGAyefm2cehro4o9K8RaBfeNfhjFNpM+k+W2raIzYSQEbiML8rofnVWIBO3kDigDu/EulTW4htdYSMTt89hfQSbj7FW64z2NeeeL9OOteG71NTt4f+Ep0oAXbINv2u2J+WT/AHhnk16h4Q1G08TeE59NQtJa3tsb/TDJy0LLy8QPttPHtWK8cUeqaDq0yKSxbT589XjYHGfUUAfPnhl1s72XT7wEW0xaN1boyN0P1BwfasDxDZNZ3sisfnjcxN65HQ/lXV/ESxfStdvFRV3WtwU46Yz/AIGsPxUyzhLkEnz4kfJ7sAAT+VAGHp109jqFvdRkho3DjadtfWGuyXPiTwH4d8SsS091AouGyOZowRn8VHXPavkp1Bto3A5BKn3719QfA69N98F7+JWczabdRy7TJ/DuK8HsOelAG54Fe3v7HXYJZZ2coksdq+GWM5xn15B7moNPmjg1x0jnSSMxyW0yAfIT6jt2p3gdJP7S1pXnaFtu8qzcEE8EHue1W9Vs4tMnmu/K3WhRJGIxnceDnHegDO1lEuryTTYIZGkEbFFHzIV2ggsOoJHB61x+u6YLm1gnW38w2ivCijHCsBke/PNdhcI0d5LdqZYX83dEd3DqBwPXkZ61j71S3vnmHmWcgEhj6lR0UD1xQB5rrMMq3tteRTAllHykcgqcEH0H88Vn63aG68MwEJst2vPMiYfxK4O4D6EV2OoaZ5vmG02s0ClCMcZXkjP8utVdDtLmbwxq1tJDE0W1XtcnO05wV9utAHL6Dp0ktjciBWWKb95FITyWAzjHanC3FvrWJPvSQ5kVclR349q6TRI5plt3iVBb2cbPIg4ORwRWLLLHPJaTsGDGQxZPG5R/TmgDm720nOpahNGqSxMwjfP0qrPayy6ak6YVQCJ+RuYKePrxzWhrFjIl80COVmMJYc8Kpzx9az3il+zAISAIQ5TP3lztP50Adbq0bQfACCJ33keKpTu9R9jix+hFFO1mHyPgHBGM4XxVLxnP/LlDRQB5dRRRQAUUUUAFLSUUALSUUUAFLRRQAClJyxIGM9hRGFLqHOFzyfalCnIB70AbmkWBu9OubhWVVQqhyORhev0qfS44/sN0jKuTGYyOM7getV9FnZIL2NCFE0GAvY4HJ/SkspJJpmLKEMyKAR/nuaALNhpiNYSzXC7mSORlJHXHGD75pi6S0F0I5nUoUGcg4G7nP6VvzXb27CC7Q/vISxCcbgRjA+nWqotLqPU7OOXMsLBAZs/eUg4GPx60Ac9HbSXdy8RyA7DaqD73oR9ME1q2ukm2+yyyvkSMS0oPDBT90j3x1NSwW7WrqoYJLDc5jVeSQGwfw5Nbmq6ZLbtYGI5iRGR0xnqSSf1oA5nH2e7mlWMAjzFUqAQnfGT0I6/Q1qeF0aS7SRSQDDudidu3PGV/HiqrWMluW8mRJgUCsW4G0nPPrxiuj0OZbmGd9gUn5Yo9wKkDrzj1oA2riZk01ZrNnKW7B2XAO4YK7g3Xr3qjMselaZbL5G1gmZ3HJlLA5AJ5A+gxW41nI1hG1u/lxzIscYIz5Z/ix6c03xJYsbq0tDLvWFI4l2jaFXHU+uTwaAOdMJt7GVWKtcuiyxkoSMZxlgCBjHIA56E10uk2Ru9P3hA0zymYABQ2wfwgNgBvXLVWfT3mSQK6O4GwFV2qrE5Kd9vTIPGasabJ9i01pEcvGLgeW7xO4VSOcevrk0Ad1o9uG8MSGNI5NywRiY5+Vi5J247+2a63xFJBc6FcvaTBjDchWDE7vuAEf/Wrj/DIj1S3vdPhhKrJhI8k4SRASOnr7Vo2t3/xN57S42AajbrdRBQOSMq6k9yCKAE+NYL6BqrDcFbQ/wB3g5wARnA7d815f+0iWPh/4eNDkWBsbjygv3N3mLux742fhivZdet31XwcGkjaVtJR7W6CEHfbSKQGX2HPWvLYotLTwxH8P/H8rCxlf7RoWvQDIibG0cEgHsrRkjjGCCFNAHz1Xr37MYlPjfWdn/HsNCvDc56eXhev/AtlaEnwEzcFrfxro0mn5z57W86vt9dgUj8N341uac+maB4fvPh54EuZdT1DVZC2q64YhEkUfKgEKSQqrkhSxJZmPGQKAOg/ZykEjaMqhjFFf3vQHb5RU/pnNT60SnhmEStkLqoxjngycYrp/CWm2Oh+D7nUNK+WCG2bS9OL8GViPnmPPfJP51zkES3Wu+HdGumUrAZNVvCMlQiKSOPc4oA8r+K+Jte8UYHzHyZBk9M4H9K4vXoseH7NAAxSCMknqB3rqPiDqEeq+INRlhwBdyoi+mF5J+nQVyviyUeZMkbjZBGlt/wLgnHtQBz/AF0n6T/+y19Dfs6xhfhr4ucr5weJTsOPlIkA4+vWvnichLC3jxgsWc5/IfyNfTPwctF0n4FXN9NgHULoKVztyqMSDn6igDf8ATg6r4oklRUmNmqM7qA7ZIAwBwOPSkuWhuL+Vmka3tY0MELlsqQADuOeM1F4YRX/ALZundZLeW3QPHGM/LuHIJOCaS/2/wBnxx2+Cj3atEk8fcdBnv8ATpQBkarNcKt5C4XzFaGLcT2bkdeSw7msvw9Y3F5qWmWMjqS8wVXDlg43kKu72I6mrms25tNRnktb6O5eacSFUz99gWcD0xiszw9cTw3yTPi3tyVdZgdoA3Fhgeox+tAHQ6bY30t3c3NutkUm+0OgH8HzYAbj73BHHasGGURW13HAiiJrYSMrdA275v5da177WWspZL2WJ1gK7oyn4lePqck96ytFuY4NNuYp03TeW8IL9Dnkn8+1AHM6XfwaZpOpoYpWlnRo2aMdC3APPYZrMu7R7PT7eOTabaLe2W5Zxxx7HPOfen2t6lxLkGRbhE2qrjgj3HrSTbns4XL79qvtYd88Z+nFAHPeIGC/agZHkuEdRuB7kgv+HIFPtomBjiiRZSuCu5uNhY4XOOxBqpqbb4EiSN8x/vJvXjopp0c8UV/Z4YmLb5k2D90DJA/OgDrPGNpp9j8EbeHSNRu9Rt/+EmlLzXVmLZt/2SPgKJHyuCOSQc546GiqWrsz/AKBnJLHxVKen/TlFRQB5fRRRQAtJRRQAUUtJQAUUUUAFFLSUAPhXfKi/wB5gKtNaPDO65+aIbyD7HkVVhOJUP8AtCti5nF3qUrQ/JviKsCM9qALunxoNMmv9g3AcL6fLgj+tWruUQywmFQWjaJQoP8AeXgmsVGaPRmRWY/vipAPtWlFPCLW0mVtkixhJQT1weM+mKAOihv0bS2F1GDPbRHHqQWwcfnWmbZLjQhaqWinhBj3459R/OuctbYzXMjSOBksjKDxhl4I/Gtqw1E3MZhu1CK0f2eQg8BlGQR+AFAFBLSO1ht7i6VjLsYyYP3WDAE/yNbem6gkOqrZzQtJC0qNv35+XoRg+mawzrME9jNGTmSKZcc/fTGTj15FY9/qpupZXEzQiWcMrRruYBQBkL+FAGtrEE0Ov3UMWxLaGZ4g5XJcEccenTpW1oMUcVgYkcRrnLybQSDuzgA9BWAJH+0xm4VTKdygc7ZOc7h6GuvsPLNgLlZAty6gywOMbWU4IYdeR3oA6xorh9Lt5rcxmO2uBIwjG3jHU+/saZ46sEi1We73M4utjmQDCgqRwueADk/L0rXhgtPsSLFu2TxLvjB5UqMgjnk9ue1dDdqNY8PfZf3RuoY1kjXaOGX1Hpjg9aAOGtJma0Zs2bCI5ZSgyULHt/8AX7VlpNFDFOsiyR24cMAgJ7YKnA985xVq1ihEVw8kwKSIwWAfLhwR8pPQk9enbpWVLGfLlnIMPyhx82fujHPQ9+h9OlAGv540yZp1d1iICSOs7Aqc/IeP59q7d7W3162VIgtjfwyme0kU5VZcDcn+4+B+Oa4Lw+Y57tUjKlvLZQsh2rKh5C7icfnVjRr5tEuxZsvmWnmKcmXkHPTbj5l/LFAHbeG/Ek11dyPCDYa1p/y3FnIcq6nqrA9VPPPatOTTPDviBZVLxaFI7Ay6ddxi4s5j6rngZ6ce1ZHiHRbTXoLDVYp542tWLGa3dXntlz7ctH7Edqmm0zWBA8+lxaf4iQLlhFKLefHvE3BPPGKAGT/B3SPNDw6F4cuQxz5qXboo5/u78cY6dOa2YtE8O+GIk+33tlJtJ2aVpUKpEWx/ER3OOSa5PV7mdLdzqPgnxBGvVisA/wDQsdKr6brurzx+Zp+j6boNn/Dd384MiepWPjJ+uaANnxd4onjtY9Xv7VbWNFEFhpqgguScKAPTPXjmuL8X6pc6J4Xu7O9yNc1pBNcy/dNrag8KT1yccLVG/wDFdhoeo/bLK5Ov+I3jYx390D5cJ9ETuevPSvNNQn1HxJqpWczXM904B+YsWPX8/wBAKAG6dOr3r3c6ZS0Tfs5+YfwKPdjgmsfVRNeanDYglpmfLnH8b8n8s4/CtfxLKmiwDTLUJvifM0ucl5MdBjsvTPrWJpm63jkuwzNfS5jt0A+Ylsgvn8x9aALFlpZ1vxXFpdplgZBAmO4UYyPrjP419W+JLP8AsXw/oPheFCYtJijaQIApMh+Z9wH19a4T4J+EB4O0218Y6pHENRnQjT4pJMbi3G5h2UDJz9K0Ly9nurySewCz3krEM24uArZ3vj07D8KAJ5Llbe4uNhXy7iVllAfDRncMsCOoFXtRna1lleSRpbRgWjYksEJ6Z7e9cnc6fdNLpcNulw3mSndNM3yy49uwyeRWlc3Ec1zcadbyEqvzu5XvxnB6dRQA1ru21O8kkcCELw7DnzADwfYNWdr1rbw2NzJaokIktZpktlbklmABc9s4OPpWtbJDYQPdQQGZIQ0o8xsh2YYH0HFcxrFnLODbRRNNJMPNmuFOUHc8+gzQB0es/aHstPtplEVsLRZSynd5i4AXcT3yO1c1DdSpbzJeqpL7WQjrkHGQPx5NaDRf2jal5km8uJYwgY9GPyj8MYP0NZLvPBNJcqha3t0FunOQUyckfWgCjqrLBb3EbRDztgBbG0cnPAHam668VpolnAwxNdKRIy/8swSOPbrVPUruK9igF0R52ze/l5wvzdAe5qvr9ubSCO3RvKE2X+YZZjxigDDto4R4tsV6huZPR+2P0qqIfML3Cg4uUYuOyqQcH8K1FtPsU9w4fEm0JjqQT/XBNVruPZZIsabYEjCglslwT09RQBuaqJB+z/aCcESDxRIGB6/8eUNFWvEu4/AqMyOHf/hKpPm9vsMNFAHlFFJRQAUtJRQAUUUUALSUUUAFFFFAD0IWRSeQDnirjzbrmKcjaCvzbT+dUVzkY69qmkUowRgdo5BPvQBbWQIzMJBkh1ZemT2I+tWPPjeydkVizS8EjjOBkVlrsVnVhuIyAR0NWtPk23MP3jEjbsD9c0AaMmqSlnDIN7AHbnoQMcVUMsj286NI6o/z+WRyMH/CtU2cBklZn4SQDPcqeVNVdVRvPNzHKCxwrD+uKAI7KEW0iFsSROuAw43DGTj+VXYFigaNYtrxhvMEsmflOcjkeoqlZytA6rnzIYWPlqeOWU8H2OasROv2go8ghheLdsjfjI6AenpmgDdgmhkkmt5EecCT5fJbJzjhkPpjORXUeGojd27yiaTcg8t+QMgdGHr9K43SpI7do9wEeMSMd3KEdMf55zXZ+E7RpL7U55Z4w0pMjiPoGP8AdH64oA63QJpbS3lurm3Nsjv5cknUYI4kX29evNdHod0nnicElEbcpH3y2MAj2PPWufsorrFlG81vJDMfLiaWTIWQev8Ad+hrdttKu7WNorlIhhv3kbNnZIDwF/vL9aAM/wAVaVbwahBfWlwrwXM3mSFkG23mXlTg9C2WXPFYnkob95YN6w3KMdhG07xnIPXn6da7nS7tlZUaKO6t3EhmiZcsY5MBl9eMZH0rnNT01fDavI9u+oaFe/J5zZR1fnBcjoR2YdaAOZMHno8QtXEsRDArISCRwSDnJJ647YxVhryO/CvqLLBdMTGj52+bjoGH8J6AGr+raRNbQR3ETNeWapn7ZAoJizyN4GT+I61ScWOoeZ5rW0WBhJ16M3uCeD60AVtIW/029afSZWSZELSpJKdxQcnB7/Stu5vbfWrHZqy3G6KMsjQrx3xhjyMEceuawfOv7D5JJFlhA5lU5VsjH0/PioW1JzO8kUW0MNhfDAtgcHrjJwPbAoAlvfDGreW82lX9+JkIH2SVm8xRjk8HBXvnvXn+pT6rBdn7dplxNcsOJHQlx6YHp1r0mw8Q6haRQJ9pV4Igu2CZVkDAkgOuCMHgjg1sw+LbG8gA1GAS4kwiSn5GVscnPK9MDH4UAeOWOmahq3LE6bZMf31zctsyPQDr+A6/jVi+1iz0LT7nT9D3NNL8sl63E0i90RR/q09+pr27VNE8LXNlbz3FlIbiUkL9lWRjz6ZHb09KXSvC/haeKeDT9CZpYflkkuEEaRDu0h7fXP4UAfNuh6DqeuavDBDZzyPK2cbG+b2zXufhz4caZ4WC6z4ovYrjUkKbNLh27lPIAOeijjIxmruq+O5NKebT9DWztLWA/NPbksCQvLAnk+ma5rQbltRD6hflrq4yceZ84ywwM5GSfTmgDrtY1VL+a5vr+6NsMGGG2QghQBwFzwB0GB0NULW8ks/Dun6Pa29qr7muZpSxDvkkff6HaDwoqL+y490UkoImMKzFZ2BjHdgBjg/X1rUhgWTy5roRwQKN0DZY5Uk8Io+p5oAxdTSOzsFezuw7q48sFvnAJ568BjV7RJBdyS/P5dvEMFo1yGPfnufU1BfzYS3tpoz50shdTId/lqo4fjqxyOK09Btha6IuyPcGIwWXOc8HcSQB+VAGPbQzJcXVpErbJGJDTckKQfmx2XmjTLSOXWoYopZYopSFQknCxLjPBPCkjNdBJa/2fDFZ2/mG81AeZIzIXKRD7nA6g/hxUOkeUb3UQ8ryGWLY7pyVwR8qe5OB7c0AXZLmJfP+zlS7QusRHTzJPvED0CgVyl1E0ekXLWjCSKXKxhj90IPvD61r+J52LQRmVYA+4x7sKcdSR6ADjnrXK67f2F5K62zN5kMXlDy2HzZx8vsP8aAOWW1bUf7NkI8uQruWJWysQz3/ALxqx45n36wzRSgi3XC4OR8vc/n0pFmEetWrfaULI/MMZ+UOOij29azbgmW5uIlJkhiG4yDoTknn6mgDJtkZHgmZ2kuNwLcctkc/p3qO4UqwKoyzTgDDDhAv8z04963dAtTcXkc8mBDBGqFjwWJJJH8qz9UMh1eCSFVcwSszAHPTk5oA7H4gXGl3XwUtpND0u40q3HiaRZLee9N2zP8AZIzuDlVIGCBjB6de1FU/GMJt/gnAjElm8TySNn1axgP9aKAPI6KKKACiiigAooooAKWkooAWkopaAHQ7vNTYCWyMAdzWkptxbzQsGIb7hJ5Vu36cVQtTi5hOcYcc+nNW7hkco8qgOAElwOuejCgCtECs0LEfKcc9Qa0rILDJFtAxuZDnkjuPwqolshh3s4Ee4qGPQelQoN5jLyHBba/PI96AN64mluPOZYVjj+6rdjj3+tU9PCS20xkO6aMmVI889RmrF1cCK3t4kZTFgpLgbgfQ/lWQWiSRWCsjqMMAfve4P0oAusXSIyR7dkhClnHAwf5VMVMsgELI548sqckA9UNRBbm4BBUsjpuTcNucdvrW14c0ozmTZgYXneOQenX26UAOsre5V0hFtv8AL/dtuHzbDwwPrivVNJGmWVjbx28JEkahmuOmVHQH1Nc7BYRMVhi3GdNjkqxHGOVz61a1GKOM/a4t0arhw4Jzu6EP7UAdDJcQPZXSzJKI5SpAA3EOe6kdiK6nw5qD39pdrd3J+1W0I8gTYHnEcFWz2xjmuEsbsPs/0uKOJjuMigjDAcEDt34rQtNQU3dw11DCAE+0JcqCAyr3z0wQTxigDtYZDBdR3EbsLmSRXa3Zt6bu8YxzwOfcVtzTadfLELm4ItZySIySyJIOoI7LjOK5DQ7uyuZfOit0TUhtzFEpBkQ9DknqMDkdK6i9l3st1KEMQxtkCgFwccE5xgYoA5STRdS8Ol5vDyTX9tMzCSymba0foYyPvqR2PTFc1PPoeuRtIZIbWdifNa0XLBj2aIjKntxXoEksxuFRTPHcpMWV5G+R+Mjbjgf54rnvEHhyy1vVYb2Ay2OskZa5iJX5u4JC4Jz29KAOV+w6xBbTHSI7e+TyirlHBITHC7ck5xntWDNqlw4livtMNqY/mwyMBJg+ndRk/Xmug1WHxBp8yT6vpEd0ckC+09fLKYI6spwSeoGKc+vWlwiQ3d1IhMwV4r+Py3QHuD0I6cetAHN2N8izGK6jVrN2woPAjGBtx7jJ+laayiGKK7QRWzq6gjBlIK5CjPfjke9XJvDctxtuNGIBQBR553AH/Z2j7uOB61BZ6Rqywv5lmrRu7NILWTJxj73PIPfB9qAJNQ8XardKtzLPdIY/lc7tmCMA4Hpg9Ov5Vnwa7fpYPY2rGWCZiTGGLhznJY+uPetHSrXUIYYIGsJgPmBZ4VbaMcZOc7vpSW+izkyRyJBasx3GHzN78Acnb6enHvQBmxWX221hupZpnNyx/cyYXPqOmfwrrtEudOsZlEKTyzOQv2WOMDc3uRyMAZ5qF7NbCYKqs7zxj57lVQKM8nBIx9TWhZaptkH9nvDPJIu2JIITIVfPVdo5/OgCa3v5/tbXV7bpHayDO1R8z7SAgB6A4xn1qlqGtvbQC4vLkTztub7OSNqgnoCPvEccdOtWLfSdc1KGVIrd1uv9d500pVUHO47egyfU0ln4Oa0eKWW3ivIowC0kXIU+qqeq57mgDO8PLPqmpSTmRVBTCllwqrnHfofYV39xFBFpFnHaqrWNlGY45ZCFWSU/zOcmqm27s4I9k8SwhSqxlFBCE8tgDJbtVrXkt1sbBIHjQROAIy+TEWGCz9gxHbrQBUt5YnniZZYBchTCZVJJYAYZvoOcVQEtlp2nyXskrLE7/LCh5VFztAPbcTyazIMX2rGFYmeJZCCkROdq9AW/mKra8o/s63sbL92LgiKPJJMhUks/rtGcUAcH4g1O61C9vbqUiQQ3DRJnqf8Ad9gMiufivglxCQCxUeYflwSeg4/Ada3dedQ0kMUHyQEx7GbO4Y+82PzxWJaWLSt5kMkhkkUvJg5KqDxn06mgCfQGV2mmLBLqQbW39Vz1IHrRfNDFA1tC7uUmVzGo+Z3zhQT2Uda0fCGl/wBoTXUrQyQwx4LSMuC+O/PSo9VtLR5FvLcLhW2kqcZGRjP+NAGX5yWt3fx2LxtGhMcbuSRIw5ZvzqvpiRRTxW80bvcMQ0kjnsxyalh04z2js8LGaMOY4oyWGfX3+lOsStg2ZExcLH5aRserYzkj26mgDpPHLtJ8GizMrN/wlL529P8Ajwg4H0xiiqXiIsfgXEWbcT4qlO7sf9ChwaKAPK6KKKAFpKKKACiiloAKSiigAoopaAFjyZFwMnIwMZq4oxBL5hDbgMnv1/nVOMssilDhgQQfepsNtZzkA53/AF5xQBOySx25hYHBAYj1B5VqrRAEqvKsDncOwxVqGdtka3GDEBgZHOPanW6xI4Vz+7f7rDg0ANgt32MA7bM5cqeCvqPWprhDF5e/DbDznkEdPyxirOnqsFwcn/Q/4z/EE7sB/MVctIorO6YSyrIiqWSTdnjqDQBJp1uXsBKlu4MedibuHXPI56HHIrSt4z5bCNlaFjtdWOAd2Mbu4IOORTbfz4NOUxxKsUrblDfMrKewPrnp9a0ZY4Ws1mKJLbkhJVDbWU90J7H0NAGlZXAWARAsbxGCyKBuLBRg5I5OBjnrV+4u2ZRPbhHhONgWX5nGPnX3A9Otc5PNPFvlsEDzQt8sm4b2XqGx3OPSr1nPbzxNb3f+rlkMhkP8GeeMcg56jpQBoRizt7hZN8sDykvHhjtOOcYHX+daqh4LqKa9glRZV3QeW+zc3oB/SszT7eNS8ct00Mw/ewmQBlK46ocZFTXeufYdKRoJZruK3b51aPzV3DoRnp6UAJbajPd35eVN/klfKmiba0OM5BPYD3ru/DmufbbiSO9t45bULlVc7CVPXAHB55rk447UwpfWsJiuLqQSPtJMTMBzg5xnnoa1NHv0aWWTyxFGg4dB1z2btigDtrq00qCSS4t49QMUb/KjTEIx64xwah1bUY1nl8iD9zOhOHyQr/Xt+Fc7a3EM0U8Uk7XEFxkGM/KoIP8AP/CoIdXhRvIgnjaGBf3Y3sQOeQVx6+9AHT6brE2nhiksTLN99JoQoOP4QBxmqmraTpfidSmptZWNxFlWYqweUHnhGG0H61Tvtet5kW5uruOJojt3SIWKZHVQB1+lJDr2kKjyz3ly0rgowMDKqkD72TknjOTQBn3nwvlt4WOgarN9jVS3ki5w3mDkNvU7QmOMVzMnh3WPs8c0d27R4DGT7Vk7uhABHJ9jXoNnbW9zbyHTJpbu3kKsVQLGnTuM9e34VE93L+5jWJBCj7XacklOehA/nQBymjeGNdnWBr+9tGittzRJ9tTzVyOW9s+ntWx4a8Kak8f2OXUVt5JJWKxQkCQr1JyMk545rqYbqGMi3gFqZA29ESParDr87npVLxNq9zD5b6PiGYsFdoAp3kD7quDuB/SgCG48C6HZXhfUYPMv1UyL9uuGlYjHQr3Hsa19Kiis47WPdHZ2KRl2+zxFUUH+HHXNcraw67ZS/a55VnuHYzC23+ZIV7b36DPpV+fVNQjUxvZw+e0u/ZcEtjcOSQOAM9MntQBuf2pLDp+o3k1ncfYXl8m13t5Yc8EuwHOB6HiqWn6vcWtt/aMsubuWXd5Ei7lBIwoGOvHYdKjtr23urKO3uHNybZNzMylYIscnCnl3J6dhWLK7hra+DkWkjMsImAGD/sqOB35oAW/1m7vtWmvZLhS4AkIRMbR9B29qkS4k1KO1jtNzPu3Roi7izn70jZ6fjwKn0rwtJ9iutRkZYopCGDhioBPr6/StY6vpHhmzKvZLGWVVkYndcXcv93/YQde1AFiOztNE08X1zKILRncJFCMec5XLLuP6mvPpr9He0LXyPP5TcxqNq5P3U/kTUeveMNQ1q2bylZpJmaGLEe4Qxc7ti9geMtXMy27zQPJZoLi7QjMKn5UjHTcc9yaAJPEEsccq/Yo4jhSFRRncT1JPt1JqPwRpPmam1rKxMVywaYjgy+vXogFZl3d/6akcZknlICt0VWYDLAY/hHTNb2mWsv2VrmJt17MCHfdhI0x/XpigDsYLM+ILy4sNJVoNKCtNcyqOkCjAwe2Tn3NefeJYHtgLaCIRRBQLaDHLc8Ow6nn1ru9N8QW+h2lxplu2Lq8ZDczOMhVA6AdgBzUVjZW+pSy6od8rgFLVpDgfN/GR7DpQBwdtIdMSCKQeTLI20J95nA5JPoSakure1kiup2bdNIhjWQ5BRc/O5/E4GKueIbqCPVs2sQcxL5CzPxsB4J56msW8JeeOC1lLWm5YlGPmncHcc+gz+VAG58RNUm1j4NW1xcW1jbNH4lljRLGzjtYyv2OIglEABbnqecYHQAAqn4xZX+CyshQqPFUgyp4z9hgzj8qKAPI6KKKACilooASiiigAooooAKKKKAFHUVZACsBIMDIyPY9arpjcARnmrhUMp3Z3AAICc/lQA6GELyQDCx/1g5wvfPpWgtuUtnMiiW1U4dR9+M9nHqKrwp50fl2r4dky4Bx83fHr9K0dJuI4VW2vCFLAgPn8vwoAlAia3UugV5P3ccuPkz059M9KU6e8SI724idTtIZsjPTBx2PrVeedEeWJ9stsuBMvQlM8MvqRWzYSJdxTLcgTCLHkXBbO5Tj5W/xoAmhlmstthfwhrM5UqvPXkEfQ1WumkhkmETKsKbWHup9T6Zp0V61xcCIvHLbD5FDnBUjoD6EetXJilrHcziBY7rjJn5imBwGjfsD6GgDNW6j+zec0Zf7PIC6MNxQEYBUjt0/OrzXFxb73ISKJ1XaCNwb+o47VN/ZEtrBNNCkNvCx3JGTuXB/gb1HXBqC5nikTysZRsfui3AYdgT39PWgC4l35RWOJFWdlGxnkwJE/2c8Zz2qKx82GaWfc3kyE7134IB65HoD3FUpxci2itXtt8CkOPMP3D3I98dhS2InVpI7YrNaHIKuQ236LQB0umyXLWTW6ywWkBbYUmVjufPp1Geze9bn2iKLTJLSJLoJF8vmAbTj068rXK2+qsl4kqzSzLjZLbM33COhBPBHpWpb6xLAJpQ9zEkvIfGNo9GWgDVeCPaVkKMJgCcHCk9mBzwexFX7dGjQQRmP5h3Zd30z6VzltdxfvlmaIpv3G4K7lDHoNo6fXvU9wtxJBHDHEZZM73YOG3c/w9xQBn6vfNc6vFaXkrLNGu0GORXwueh29OlLfEXK77eUTrDnEUmV4HZvXPQVmTxzWmo3El7ataTXgBhd1EgLD+HI4JqqNQl2oLrZHJHJgNgRbvQkdqAOg8LX8o1COadre3myojhMhCAZ4IA4J/wBo9K9J+y3bIjXFvbqkq7Zd96qrJ7k/eJ6dOa8shtXk1WFZ5Y5ncF12nGDxkZXqemSeK7o25LWsgiW2UKVaNx5i7s/eOeemaAOnRfIlh+0RCSEcG2aQjc3rj7zdOlQT2i2988iW8Fnpq5dhFlWBPXrknn2rNWZtPSTYuQq5Vy4iKfQsd35c1kXuoS3VvFJBKkdxySmGlz+A6mgDrrm/0SCOGSK6ZskZgCFAw9Dt6kdRUF7HHJFLDGLlvOG9YIeSB1+Zz3IrntL3PcwHUvNlu1fcAUEcUeOQwHGT7Gtaxa+u5JXtbuG0t55dhkjUMzL7vyefQfSgCC306S8uhbGNYrnbuWBnLbTxhmboOB0pov4obyWCJLa8v4wCcKzoijj6KM1oajpMXhrR2m1Nh5LkycSbXdm6nbndt7c1zdzqst9b22m6FZxw2lz/AKwxJyw/226t9KANPWvHl9Zra2toyK5yPMeHcqerKoyAT2JrlbTSpNVm+1TzGGKXLPNJITgHt0ySfaugfT7KysJDdk3VxGcCN1KxofoPvHtWcuoTS7jG+EiGxpE5cf7Azwg+nNACap5NvGbbSw4aMgSuxCqq9gT/AEFcVa3raXetCVWKO4JkPzck9uD0A61rXO+LzDNNEICC4icnao9T6k881zsHh+81u/JtWkud3zSSsAAFz0/kMUAWtH0W917UPMtCI7OaVtwjHzMpPQfXua7LVJG0SYWbfZYEtk2lIl3be5AP973rfMVt4F0GC3tWDa1KmZJSMrEfQfT1rybV9Xlv8jzG+zsxdpTwHPck9Tk0Aa+qX0eop9oAZZpSIYVQZMaN1JHqfem2vie406MxliIi+1GkO4cccf4DisKGaW2FvEm5A7ZeQJz/AJxxVS9une9hRkEuchUGPlUdQT6DrQB0PiG9tXhjjsh5jk4eVu8hPJ+gH61zM2pva3EsNuG8xtyrI3SMY5I96gt53leBYBm2izjJwHft+A4qHMdszM8jSyBCis3TJ+835mgDrNRZm/Z9ti772PiqUlvX/Q4qKu+LNK1HRfgZZ2es6ffadct4lklSK9t3gd0+yRLuAcAkZUjIooA8looooAWkoooAKKKKAFpKKKACiiigB8WTIgXrkYq4xV7hOdoBzgevtVOP/WLk45HNWJmkjUJMmJBgq/Q//XoAkhl8mYStIXAbggfeB9avXKxTSD7NtZyp/dP1B68VTgXzYSNyBye44Ye/pVhJFtnt3MasuOg68UAWrS7CmMNCskYHCMO38SkVLMXgD/ZCqRfej56A/wAxn8qoGVjI13GxCs33AfmX6A9asyT/AGmAQnaGflJAu1T9fQ0AQPu+0uQ5SeQBgM8SL7EdDXTaFcBkHmTrNbMPLbz13FSP4W9RnHWudUQpEglyjo/zxsPlOf4l7g1pW7SWcZmRFaNugIyrHsc+/egDrZpvLXbbqxQrlId2Vx32Ht64rLsWju5AGl8t3JKNKuVIH8LAjjHrWTNqa3UzqEKQZ+eIEq0bDv8Ah6iktr/ybnyRIWZhzuzj2cEd/WgDUu2lgSRbmZbaOOUeXPE+9fpz2pSqyX8cccY3FS27zAhb1xjt7VHp9rcSM8n2uG5jQhpIch1X1BUjkGuieztJ0WQxJGOGjZMFD7bl5U9vSgDKmMAhQLMtn5zeUJI1SRGYdFPpnnj2p11fvNbW8Mssfmo+PODhR+HH6Gp9S0SG0mM1xdW1vE5BKXDEpJ9eMZqC8tLKAJHciaSH78cuRzn0I4JoAnSaSS3EeUeTdtPkR7Dx6jGPxr0zwJ8KfEXi/Tk1GPUrfTNGuB+7eVhcyMV6/ukIAGcqQ0iurKwKcVw3gzQdQ8Q3kei2Nq97qUjZhnEnkmOMdZJSAR5a5GTgnJAALMFPv0Oq+H/grYQaJZR3Gua5dOlzqbpIEfGMGQgnahIG2OPI3Y5b7z0AYXxK8E+E/Cmk2WmyRtfXl9IwLXIDeXEP4wqbQrZ2qGwc5Ydxjyv/AIQqyu7loNP1KJFjwmy6Xy1HHUHufpXdfErxDD4y8TT3FjdzXFhEiQWUMcTghMKzyNE4DBy5YE8ZWNPTnFvdFlWNA89zICflkjz8o7hsj260AYUuiyaVMbWKW3muHA33KS7VjBOOnGc81o2unzXEgtDqaTO7BW+yxsm76liOa07qzszo7yXCzXYVgE3yICzc4BweRVrw9Z6M9gJb6wXe33g9yd7+wB+b86AM2Tw/cQaj9ngNndzJhlS4lU7B9BkDHrWdq11Lot7tnd4bnB2fZ3JIU9TkDrWz4ptkWNZNGsFhtlUqFZsEH8eTXN3+jzxWcX+nrDuw0v2QEyEHtgcD65oAxRfLJcD/AEm73s+ZIn3EnHTAblvc5rpNH1gafFNPdzNp1mBhZkJeUf7oA+VifSsu7sTpiRuIC0W793tZml/4ExySc/lW9ounvOim/s7q8KybwsJyoB6KD396ALky3mr2ov1hNppAUENcgFnPZjuJZmPXngVWt7o2lmkdhetbo2WZxGPNdAeST2X8q0NekhuJktryKW2toRzbwEF0x0DMTj61yQneZrp9PsYobYHBmnJKjtlnPDH0AGKANybVobqzMMczTOx3ea/TAHRV/mTXG+INZnFsIYXPll87WTaMDqw9R71rCFY4zFayCZpOXugCyr7jjGPQVak8O2wtI5YI2nlKYknnJLux9F7CgDHFml5tF68l1JKgYQoCS2e5x0HtXomi6f8A8IZpa3uurbJdzkC3s4xllXtwB16VS0bxHpHhqz+zabGkl7gmW42733/xEsemOgxXCXWoalq0s11czzyvI3+s5YhewGOp9hQBY8Ra6mqX7G6aa7lnPyptO1IwccAdfqa5OdFuriaR0JVWGPM+VY1H8KKK171roXAjiAhZlHmLEu524yAT2AHUdOaw5W37mmjDohyQTgD0z60ALfam1pG0O9JpGGdxXhOfur6k1lMJxM8szYZvlWIcKgPr6/SrF5aeYIjbOrSTPjI5x/u+/vVO8LbTCs2+VMpJcOflQZ6L6k+tAECzQFAkIJbG4N0wOg49T6VUmWdowp/1K8u/qe+T6+1WpPLlhkjVo4mzztHYe/8ASoSWSJFdjtB3bT/AOxP+0fSgD0PxTqup618CbO51vUr7UrqPxNLEs17cPM6p9kjbaCxJAySce9FUb7af2fbdk4Q+KZAB9LOKigDzWivdPAV3Z6h4Is9AbxGlqk8Ugu/Dk+ljbPDktNerdNhVaOJWmXJ4aADB6G9Dq3iPV/HHiPTbKDTLKHwxNcf2PNcQx28emsgeNIg7jaA6AvtfOWiDAjDGgD58or2X476aNP8AC/g57kWsmr3r3l1qE9uY3SWZhBuZZEGGBOW4JAZmAwOBf+LmtR3Nrb6TZ+NRrWNRhjbwyNI+yJaqgYBBPgKwU4Tjru3c9aAPC6UV7Hp4tLX4k/EazuPD9nYXMmnaqkVofLkjsQttM5EW0YD5VAGXACmQY5BHbaRpUmsQaf4L1nZ/YF/oOi6hZW8UEQNv5s1rDNPG+3cspkluCSc5DHORxQB8y0V9S6X4d8Pz6doupS+HtHMupalBpMsJtV8pI7yyj1BnQDBEkckjRxtn5YgFIY/NXgvxU0610v4g63a2ESw2on8xIlACx71D7FHZQWIA7ADrQBylFFFADkUs6qOpOBVtMSxD51+TgI3r/hVNThgeevapiqYcx5ODwT6e9AFpUA3qY2TPGM/dP+FSs5e22KjNJGdzMOME+oqqkhEvytkgYwD1+lSG4xIsoODjDJ2Yen/1qAFQMBtddsbEguOdp9TWlaxrsVZgtxG2VWTP6H+h7VnzQsxabJMMn8ag8emacB5dsqqzAE8Sfw59CR09KAL6SfZY1m8ppU3FE83nP+zu/wAanmBRFnt1IGQxgDbeO/sR7iqtlPc3BeOMhhzvgdeT6Hnv71NC4RHlmeRrYgqYzgsh7gjtQAy5WF0cQo0cijcw4bb3z6iqjyTRqrHeIlI5Vgu0nuPQU6GNFuRK5JBHCjrt7EGpktkEavuNxA+QCn3l9mU0AacE1wVDwXSW8wAyWUAj3yOGBq/pmrSG5lS7jU45JUbFJ9fauWWf7M2Y1eSADBDxArg9qcjvDuysrxDny9uNgPpzyKAO6nvpBazNcSI7gYi8o4H1IPB4rY8C6fqur6/Y6ZoFtHfy3aFnRuI0VcZkk4OxVyMtgnkAAsQD5vZlEaMQ3sSBpQrSTFgEBIyWGCQB14B6HGa+p9U1/wAO/BbwQmm+EJ7bVfE2p26XUl8oVw6EfLOcHHlgE+XGCc5Jycu5ANXXtY0r4P6HLo/h5be/8X3sYmu7llVQgAIErqDwi5bZEDzyScl3PiOl61Yfa5b+91Ca6vbpjI823zfOc9S54IP04A4GAAK8/vtXl1C+mv7u6N9ezyF5Xn+WR3PU5684H0AAwAAKn0262ykS2kqXGdwDEKPwagD0ebxZbpcxmW5FtK3C/MSWHoOM/gasReJytu0lrcXTEHkzRllz9PSvOBLBFezXEdtdnaN0iO+5fz/wq7aaogXMcRTPOwOwVfw6mgDf/wCEmM17511EsoYhG8qIRAjPYjjPsRW/eeJI2g8m3nvLeNgVZoHUdenTvXmd5NOZ2WOKCWMuJEVywH1Hr+NVVmkhuJvtO1DuyypMqBuOhHOaAPR5/EUongtZ72S/ULkxzkkAe5H9KnTxzH9rktxaQpDt4Bt2MQ9z6n615gmo20UqfZ7oQKeShU5b2J9Kfba3I0kiFdxJ2jLEE/7ooA9Qj8T2c0Bjh09JLheHmEYjZ8fyUelZ0/iy8uopLJNRuLa2nYgrCuMKe2QQcf8A164+6vPJCwzbYQ2Cy5Ls3+8ew9qpR6lKz+UrJEh+WMomCw9s0Ad9pS24KvBFc3e770szbUAHpknj+daE0aahEUiLXkobzHQvhUUdgOgH864W3lupvL+1TSRQD7xabn9OB9K2b3VhY6etvBK5tmx+6dQAx9/X8aANiysJb2b7Tc3T29pB/t8EdgAOBVLW/F8ss7WdgimNDw0mFUAdyO5+tcb4g1KXZGkEjg5yViOce2enFUhLbRKLjUGj+zjgx4ZjI/q3r/KgC5eebdXTm4uRMufMKhsLgdBj0q7Z38l7ZtK10kQTIUA4Ue5A7ewrDLtPIzri33AMIxjfIP8Aa7KPamzajFCkQ+yqwJIVz91iOpwOvtmgDZt/7TW2VbYqWnY5Y8sR6n+6PaqWrzFboLJh9q7tvRFP95j3+gqhPrdyZXRSXLfIscfyBPb61b+zyCYRzyL54XzLgqd5C9kHbNADoDE1vLK27KoURsbeo7D3rGuFNpDAtyA8vLgHnnoOParGo3ctzbkiFraJWAAJ+Z29P8apzlo/muJQXcFic5NAFLcHV33nex+VcdAT1P8AhT79RvSPlI0UfKOSzHr+NSysqXMAjjYbcFlxgfie1Vrl3FxMM5XPzFRnaPQUAd/qSlf2frcFQoHimTAHb/QoqK0/G2iXHh74H2ljdy2EzN4keRXsrxLpMfY4xguhIB4zg84OcYwSUAXLZ7uL4G6Xpdjq+oLearaXt6lr5FuITBBMxnjEu3zgfLR5D84BCMmG3gVJLrLa7Jp2k6xqXiK90iy8NJc3cFtbWomllaOPhCF+ZApjG+TdINrn+KuXbxpo6fDzQ7C3/tJfEOmWN7YLmCP7PtupmMjB95P+peRMFOr5BG0ZpweMLXTNR+3aLd6vBdNoUVj50R+zyQ3KpGp2skhJj/d5zwTuwV45ANzxJ4/8S+EpLfQtB1cv4fW1insrfUNOtZZYYpY1by3LRn5sEA44PXviue1f4heKvF8EGj61qdtJbTTxZb7DbxMGBwrF0QNxn1rE8aazH4g8Q3GrIJvPvFjmujLjJuCg85lwfutJuYDjAIAAArJsplt7yCeSJZkjkV2jbGHAIODkEc9OQaAPZvBEt/4Q+KHj3TG12+mubayv3kvora3le6e3BkYSeesm1XVXBxk7iucgGuo8N6d4gnk8NaVa+KZY9HNnpt/G0en24e2u3urKVrfcV3NGn26KVR9z5lXB2EV5Xoni3Q/+E68Sazf2dzpWn6pZX1vDa6dBHN5BuI2jAwWjG1Q5PGM7QMc5Fm18f2Vt/b3kJfwy3uhWGn200eFaK4t4rdCxAb7uYXKtkkfKQATwAdl4E1O+b4Y23iXW9V124trPxAlvbWOkWlt5iTw2KJFMWeNshYk8srjB4Y85zUn8K6B40vbS5urnxKut+IYLy8tLy5SAW0KW7TqiTBUGX2WvzbdoG4HnHObN8TLCeM2mmX2veFLYYuPP0aNN8k8jyyThkSSEbMyRop3HC26fKu7asUXxKso9HHhya98QXnh+bSLqyuWciN2uXupriO58oSkEgtGG+cFhuBJAwQDTtvhx4Om1LWbMz+KUn0C2uJry3aGPfqXklVZ7Vtu1FDZYh9x2suM/MR5f4xh0SDVxH4ct9ZtrVYl8yPVihmEhyT9wAbcFccZ616nofxU0XSrXVrNNV8XSwX1u8NjPIA02gj+CO2JnJdeisQ0WRGuQc4XyrxfeQajrLXkGs6vrUkyKZrvVYRHOzj5QDiWXcAoXBLe2OBkAxo13uq5xk4zVpY2jViSA6849R6j/AAq34V8P6n4p1220fQrY3Wo3G4xxB1QttUu3LED7qk9e1egD4DfEcqSfDFxvzx/pducD/v5QB5kR8xfysbT820/qBTmKyJ86jzSMqf73/wBevVdK+Anj+8vbW31Dw/PaW0kqpJcCa3cwoer7fNGcdcZqvF8CviRsP/FKyln4+a6tz/7U/WgDzW1uJbdQUYhR1HTmpJJEkl3eWVVhn90ccjvjpXo4+A/xFRiP+EWnIPY3Vvj/ANGUs3wJ+JDbjH4YmAyCo+1Wwxjt/rKAPOhJtklG3zHAwTIcHBHqKntYDMBuGJOd3zfMceoPX8K9L0r4EfEF53F1oclmiW80iyNJBKJHWNmSIqJf43Cpntuz2qH/AIUf8S2O1/CziNhjC3dtx6YPm8UAecSq3m+U3DMcgD7rj/Zz0+lWAwjmigm24Tp5q/6wHtkV283wH+IzfKPC9xgMfmN5bnPvjzOD+NSRfBD4nRxFV8LyDgZzeW7A49jJx+FAHBzghi0AJKnDRvztH9RQs8SwBre3lTnawjIYKfcdRXqGj/Arx7PPdPfaPNZJHaSzxiSSC4WWZVykWBKCu8/Lu5xnpjOKa/BL4jLdrOfCUgGMbftluePT/W0AecRzW8TzSbv3nBIdCAR9Oopyrt4tr0RuedgjyMex/KvQD8C/iK0zOnhe4RT/AA/bLYj8My0ifA/4ivN5reE5UI4IW7t8D6AyCgDgInhmV+P9JGd5m+cE/wBKXThbly88O7GAUluCn1IPpXpen/s/+O501E3Wjz2DJbmaBftFvN9plDqBEMSgJlWZsnP3Mck1Ba/BH4lW0DJD4XlDnkE3dqQPzkoA427vLfB/s6eOPf1jU4J98+tQWmpSy+apULkFR5hP+TXcw/Br4pou2TwyzqT8wFzajP8A5Eok+CHxGZ18rwpPHEByPt1scn1x5g/nQB53LIGaSIhJSM4VJCCOPUcEVFE0q5AIkHBAAHymvSIvgF4+lW8ebRZrZ4YRJbxLLb/6Q/mxqYwRKQp2M75P/PPHfiNPgf8AEfkDwxdqp4IW9txn/wAiUAedT30m5Ibklyf744Uew70sl21vEFtWEinnZksQfX2r0dPgd8RUI2eE5GAOdz3dsW+mfN6fhSSfA/4kSD974WlI/wBm7thgfhLzQB55JJP9nEs6bEzggtyB7CohdiSQrF5jNjgkfKo9Setem6f8B/iIiX850ea1mhhWS2hae3k+0OZEUx58z5cIzvk/3MdxUTfA/wCJsjsZ/DcxXOfku7UE/U+bQBwlvqEYuArwPMY+AwBA+oBPH86t3ss0hWaVzIQABHHkrGewyeprrT8DviISu/wpcHB6C8tzuPqW8yrMnwR+IUluIl8KT25XvHeW7fqZqAOBkeV0ijuIJG3dI0P6k9qAwNxIoGNowrMd4j9cL616IPgX47GkTyp4cuReJJEqwPdW/wC/Uh9zEiUbQpVBjBJ39scwS/BL4iS2wjXwtOF4JC3NtGM/9/SaAPP7VPtF3IEYpHGc5MeZGPfnp+NQX0gkjXynkDzPgKXAxj+QFegt8EPiQsRWLwvMijgKLq2wfr+95pn/AAoz4lgFk8OTh2++/wBptQceg/e0AcRY3H2MtNC6yyRjaGcbUX3UDknPeoLa9dPOmKs8ucNu+VV9Tjua9Fb4GfEWLSxJD4enF0JTGYvOt/u4GHLeb1ySMAduvNU0+A/xIVVEnheZm9ry3/n5lAHB6g0c0XnTrtkAwkYbJ+p/wqrJKjBY9m/5cnnGef0FelRfAr4iAN53hSZiemLq3/8AjlMl+BvxMmYsfC8inoMXduAo9APMoA83eW6uHAllA39A3APvim8yNHAka+YSNx7V6pJ8AfHqaJDeJo87aj9raF7EyQHbEEVhL5nmYO5mZdoHG0knkCpl+DXxHSwEK+FZwX5lb7VbAuey/wCsyFHrQBz9+ix/s/wKhVv+KqlBYDGcWcX+JorX+Iehah4Q+ENjoniS3XTtXn1+S9isi6MzQfZY0MnyFgBuGOTknp0OCgDx2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image of a rectal cancer with involvement of perirectal lymph node (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15539=[""].join("\n");
var outline_f15_11_15539=null;
var title_f15_11_15540="Fosphenytoin: Patient drug information";
var content_f15_11_15540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fosphenytoin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     see \"Fosphenytoin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=see_link\">",
"     see \"Fosphenytoin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cerebyx&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3597444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause risky heartbeats or low blood pressure if given too fast. Your doctor will watch your heart closely when you get this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fosphenytoin, phenytoin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you. Confusion, being tired, mood changes, or slurred speech may also happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695987",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11949 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15540=[""].join("\n");
var outline_f15_11_15540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174565\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020869\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020871\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020870\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020875\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020876\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020878\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020873\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020880\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=related_link\">",
"      Fosphenytoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=related_link\">",
"      Fosphenytoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_11_15541="Punct epithelial erosions";
var content_f15_11_15541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dry eye disease with punctate epithelial erosions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15541=[""].join("\n");
var outline_f15_11_15541=null;
var title_f15_11_15542="Eszopiclone: Drug information";
var content_f15_11_15542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eszopiclone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/12/28868?source=see_link\">",
"    see \"Eszopiclone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lunesta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hypnotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: Initial: 2 mg immediately before bedtime (maximum dose: 3 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Concurrent use with strong CYP3A4 inhibitor: 1 mg immediately before bedtime; if needed, dose may be increased to 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Difficulty",
"     <b>",
"      falling",
"     </b>",
"     asleep: Initial: 1 mg before immediately bedtime; maximum dose: 2 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Difficulty",
"     <b>",
"      staying",
"     </b>",
"     asleep: 2 mg immediately before bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F167835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F167836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: Use with caution; no dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Initial dose: 1 mg; use with caution; systemic exposure is doubled in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lunesta&reg;: 1 mg, 2 mg, 3 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F167847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM134691.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM134691.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F167812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of the rapid onset of action, eszopiclone should be administered immediately prior to bedtime or after the patient has gone to bed and is having difficulty falling asleep. Do not take with, or immediately following, a high-fat meal; do not crush or break tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of insomnia (with difficulty of sleep onset and/or sleep maintenance)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3370803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lunesta&reg; may be confused with Neulasta&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Unpleasant taste (8% to 34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiovascular: Chest pain (&ge;1%), peripheral edema (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (8% to 10%), dizziness (5% to 7%), pain (4% to 5%), nervousness (up to 5%), depression (1% to 4%), confusion (up to 3%), hallucinations (1% to 3%), anxiety (1% to 3%), abnormal dreams (1% to 3%), migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 4%), pruritus (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (up to 3%), dysmenorrhea (up to 3%), gynecomastia (males up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (3% to 7%), dyspepsia (2% to 6%), nausea (4% to 5%), diarrhea (2% to 4%), vomiting (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuralgia (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (5% to 10%), viral infection (3%), accidental injury (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal gait, abnormal thinking, agitation, alopecia, allergic reaction, amenorrhea, anaphylaxis, anemia, angioedema, anorexia, apathy, appetite increased, arthritis, asthma, ataxia, breast enlargement, breast neoplasm, breast pain, bronchitis, bursitis, cholelithiasis, colitis; complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls); conjunctivitis, contact dermatitis, cystitis, dehydration, diaphoresis, dry eyes, dyspnea, dysphagia, dysuria, eczema, emotional lability, epistaxis, erythema multiforme, euphoria, facial edema, fever, gastritis, gout, halitosis, heat stroke, hematuria, hepatitis, hepatomegaly, herpes zoster, hirsutism, hostility, hypercholesterolemia, hypertension, hypokalemia, incoordination, insomnia, kidney calculus, kidney pain, laryngitis, liver damage, lymphadenopathy, maculopapular rash, malaise, mastitis, melena, memory impairment, menorrhagia, metrorrhagia, myasthenia, mydriasis, myopathy, neck rigidity, neuritis, neuropathy, neurosis, nystagmus, oliguria, paresthesia, photophobia, photosensitivity, ptosis, pyelonephritis, rectal hemorrhage, reflexes decreased, skin discoloration, stomach ulcer, swelling, thirst, thrombophlebitis, tinnitus, tongue edema, tremor, twitching, ulcerative stomatitis, urethritis, urinary frequency, urinary incontinence, urticaria, uterine hemorrhage, vaginal hemorrhage, vaginitis, vestibular disorder, vertigo, vesiculobullous rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to eszopiclone or any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal thinking/behavioral changes: Hypnotics/sedatives have been associated with abnormal thinking and behavior changes including decreased inhibition, aggression, bizarre behavior, agitation, hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving). Administer only when the patient is able to stay in bed a full night (7-8 hours) before being active again.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions including anaphylaxis as well as angioedema have been reported, in some cases following initial dosing. Patients who develop severe reactions should not be rechallenged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep has also been noted; amnesia may also occur. Discontinue treatment in patients who report any sleep-related episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression; worsening of depression, including suicidal ideation has been reported with the use of hypnotics. Intentional overdose may be an issue in this population. The minimum dose that will effectively treat the individual patient should be used. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug dependence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment required with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD or sleep apnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; dose adjustments may be necessary. Effects with other sedative drugs or ethanol may be potentiated, including risk of sleep-related behaviors. Use with alcohol is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Use with caution in patients taking strong CYP3A4 inhibitors. Dose adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dose adjustment recommended. Closely monitor elderly or debilitated patients for impaired cognitive and/or motor performance, confusion, and potential for falling. Avoid chronic use (&gt;90 days) in older adults; adverse events, including delirium, falls, fractures, have been observed with nonbenzodiazepine hypnotic use in the elderly similar to events observed with benzodiazepines. Data suggests improvements in sleep duration and latency are minimal (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Tolerance, as assessed by sleep measurement, did not develop over 6 months of use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid onset: Because of the rapid onset of action, administer immediately prior to bedtime or after the patient has gone to bed and is having difficulty falling asleep.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt discontinuance may lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Onset of action may be reduced if taken with or immediately after a heavy meal. Management: Take immediately prior to bedtime, not with or immediately after a heavy or high-fat meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may increase CNS depression. Management: Avoid valerian, St John's wort, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F167806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. Eszopiclone is the S-enantiomer of the racemic derivative zopiclone. There is limited data on the use of eszopiclone during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15391067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eszopiclone is the S-enantiomer of the racemic derivative zopiclone; zopiclone is excreted in human milk. There is limited data on the use of eszopiclone during breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid taking after a heavy meal; may delay onset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lunesta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $251.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $837.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $837.60",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Eszop (CN);",
"     </li>",
"     <li>",
"      Inductal (AR);",
"     </li>",
"     <li>",
"      Isoklon (CO);",
"     </li>",
"     <li>",
"      Lunox 2 (UY);",
"     </li>",
"     <li>",
"      Neogaival (UY);",
"     </li>",
"     <li>",
"      Noptic (CN);",
"     </li>",
"     <li>",
"      Valnoc (PE);",
"     </li>",
"     <li>",
"      Wen Fei (CL);",
"     </li>",
"     <li>",
"      Zolnite (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May interact with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; high-fat/heavy meal may delay absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 52% to 59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via oxidation and demethylation (CYP2E1, 3A4); (S)-N-desmethyl zopiclone metabolite has less activity than parent compound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~6 hours; Elderly (&ge;65 years): ~9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (up to 75%, primarily as metabolites; &lt;10% as parent drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15542/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krystal AD, Walsh JK, Laska E, et al, &ldquo;Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults With Chronic Insomnia,&rdquo;",
"      <i>",
"       Sleep",
"      </i>",
"      , 2003, 26(7):793-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15542/abstract-text/14655910/pubmed\" id=\"14655910\" target=\"_blank\">",
"        14655910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8830 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15542=[""].join("\n");
var outline_f15_11_15542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167830\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167845\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167833\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167834\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167835\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167836\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167809\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167798\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167847\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874645\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167812\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167811\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3370803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167843\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167815\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167800\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167840\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167804\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167827\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167806\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167818\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167838\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15391067\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167819\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167817\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961918\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167799\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167814\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/12/28868?source=related_link\">",
"      Eszopiclone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_11_15543="Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection";
var content_f15_11_15543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Francesco Negro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15543/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/11/15543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis D is caused by a defective virus: the hepatitis D virus (HDV). HDV is often referred to as hepatitis delta virus or delta agent. However, the term HDV is preferred.",
"   </p>",
"   <p>",
"    HDV infection is closely associated with hepatitis B virus (HBV) infection. Although HDV can replicate autonomously [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"     1",
"    </a>",
"    ], the simultaneous presence of HBV is required for complete virion assembly and secretion. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Virion structure'",
"    </a>",
"    below.) As a result, individuals with hepatitis D are",
"    <strong>",
"     always",
"    </strong>",
"    dually infected with HDV and HBV. Due to interference mechanisms that are not well understood, HBV replication is suppressed in most HDV-infected individuals.",
"   </p>",
"   <p>",
"    This topic review will provide general information concerning the HDV structure and replication strategy, the nature of its strict association with HBV, and the epidemiology, pathogenesis, and clinical features of HDV infection. Issues related to diagnosis, treatment, prevention, and liver transplantation are discussed separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIRION STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HD virion comprises an RNA genome, a single HDV encoded antigen, and a lipoprotein envelope provided by HBV (",
"    <a class=\"graphic graphic_figure graphicRef63575 \" href=\"UTD.htm?42/16/43279\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HDV genome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HDV genome is a small RNA molecule (1676 to 1683 nucleotides in size) bearing some structural analogies with plant viroids and virusoids [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"     1",
"    </a>",
"    ]. HDV RNA is a single-stranded circle, with a high degree of self-complementarity and G+C content causing the circle to collapse as a rod-like structure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"     1",
"    </a>",
"    ]. Significant sequence heterogeneity (as high as 39 percent) exists among the different HDV isolates that have been sequenced, and a classification into eight HDV genotypes has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hepatitis D antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only antigen associated with HDV, the hepatitis D antigen (HDAg), is a structural component of the virion. It consists of a phosphoprotein encoded by an open reading frame present on the RNA strand complementary to the RNA genome (antigenomic strand) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 70 molecules of HDAg are complexed with each molecule of HDV RNA to form a ribonucleic core-like structure.",
"   </p>",
"   <p>",
"    Two forms of HDAg (with different functions as described below) are coexpressed in infected individuals, differing by 19 amino acids at the C-terminus. The molecular weights of the two HDAg molecules are approximately 24 and 27 kilodaltons (kd). Their synthesis arises via an RNA editing process during HDV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stop codon UAG of the antigenomic HDV RNA causes the translation of HDAg to terminate, thereby giving rise to the small HDAg. This stop codon is deanimated by a cellular enzyme to UIC (where \"I\" stands for inosine).",
"     </li>",
"     <li>",
"      Further base changes occur during the next replication cycle, resulting in the replacement of UAG by UGG, which directs the incorporation of tryptophan into the nascent HDAg. Translation of HDAg then proceeds until a new stop codon is reached, 19 amino acids downstream, thereby giving rise to the large HDAg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lipoprotein envelope of HDV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipoprotein envelope of HDV is provided by the HBV and consists of the same proteins (large, middle and small S) that are found in the HB virion; their relative proportion depends upon the level of HBV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HDV LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDV replicates at very high levels in hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/5\">",
"     5",
"    </a>",
"    ]. The receptor of HDV is unknown. The steps in HDV replication cycle can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once inside the hepatocyte, HDV RNA is found within the nucleus, where it is transcribed into its complementary RNA (antigenomic HDV RNA). Two forms of antigenomic HDV RNA exist: a 0.8 kilobase (kb) RNA, which is the messenger RNA being translated into the HDAg [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/6\">",
"       6",
"      </a>",
"      ], and the full-length 1.7 kb RNA, which is the template directing the transcription back into the HDV genome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"       1",
"      </a>",
"      ]. The host RNA polymerase II appears to be involved in the transcription of the 0.8 kb mRNA in a process that is regulated by direct binding with the HDAg itself [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In addition, the transcription of the full-length genomic and antigenomic RNAs occurs by the cellular RNA polymerase II [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HDV RNA replication is",
"      <strong>",
"       activated",
"      </strong>",
"      by the small HDAg through direct binding of the HDAg to the HDV RNA.",
"     </li>",
"     <li>",
"      The large HDAg",
"      <strong>",
"       suppresses",
"      </strong>",
"      HDV replication. In addition, it directs packaging of the HD virion through an interaction between the extra 19 amino acids at the C-terminal end and the small S protein (HBsAg) of the helper HBV [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Completion of the HD virion assembly and release is dependent on the simultaneous presence of HBV which provides the envelope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HDV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to its dependence upon HBV, HDV infection always occurs in association with HBV infection. The clinical and laboratory findings vary with the type of infection (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link\">",
"     \"Diagnosis of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection of HBV and HDV in an individual susceptible to HBV infection (ie, anti-HBs-negative) results in acute hepatitis B + D. This entity is clinically indistinguishable from classical acute hepatitis B and is usually transient and self-limited. However, a high incidence of liver failure has been reported among injection drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of progression to chronic infection is not different from that observed after classical acute hepatitis B, since persistence of HDV infection is dependent upon persistence of HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Superinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDV superinfection of a chronic HBsAg carrier may present as a severe acute hepatitis in a previously unrecognized HBV carrier, or as an exacerbation of preexisting chronic hepatitis B. Progression to chronic HDV infection occurs in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/12\">",
"     12",
"    </a>",
"    ]. However, HBV replication is usually suppressed by HDV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis of HDV-induced hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detailed mechanisms by which HDV induces liver damage are unknown. However, the pathogenesis of hepatitis D-related liver disease appears to depend on the interplay of three major factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HDV-associated factors, such as genotype [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/13\">",
"       13",
"      </a>",
"      ] and the expression of specific HDAg species [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Host-associated factors, such as the immune response.",
"     </li>",
"     <li>",
"      Helper virus-associated factors, such as the HBV genotype and the level of HBV replication [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HDV is believed to cause directly cytopathic damage during acute infection, whereas immune-mediated damage predominates during chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF CHRONIC HEPATITIS D",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical sequelae of HDV infection encompass a spectrum of manifestations from fulminant liver failure to the asymptomatic carrier state. The severity of the clinical course is influenced by several factors (see below). A study of 299 patients followed for up to 28 years found that persistent HDV replication was associated with annual rates of development of cirrhosis and HCC of 4 and 2.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/16\">",
"     16",
"    </a>",
"    ]. The only predictor of liver-related mortality was persistent HDV replication.",
"   </p>",
"   <p>",
"    Other studies have suggested that clinical outcomes may be related to the different HDV genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. HDV genotypes and, more interestingly, specific clinical features of hepatitis D, seem to cluster in distinct geographical areas. However, superinfection, or mixed infection with different genotypes can occur, particularly in patients who are at high risk for multiple exposures. In such patients, a single genotype usually predominates, with the minor genotype representing only approximately 10 percent of the total viral population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genotype I",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Western world, where the predominant genotype is genotype I [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/18\">",
"     18",
"    </a>",
"    ], acute hepatitis D has an increased risk of a fulminant course when compared to acute hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/10\">",
"     10",
"    </a>",
"    ]. Once chronic HDV infection is established, it usually exacerbates the preexisting liver disease due to HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/12\">",
"     12",
"    </a>",
"    ]. Progression towards cirrhosis may be rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. HDV-associated chronic liver disease may also run an indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/22\">",
"     22",
"    </a>",
"    ] and asymptomatic HDV carriers have been found in some geographical areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are currently referred for HDV infection appear to represent cohorts infected years ago in whom the HDV-related disease rapidly developed to cirrhosis, but whose subsequent disease progression has been slow. This was illustrated in a report from Italy in which the estimated 5- and 10-year probability of survival free of liver transplantation in patients who had already developed clinically overt cirrhosis was 49 and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/24\">",
"     24",
"    </a>",
"    ]. A more ominous course toward liver decompensation has been documented in patients with active HBV and HDV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether superimposed HDV infection accelerates the development of hepatocellular carcinoma in patients with HBsAg-positive cirrhosis is controversial. However, a retrospective study involving 200 patients with compensated HBV-related cirrhosis, of whom 20 percent were anti-HDV positive, found that HDV infection increased the risk of HCC threefold and mortality twofold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/25\">",
"     25",
"    </a>",
"    ]. After adjustment for clinical and serological differences at baseline, the estimated five-year risk for developing HCC was 13, 4, and 2 percent for anti-HDV",
"    <span class=\"nowrap\">",
"     positive/HBeAg",
"    </span>",
"    negative, anti-HDV",
"    <span class=\"nowrap\">",
"     negative/HBeAg",
"    </span>",
"    negative, and anti-HDV",
"    <span class=\"nowrap\">",
"     negative/HBeAg",
"    </span>",
"    positive patients, respectively. The corresponding figures for hepatic decompensation were 18, 8, and 14 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genotype II",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Far East, where the predominant genotype is genotype II, there is a less frequent association between fulminant hepatitis and acute HDV infection and between rapidly progressive liver disease and chronic HDV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/17,26\">",
"     17,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genotype III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe outbreaks of acute hepatitis D with a high incidence of liver failure have been reported among the Yucpa Indians of Venezuela [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/27\">",
"     27",
"    </a>",
"    ], the Sierra Nevada de Santa Marta in Colombia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/28\">",
"     28",
"    </a>",
"    ], and some remote areas of the Brazilian [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/29\">",
"     29",
"    </a>",
"    ] and Peruvian [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/13\">",
"     13",
"    </a>",
"    ] Amazon basin. Viral factors have been postulated to be related to the fulminant course in these outbreaks, as HDV isolates from Colombia and Peru belong to a distinct viral genotype denoted genotype III [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other genotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least five additional HDV genotypes have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/2,30\">",
"     2,30",
"    </a>",
"    ]. Sequences previously assigned to genotype IIb are now classified as genotype 4, and African sequences seem to cluster into four additional genotypes, named from 5 to 8. These new genotypes are less well characterized as to their disease features compared with genotypes I to III.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF HDV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The commercial availability of assays for the detection of HDV antibody (anti-HDV) has improved our understanding of the epidemiology of HDV infection. However, these assays have limitations in the diagnosis of HDV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link\">",
"     \"Diagnosis of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assay most readily available for the diagnosis of HDV infection detects total anti-HDV. In acute hepatitis D, anti-HDV appears very late and may be missed if repeated testing is not performed. Thus, the true incidence of acute hepatitis D may be underestimated. This is especially true in immunodeficient individuals (eg, anti-HIV-positive) in whom a strong antibody response to HDV may be delayed or absent. Furthermore, after resolution of acute hepatitis D, anti-HDV may disappear with time. Thus, recognition of past HDV infection may be impossible.",
"   </p>",
"   <p>",
"    Data on HDV epidemiology have mostly been gathered in chronic HBV carriers superinfected with HDV in whom HDV infection has progressed to chronicity. Anti-HDV is present in high titers in these patients, and the prevalence of chronic HDV infection can be reliably determined.",
"   </p>",
"   <p>",
"    Available data suggest that approximately 5 percent of the HBV carriers worldwide may be infected with HDV [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/31\">",
"     31",
"    </a>",
"    ]. Since the number of HBV carriers has been estimated to be around 300 million, the number of individuals infected with HDV worldwide is estimated to be 15 million. The geographical distribution of HDV infection, however, does not parallel that of HBV, as areas endemic for HBV may be almost HDV-free. The level of HDV endemicity is partly related to the route of transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     The Mediterranean basin",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDV infection is endemic in the Mediterranean basin. Infection tends to occur early, affecting mainly children and young adults. The main route of transmission is inapparent, permucosal, or percutaneous spread. Intrafamilial transmission is common and may be facilitated by poor hygiene. Thus, economically and socially disadvantaged populations are more affected.",
"   </p>",
"   <p>",
"    A study from Italy suggested that the prevalence of HDV infection has declined in the past two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/32\">",
"     32",
"    </a>",
"    ]. Anti-HDV antibodies were detected in only 69 of 834 HBsAg positive patients (8.3 percent) compared to 23 and 14 percent in studies from 1987 and 1992, respectively. The decrease resulted principally from a reduction in chronic HDV infection in young adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     The Far East",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of HDV infection among HBV carriers varies from 90 percent in the Pacific islands to 5 percent in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/31\">",
"     31",
"    </a>",
"    ]. HDV infection is not infrequent in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/33\">",
"     33",
"    </a>",
"    ], being predominantly transmitted sexually, but is rare in Hong Kong where it is largely confined to intravenous drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Western countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDV infection is uncommon in Western countries and predominantly confined to high-risk groups: intravenous drug addicts and multiply transfused individuals (eg, hemophiliacs). Interestingly, transmission of HDV among HBsAg-positive homosexuals is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in HDV epidemiological trends have occurred in recent years. These changes are most noticeable in Italy, a country which was endemic for HDV infection and where HDV was initially described. Improvements in socioeconomic conditions, an increased awareness of the risk of transmitting infectious diseases fostered by AIDS prevention policy, and aggressive vaccination campaigns against HBV have all contributed to a dramatic decrease in the incidence of HBV infection and the spread of HDV infection among young Italian adults until 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this decline appears to have stopped, and some recrudescence of HDV prevalence has been reported in both the Mediterranean area [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/36\">",
"     36",
"    </a>",
"    ] and in Central Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15543/abstract/37\">",
"     37",
"    </a>",
"    ]. Immigration from endemic countries has been suggested to be the cause for this trend, but is not the only reason: IVDU, sexual practices, and body modification procedures may also be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98309363\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HDV infection is closely associated with hepatitis B virus (HBV) infection. Although HDV can replicate autonomously, the simultaneous presence of HBV is required for complete virion assembly and secretion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to its dependence upon HBV, HDV infection always occurs in association with HBV infection. The clinical and laboratory findings vary with the type of infection (",
"      <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link\">",
"       \"Diagnosis of hepatitis D virus infection\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'HDV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical sequelae of HDV infection encompass a spectrum of manifestations from acute liver failure to the inactive carrier state. The severity of the clinical course is influenced by several factors. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Natural history of chronic hepatitis D'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HDV infection is endemic in the Mediterranean basin. Infection tends to occur early, affecting mainly children and young adults. The main route of transmission is inapparent, permucosal, or percutaneous spread. Intrafamilial transmission is common and may be facilitated by poor hygiene. Thus, economically and socially disadvantaged populations are more affected. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Epidemiology of HDV infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/1\">",
"      Bichko V, Netter HJ, Wu TT, Taylor J. Pathogenesis associated with replication of hepatitis delta virus. Infect Agents Dis 1994; 3:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/2\">",
"      Le Gal F, Gault E, Ripault MP, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006; 12:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/3\">",
"      Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996; 380:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/4\">",
"      Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 1986; 58:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/5\">",
"      Negro F, Korba BE, Forzani B, et al. Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks. J Virol 1989; 63:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/6\">",
"      Lo K, Hwang SB, Duncan R, et al. Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA. Virology 1998; 250:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/7\">",
"      Yamaguchi Y, Filipovska J, Yano K, et al. Stimulation of RNA polymerase II elongation by hepatitis delta antigen. Science 2001; 293:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/8\">",
"      Modahl LE, Macnaughton TB, Zhu N, et al. RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol 2000; 20:6030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/9\">",
"      Chang J, Nie X, Chang HE, et al. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol 2008; 82:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/10\">",
"      Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/11\">",
"      Caredda F, d'Arminio Monforte A, Rossi E, et al. Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res 1983; 143:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/12\">",
"      Smedile A, Dentico P, Zanetti A, et al. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 1981; 81:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/13\">",
"      Casey JL, Brown TL, Colan EJ, et al. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993; 90:9016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/14\">",
"      Tang JR, Hantz O, Vitvitski L, et al. Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic. J Gen Virol 1993; 74 ( Pt 9):1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/15\">",
"      Smedile A, Rosina F, Saracco G, et al. Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology 1991; 13:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/16\">",
"      Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/17\">",
"      Wu JC, Choo KB, Chen CM, et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995; 346:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/18\">",
"      Niro GA, Smedile A, Andriulli A, et al. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/19\">",
"      Wu JC, Huang IA, Huang YH, et al. Mixed genotypes infection with hepatitis D virus. J Med Virol 1999; 57:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/20\">",
"      Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/21\">",
"      Govindarajan S, De Cock KM, Redeker AG. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatology 1986; 6:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/22\">",
"      Bonino F, Negro F, Baldi M, et al. The natural history of chronic delta hepatitis. Prog Clin Biol Res 1987; 234:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/23\">",
"      Hadziyannis SJ, Papaioannou C, Alexopoulou A. The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece. Prog Clin Biol Res 1991; 364:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/24\">",
"      Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 117:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/25\">",
"      Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/26\">",
"      Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/27\">",
"      Hadler SC, Alcala de Monzon M, Rivero D, et al. Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol 1992; 136:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/28\">",
"      Popper H, Thung SN, Gerber MA, et al. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 1983; 3:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/29\">",
"      Bensabath G, Hadler SC, Soares MC, et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA 1987; 258:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/30\">",
"      D&eacute;ny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol 2006; 307:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/31\">",
"      Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res 1991; 364:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/32\">",
"      Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology 2000; 32:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/33\">",
"      Liaw YF, Chiu KW, Chu CM, et al. Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study. J Infect Dis 1990; 162:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/34\">",
"      Lok AS, Wong A, Sporton S, et al. Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. J Hepatol 1992; 14:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/35\">",
"      Weisfuse IB, Hadler SC, Fields HA, et al. Delta hepatitis in homosexual men in the United States. Hepatology 1989; 9:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/36\">",
"      Gaeta GB, Stroffolini T, Smedile A, et al. Hepatitis delta in Europe: vanishing or refreshing? Hepatology 2007; 46:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15543/abstract/37\">",
"      Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology 2007; 45:1331.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3666 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15543=[""].join("\n");
var outline_f15_11_15543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H98309363\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIRION STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HDV genome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hepatitis D antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lipoprotein envelope of HDV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HDV LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HDV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Superinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis of HDV-induced hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NATURAL HISTORY OF CHRONIC HEPATITIS D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genotype I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genotype II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genotype III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EPIDEMIOLOGY OF HDV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      The Mediterranean basin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      The Far East",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Western countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98309363\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3666|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/16/43279\" title=\"figure 1\">",
"      HDV virion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/58/43947\" title=\"table 1\">",
"      Diagnosis of hepatitis D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=related_link\">",
"      Diagnosis of hepatitis D virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_11_15544="Metoprolol: Pediatric drug information";
var content_f15_11_15544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metoprolol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"    see \"Metoprolol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/28/25030?source=see_link\">",
"    see \"Metoprolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lopressor&reg;;",
"     </li>",
"     <li>",
"      Toprol-XL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metoprolol (Type L&reg;);",
"     </li>",
"     <li>",
"      Apo-Metoprolol SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Metoprolol&reg;;",
"     </li>",
"     <li>",
"      Ava-Metoprolol;",
"     </li>",
"     <li>",
"      Ava-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Betaloc&reg;;",
"     </li>",
"     <li>",
"      Dom-Metoprolol-B;",
"     </li>",
"     <li>",
"      Dom-Metoprolol-L;",
"     </li>",
"     <li>",
"      JAMP-Metoprolol-L;",
"     </li>",
"     <li>",
"      Lopresor SR&reg;;",
"     </li>",
"     <li>",
"      Lopresor&reg;;",
"     </li>",
"     <li>",
"      Metoprolol Tartrate Injection, USP;",
"     </li>",
"     <li>",
"      Metoprolol-25;",
"     </li>",
"     <li>",
"      Metoprolol-L;",
"     </li>",
"     <li>",
"      Mylan-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Nu-Metop;",
"     </li>",
"     <li>",
"      PMS-Metoprolol-B;",
"     </li>",
"     <li>",
"      PMS-Metoprolol-L;",
"     </li>",
"     <li>",
"      Riva-Metoprolol-L;",
"     </li>",
"     <li>",
"      Sandoz-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Sandoz-Metoprolol SR;",
"     </li>",
"     <li>",
"      Teva-Metoprolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class II",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"      see \"Metoprolol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Hypertension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablets: Children and Adolescents 1-17 years: Initial: 1-2 mg/kg/day, administered in 2 divided doses; adjust dose based on patient response; maximum: 6 mg/kg/day (&le;200 mg/day) (National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablets: Manufacturer&rsquo;s recommendation: Children &ge;6 years: Initial: 1 mg/kg once daily (maximum initial dose: 50 mg/day); adjust dose based on patient response (maximum: 2 mg/kg/day or 200 mg/day; higher doses have not been studied)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release tablets: Initial: 100 mg/day in single or divided doses, increase at weekly intervals to desired effect; usual dosage range: 100-450 mg/day; doses &gt;450 mg/day have not been studied; usual dosage range (JNC 7): 50-100 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Lower once-daily dosing (especially 100 mg/day) may not control blood pressure for 24 hours; larger or more frequent dosing may be needed. Patients with bronchospastic diseases should receive the lowest possible daily dose; dose should initially be divided into 3 doses per day (to avoid high plasma concentrations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release tablets: Initial: 25-100 mg/day as a single dose; increase at weekly intervals to desired effect; doses &gt;400 mg/day have not been studied; usual dosage range (JNC 7): 50-100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Congestive heart failure: Adults: Extended release tablets: Initial: NYHA Class II heart failure: 25 mg once daily; more severe heart failure: 12.5 mg once daily; may double the dose every 2 weeks as tolerated; maximum: 200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tartrate: 1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lopressor&reg;: 1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tartrate [preservative free]: 1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lopressor&reg;: 50 mg, 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as succinate: 25 mg [expressed as mg equivalent to tartrate], 50 mg [expressed as mg equivalent to tartrate], 100 mg [expressed as mg equivalent to tartrate], 200 mg [expressed as mg equivalent to tartrate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toprol-XL&reg;: 25 mg, 50 mg, 100 mg, 200 mg [scored; expressed as mg equivalent to tartrate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metoprolol tartrate tablets: Administer with food or immediately after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metoprolol succinate extended release tablets: May be administered without regard to meals; Toprol-XL&reg; tablets are scored and may be divided; do not chew or crush the half or whole tablets; swallow whole. Do not chew, crush, or break generic nonscored extended release tablets; swallow whole.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab, alteplase, amiodarone, argatroban, bivalirudin, eptifibatide, meperidine, milrinone, morphine, procainamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, lidocaine, nitroglycerin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem, furosemide, heparin, nesiritide, nitroprusside.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     All formulations: Store at controlled room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Protect from moisture and dispense in tight, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets and injection: Treatment  of hypertension, alone or in combination with other agents (FDA approved in adults), angina pectoris (FDA approved in adults), and hemodynamically-stable acute myocardial infarction (to reduce cardiovascular mortality) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Extended release tablets: Treatment of hypertension, alone or in combination with other agents (FDA approved in ages &ge;6 years and adults); angina pectoris (FDA approved in adults); and patients with heart failure (stable NYHA Class II or III) already receiving ACE inhibitors, diuretics, and/or digoxin (to reduce mortality/hospitalization) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metoprolol has also been used for the treatment of ventricular arrhythmias, atrial ectopy; prevention and treatment of atrial fibrillation and atrial flutter; multifocal atrial tachycardia; symptomatic treatment of hypertrophic obstructive cardiomyopathy; essential tremor; and migraine headache  prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lopressor&reg; may be confused with Lyrica&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metoprolol may be confused with metaproterenol, metoclopramide, metolazone, misoprostol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metoprolol succinate may be confused with metoprolol tartrate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Toprol-XL&reg; may be confused with TEGretol&reg;, TEGretol&reg;-XR, Topamax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F195854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arterial insufficiency (usually Raynaud type), bradycardia, chest pain, CHF,  edema (peripheral), first-degree heart block (P-R interval &ge;0.26 sec), hypotension, palpitation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, fatigue, hallucination, headache, insomnia, memory loss (short-term), nightmares, sleep disturbances, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatology: Photosensitivity, pruritus, psoriasis exacerbated, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes exacerbated, libido decreased, Peyronie&rsquo;s disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, flatulence, gastrointestinal pain, heartburn, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Claudication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, rhinitis, shortness of breath, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alkaline phosphatase increased, alopecia (reversible), anxiety, arthralgia, arthritis, cardiogenic shock, diaphoresis increased, dry eyes, gangrene, hepatitis, HDL decreased, impotence, jaundice, lactate dehydrogenase increased, nervousness, paresthesia, retroperitoneal fibrosis, second-degree heart block, taste disturbance, third-degree heart block, thrombocytopenia, transaminases increased, triglycerides increased, urticaria, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Other events reported with beta-blockers: Catatonia, emotional lability, fever, hypersensitivity reactions, laryngospasm, nonthrombocytopenic purpura, respiratory distress, thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metoprolol, any component of the formulation, or other beta-blockers;",
"     <b>",
"      Note:",
"     </b>",
"     Additional contraindications are formulation and/or indication specific.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Immediate release tablets and injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     <b>",
"      Hypertension and angina:",
"     </b>",
"     Sinus bradycardia; second- and third-degree heart block; cardiogenic shock; overt cardiac failure; sick sinus syndrome (except in patients with a functioning artificial pacemaker); severe peripheral arterial disease; pheochromocytoma (without alpha blockade)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     <b>",
"      Myocardial infarction:",
"     </b>",
"     Severe sinus bradycardia (heart rate &lt;45 beats/minute); significant first-degree heart block (P-R interval &ge;0.24 seconds); second- and third-degree heart block; systolic blood pressure &lt;100 mm Hg; moderate-to-severe cardiac failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Extended release tablet:",
"     </b>",
"     Severe bradycardia; second- and third-degree heart block; cardiogenic shock; decompensated heart failure; sick sinus syndrome (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic dysfunction and in patients with peripheral vascular disease (beta-blockers may aggravate arterial insufficiency). Patients who have a history of severe anaphylactic hypersensitivity reactions to various substances may be more reactive while receiving beta-blockers; these patients may not be responsive to the normal doses of epinephrine used to treat hypersensitivity reactions. Contraindicated in patients with pheochromocytoma; if required, these patients should receive an alpha-blocking agent before receipt of any beta-blocking agent.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May depress myocardial activity and precipitate or worsen heart failure; use with caution and monitor closely, especially in patients with compensated heart failure and during upwards titration of dose; if heart failure worsens, may need to increase diuretics and not advance the dose of metoprolol; a reduction in dose or discontinuation of metoprolol may be needed. Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Beta-blockers should generally be avoided in patients with bronchospastic disease; metoprolol, with relative beta",
"     <sub>",
"      1",
"     </sub>",
"     selectivity, should be used with caution and closely monitored in patients with bronchospastic disease; beta",
"     <sub>",
"      2",
"     </sub>",
"     stimulants and the lowest possible dose of metoprolol should be used in these patients. Metoprolol may block hypoglycemia-induced tachycardia and blood pressure changes; use with caution in patients with diabetes mellitus. Metoprolol decreases the ability of the heart to respond to reflex adrenergic stimuli and may increase the risk of general anesthesia and surgical procedures. May mask clinical signs of hyperthyroidism (exacerbation of symptoms of hyperthyroidism, including thyroid storm, may occur following abrupt discontinuation). Use with caution with potent inhibitors of cytochrome P450 CYP2D6 isoenzyme. Use with caution with verapamil, diltiazem, or anesthetic agents that decrease myocardial function (bradycardia or heart block may occur). Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors: May increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metoprolol tartrate: Food may enhance the extent of oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metoprolol succinate (extended release tablets): Food does not significantly affect bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies; therefore, the manufacturer classifies metoprolol as pregnancy category C. Metoprolol crosses the placenta and can be detected in cord blood, amniotic fluid, and the serum of newborn infants. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The clearance of metoprolol is increased and serum concentrations and AUC of metoprolol are decreased during pregnancy. Metoprolol has been evaluated for the treatment of hypertension in pregnancy, but other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, respirations, circulation in extremities",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective inhibitor of beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors at lower doses; competitively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     adrenergic receptors with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors at doses in adults &lt;100 mg/day; inhibits beta",
"     <sub>",
"      2",
"     </sub>",
"     - receptors at higher doses; does not exhibit membrane stabilizing or intrinsic sympathomimetic activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Beta blockade:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Oral: Metoprolol tartrate tablets: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: I.V.: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Dose dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Oral: Metoprolol tartrate tablets: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: Oral (multiple dosing): After 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Oral: Metoprolol tartrate tablets (single dose): 6 hours; metoprolol succinate (extended release tablets): Up to 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The pharmacokinetics of metoprolol in hypertensive children 6-17 years of age were found to be similar to adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete, with large first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the blood brain barrier; CSF concentrations are 78% of plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 12% bound to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Significant first-pass metabolism; extensive metabolism in the liver via isoenzyme CYP2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-Life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 5-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: CYP2D6 poor metabolizers: 7.5 hours; CYP2D6 extensive metabolizers: 2.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with chronic renal failure: Similar to normal adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 10% of an I.V. dose and &lt;5% of an oral dose is excreted unchanged in the urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not abruptly discontinue therapy, taper dosage gradually over 1-2 weeks. Beta-blockers without intrinsic sympathomimetic activity (such as metoprolol) have been shown to decrease morbidity and mortality when initiated in the acute treatment of MI and continued long term; metoprolol injection is used for early treatment of definitive or suspected MI; consult adult reference for further information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A limited number of studies assessing the use of metoprolol in hypertensive pediatric patients are available. A recent article examined the use of metoprolol extended release tablets in children 6-16 years of age (mean age: 12.5 &plusmn; 2.8 years). In part one (a 4-week double-blind dose ranging study), patients were randomized to receive placebo (n=23) or metoprolol 0.2 mg/kg/day (n=45), 1 mg/kg/day (n=23), or 2 mg/kg/day (n=49) given as once daily dosing. For patients in the higher dosing groups, doses were initiated at 0.5 mg/kg/day, and increased after 1 week to 1 mg/kg/day if tolerated. Doses were increased again after 1 week to 2 mg/kg/day if tolerated in the 2 mg/kg/day dosing group. At the end of 4 weeks, metoprolol significantly decreased systolic blood pressure in the 1 mg/kg/day and 2 mg/kg/day groups compared to placebo. Diastolic blood pressure was significantly reduced only in the 2 mg/kg/day group. In part two (a 52-week open-label trial), 100 patients received initial doses of 25 mg or 12.5 mg once daily; doses were increased every 2 weeks in 25 mg or 50 mg increments based on blood pressure and tolerability, to a maximum dose of 200 mg once daily. The mean doses were 37 &plusmn; 33 mg at study entry, 97 &plusmn; 64 mg at week 16, and 112 &plusmn; 69 mg at study end (Batisky, 2007). In an older study using nonsustained release tablets, 16 hypertensive adolescents (&ge;13 years of age) were treated with an initial metoprolol dose of 50 mg twice daily; patients were seen every 4-6 weeks and doses were increased to 100 mg twice daily if blood pressure was not controlled (Falkner, 1982).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Pediatric dosing information for metoprolol, for use in indications other than hypertension, is also limited; in one case report, oral metoprolol (2 mg/kg/day in 3 divided doses) helped control paroxysmal supraventricular tachycardia in a 6-month old infant receiving digoxin (Hepner, 1983). Low dose oral metoprolol (initial: 0.1 mg/kg/dose given twice daily, then increased slowly as needed to a maximum of 0.9 &plusmn; 0.7 mg/kg/day) was used to treat severe CHF that failed conventional therapy in four children (mean age: 7.8 years) with cardiomyopathy who were under consideration for heart transplantation (Shaddy, 1998). A follow-up report in 15 children, 2.5-15 years of age (mean: 8.6 &plusmn; 1.3 years) used low dose oral metoprolol [Initial: 0.1-0.2 mg/kg/dose given twice daily, then increased slowly as needed to a maximum of 1.1 &plusmn; 0.1 mg/kg/day (range: 0.5-2.3 mg/kg/day)] to treat dilated cardiomyopathy and CHF; all patients received ACE inhibitors, digoxin, and diuretics before starting metoprolol (Shaddy, 1999). Two studies (Muller, 1993; O'Marcaigh, 1994) assessed metoprolol for unexplained syncope in children at I.V. doses of 0.1-0.2 mg/kg for tilt table testing; in both studies, oral metoprolol was given after tilt table testing to select patients; initial oral doses of 0.8-2.8 mg/kg/day were used in 15 patients (8-20 years of age), but treatment was discontinued in three patients receiving 1.8-2.8 mg/kg/day due to adverse effects (Muller, 1993); oral doses of 1-2 mg/kg/day, rounded to the nearest 25 mg/day and divided into 2 doses daily were used in 19 patients (7-18 years of age) with unexplained syncope; the mean effective dose was 1.5 mg/kg/day (O'Marcaigh, 1994). High-dose beta-blocker therapy has been recommended to treat childhood hypertrophic cardiomyopathy (Ostman-Smith, 1999). Further pediatric studies are required before these doses can be recommended.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F195773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral suspension may be made with metoprolol tartrate tablets and one of three different vehicles (cherry syrup; a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush twelve 100 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"protect from light\". Stable for 60 days.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Labetalol Hydrochloride, Metoprolol Tartrate, Verapamil Hydrochloride, and Spironolactone With Hydrochlorothiazide in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(19):2304-9.",
"     <span class=\"pubmed-id\">",
"      8893069",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batisky DL, Sorof JM, Sugg J, et al, \"Efficacy and Safety of Extended Release Metoprolol Succinate in Hypertensive Children 6 to 16 Years of Age: A Clinical Trial Experience,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2007, 150(2):134-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/17236889/pubmed\" id=\"17236889\" target=\"_blank\">",
"        17236889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, \"Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/12748199 /pubmed\" id=\"12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falkner B, Lowenthal DT, and Affrime MB, &ldquo;The Pharmacodynamic Effectiveness of Metoprolol in Adolescent Hypertension,&rdquo;",
"      <i>",
"       Pediatr Pharmacol (New York)",
"      </i>",
"      , 1982, 2(1):49-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/7110756 /pubmed\" id=\"7110756 \" target=\"_blank\">",
"        7110756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gold MH, Holy AK, and Roenigk HH Jr, \"Beta-Blocking Drugs and Psoriasis. A Review of Cutaneous Side Effects and Retrospective Analysis of Their Effects on Psoriasis,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1988, 19(5 Pt 1):837-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/2903871 /pubmed\" id=\"2903871 \" target=\"_blank\">",
"        2903871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hepner SI, and Davoli E, &ldquo;Successful Treatment of Supraventricular Tachycardia With Metoprolol, a Cardioselective Beta Blocker,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1983, 22(7):522-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/6851380/pubmed\" id=\"6851380\" target=\"_blank\">",
"        6851380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morselli PL, Boutroy MJ, Bianchetti G, et al, &ldquo;Pharmacokinetics of Antihypertensive Drugs in the Neonatal Period,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1989, 13(2-4):190-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/2693002/pubmed\" id=\"2693002\" target=\"_blank\">",
"        2693002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muller G, Deal BJ, Strasburger JF, et al, &ldquo;Usefulness of Metoprolol for Unexplained Syncope and Positive Response to Tilt Testing in Young Persons,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1993, 71(7):592-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/8438747/pubmed\" id=\"8438747\" target=\"_blank\">",
"        8438747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Marcaigh AS, MacLellan-Tobert SG, and Porter CJ, &ldquo;Tilt-Table Testing and Oral Metoprolol Therapy in Young Patients With Unexplained Syncope,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 93(2):278-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/8121741 /pubmed\" id=\"8121741 \" target=\"_blank\">",
"        8121741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostman-Smith I, Wettrell G, and Riesenfield T, &ldquo;A Cohort Study of Childhood Hypertrophic Cardiomyopathy: Improved Survival Following High-Dose Beta-Adrenoceptor Antagonist Treatment,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(6):1813-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/10577575/pubmed\" id=\"10577575\" target=\"_blank\">",
"        10577575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, \"Psoriasis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(18):1899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaddy RE, &ldquo;Beta-Blocker Therapy in Young Children With Congestive Heart Failure Under Consideration for Heart Transplantation,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1998, 136(1):19-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/9665213 /pubmed\" id=\"9665213 \" target=\"_blank\">",
"        9665213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaddy RE, Tani LY, Gidding SS, et al, &ldquo;Beta-Blocker Treatment of Dilated Cardiomyopathy With Congestive Heart Failure in Children: A Multi-Institutional Experience,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 1999, 18(3):269-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/11/15544/abstract-text/10328154 /pubmed\" id=\"10328154 \" target=\"_blank\">",
"        10328154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12605 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15544=[""].join("\n");
var outline_f15_11_15544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709042\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195796\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195797\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054023\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054017\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195767\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195752\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054027\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195855\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054020\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054026\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195857\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195854\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054032\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054016\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054015\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195842\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195761\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054035\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195763\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054022\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054014\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054030\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054031\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054033\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195773\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=related_link\">",
"      Metoprolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/28/25030?source=related_link\">",
"      Metoprolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_11_15545="Endotracheal tube management and complications";
var content_f15_11_15545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endotracheal tube management and complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Kristy A Bauman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15545/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/11/15545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of endotracheal tube (ETT) management is prevention of complications. However, adverse events occasionally occur despite proper management. Clinicians must be prepared to recognize and manage such complications.",
"   </p>",
"   <p>",
"    This topic reviews basic aspects of ETT management, including positioning, cuff pressure, and suctioning. Complications related to endotracheal intubation are also described. Tracheostomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30183736\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of the intubation procedure are common. In a series of over 3400 emergent intubations, the incidence of difficult intubation was 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/1\">",
"     1",
"    </a>",
"    ]. Airway-related complications occurred in four percent of the patients, which included aspiration, esophageal intubation, dental injury, and pneumothorax. Independent risk factors for complications from intubation included three or more intubation attempts, intubation on the general floor or in the emergency room, and a grade III or grade IV view of the airway (",
"    <a class=\"graphic graphic_figure graphicRef75229 \" href=\"UTD.htm?2/36/2626\">",
"     figure 1",
"    </a>",
"    ). Neuromuscular blockade was utilized in 73 percent of the intubations.",
"   </p>",
"   <p>",
"    An intubation care bundle may be useful in decreasing the rate of post-intubation complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/2\">",
"     2",
"    </a>",
"    ]. Such intervention bundles may require the presence of two operators, preoxygenation, intravascular volume loading (unless cardiogenic edema is present), rapid sequence technique, and capnography post placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orotracheal intubation is the most common method of inserting an ETT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/3\">",
"     3",
"    </a>",
"    ]. Nasotracheal intubation is also possible, but much less common. Regardless of whether orotracheal or nasotracheal intubation is performed, the method for evaluating the position of the ETT following intubation is the same:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insertion of the ETT into the airway (and not the esophagus) should be confirmed immediately after intubation using an end-tidal carbon dioxide (CO2) detector or an esophageal detection device [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/4\">",
"       4",
"      </a>",
"      ]. These devices provide the necessary information within seconds of the intubation attempt, allowing reintubation to be performed without delay if the ETT was inadvertently inserted into the esophagus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link&amp;anchor=H13#H13\">",
"       \"Rapid sequence intubation in adults\", section on 'Placement with proof'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link&amp;anchor=H5#H5\">",
"       \"Carbon dioxide monitoring (capnography)\", section on 'Verification of ETT placement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A portable chest radiograph is then performed to assess the position of the distal tip of the ETT. The preferred position is 2 to 6 cm above the carina (",
"      <a class=\"graphic graphic_figure graphicRef55694 \" href=\"UTD.htm?29/53/30559\">",
"       figure 2",
"      </a>",
"      ). Until the chest radiograph is performed, an appropriate insertion depth for orotracheal tubes is 21 cm for females and 23 cm for males (measured at the corner of the mouth). The distal tip of the ETT generally rests in the mid-trachea when these insertion depths are used. The ETT can then be adjusted as needed following a chest radiograph.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although useful as an initial assessment, physical examination is insufficient for determining whether an ETT is in the correct position. It should not be used as a substitute for either of the steps described above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. A randomized trial conducted using 160 consecutive patients undergoing elective surgery compared how accurate the following techniques are at determining the ETT&rsquo;s position: auscultation (ie, bilateral breath sounds), observation (ie, symmetry of the chest rising during inspiration), measuring the insertion depth, and a combination of all three techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/7\">",
"     7",
"    </a>",
"    ]. The combination of techniques detected all cases of endobronchial intubation. However, when considered independently, an insertion depth of 20 to 21 cm in women or 22 to 23 cm in men, auscultation, and observation detected endobronchial intubation in 88, 65, and 42 percent of cases, respectively. Inexperienced clinicians more frequently misjudged the position of the endotracheal tube using auscultation or observation than experienced clinicians.",
"   </p>",
"   <p>",
"    Once the position of the ETT has been optimized, it should be reassessed periodically because the ETT can migrate over time. ETT migration is an inevitable consequence of coughing, suctioning, and movement. Daily chest radiographs on mechanically ventilated patients (to check ETT position) are routine in many clinical centers; however, randomized trials indicate that a more restrictive approach (eg, chest radiographs only in response to a change in clinical condition) decreases the number of chest radiographs without worsening clinical outcomes, such as mortality, length of ICU stay, or duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When comparing the position of the distal tip of the ETT on different chest radiographs, the clinician should ensure that the position of the patient's head is similar on each radiograph because the position of the ETT will change with the head position. Specifically, neck flexion advances the endotracheal tube toward the carina, while neck extension moves the tube away from the carina (",
"    <a class=\"graphic graphic_figure graphicRef68470 \" href=\"UTD.htm?17/23/17776\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ETT malposition may manifest as a sizable airway leak. This is frequently misinterpreted as balloon rupture, leading to unnecessary ETT replacement. In a series of eighteen patients whose ETT was replaced due to a large airway leak, only 7 (38 percent) actually had a mechanical fault [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/13\">",
"     13",
"    </a>",
"    ]. Commercial tube holders have failed to demonstrate superiority over standard tape in preventing ETT migration or dislodgement resulting in unplanned extubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CUFF PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general guideline, the cuff pressure should be maintained between 18 and 25 mmHg. A cuff pressure above 18 mmHg will prevent an air leak (air escaping around the ETT cuff), will reduce aspiration around the cuff, and may decrease the rate of ventilator-associated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the cuff pressure should not exceed 25 mmHg or there may be increased risk of pressure necrosis at the site where the cuff contacts the tracheal mucosa.",
"   </p>",
"   <p>",
"    A higher minimum cuff pressure is required to prevent an air leak at higher peak airway pressures. One observational study found that a peak airway pressure greater than 48 cm H2O required a cuff pressure greater than 25 mmHg to prevent an air leak [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/15\">",
"     15",
"    </a>",
"    ]. A cuff pressure this high increases the risk of pressure necrosis. This illustrates the need to carefully balance the risk of an air leak versus the risk of pressure necrosis when setting the cuff pressure in patients with a high peak airway pressure.",
"   </p>",
"   <p>",
"    Special caution is necessary when a patient is transported to a different altitude. Cuff pressure will increase when the patient is moved to a higher altitude because air expands within the cuff. The change of cuff pressure can be large; in one study, it was estimated to be greater than 20 cm H2O when moved from sea level to a height of at least 3000 feet above sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ETT cuffs are categorized as being high volume, low pressure (HVLP) or low volume, low pressure (LVLP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     High volume, low pressure cuff",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ETTs used today have HVLP cuffs. Several unique ETTs have been developed, which use HVLP cuffs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ETT with an automatic HVLP cuff &ndash; This ETT contains a device that sets the cuff pressure. Cuff pressures derived in this fashion are generally lower than those established by clinicians, illustrating the tendency of clinicians to use too high of a cuff pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/17\">",
"       17",
"      </a>",
"      ]. This ETT has not become part of routine clinical care because it has not been shown to improve important clinical outcomes, such as the rate of ventilator-associated pneumonia (VAP), ICU mortality, or hospital mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ETT with an HVLP cuff and subglottic secretion drainage &ndash; This ETT was developed to reduce the incidence of VAP. Two randomized trials found that patients who used the ETT with an HVLP cuff and subglottic secretion drainage had a lower incidence of VAP than patients who used a traditional ETT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Despite these results, the routine use of this ETT cannot be recommended because it is possible that the efficacy was overestimated due to the high incidence of VAP in the trials. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link&amp;anchor=H13#H13\">",
"       \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Subglottic drainage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Low volume, low pressure cuff",
"    </span>",
"    &nbsp;&mdash;&nbsp;A LVLP cuff also exists, but its use is not widespread. The LVLP was evaluated in a randomized trial and a prospective cohort study, both of which were reported together [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the trial, 38 surgical patients were randomly assigned to receive a HVLP cuff or a LVLP cuff. The amount of dye that leaked from the subglottic space into the tracheobronchial tree was then assessed. Leakage was less frequent in the LVLP group (0 versus 22 percent).",
"     </li>",
"     <li>",
"      In the prospective cohort study, leakage of dye into the tracheobronchial tree during a swallowing study was evaluated in 67 patients with a tracheostomy. Fewer patients with a LVLP cuff had significant leakage of dye compared to a HVLP cuff (0 versus 49 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical trials measuring important clinical outcomes are necessary before the LVLP cuff replaces the HVLP cuff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUCTIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be suctioned using sterile technique, including a sealed system that minimizes nosocomial contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/22\">",
"     22",
"    </a>",
"    ]. The optimal frequency of suctioning depends on the quantity of secretions. The cross sectional area of the endotracheal tube will inevitably decrease over time because secretions and cellular debris collect within the lumen despite suctioning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are common during mechanical ventilation. Those adverse events that are directly attributable to the ETT are discussed in this section. Complications unrelated to the ETT that occur during mechanical ventilation (eg, ventilator-associated pneumonia, barotrauma) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laryngeal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for laryngeal injury that have been described include prolonged intubation (variably defined as &ge;36 hours to &ge;3 days), traumatic intubation, not using a myorelaxant drug during intubation, a large ETT (&gt;8 mm in men, &gt;7 mm in women), aspiration, and the presence of a nasogastric tube [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Although associated with the likelihood of laryngeal injury, the duration of intubation and the size of the endotracheal tube (including those with an additional suction port to evacuate retropharyngeal secretions) are not associated with the severity of the laryngeal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/28\">",
"     28",
"    </a>",
"    ]. Traumatic intubation may be related to abnormal laryngeal anatomy, difficult laryngoscopy, multiple attempts, or operator inexperience.",
"   </p>",
"   <p>",
"    Laryngeal injuries are more frequent in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/29\">",
"     29",
"    </a>",
"    ]. Most manifest as hoarseness following extubation, although severe injuries can cause stridor, respiratory failure, or both. The laryngeal injuries described below are generally diagnosed via laryngoscopy and heal spontaneously, unless otherwise noted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laryngeal edema &ndash; Laryngeal edema is detected after extubation in more than half of patients, even though subclinical laryngeal edema is common during intubation (",
"      <a class=\"graphic graphic_picture graphicRef70238 \" href=\"UTD.htm?33/31/34303\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/27,30\">",
"       27,30",
"      </a>",
"      ]. Laryngeal edema tends to be clinically significant only when vocal cord mobility is impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/27\">",
"       27",
"      </a>",
"      ]. Clinically significant laryngeal edema is uncommon, occurring in approximately 5 to 13 percent of patients and requiring reintubation in approximately 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/31\">",
"       31",
"      </a>",
"      ]. Glucocorticoid therapy prior to extubation is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link&amp;anchor=H6#H6\">",
"       \"Extubation management\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mucosal ulceration &ndash; Mucosal ulcerations usually occur along the posteromedial aspect of the vocal cords (",
"      <a class=\"graphic graphic_picture graphicRef51107 \" href=\"UTD.htm?37/2/37935\">",
"       picture 2",
"      </a>",
"      ). They are most common when endotracheal intubation lasts longer than four days and occur in about a third of patients (",
"      <a class=\"graphic graphic_figure graphicRef81347 \" href=\"UTD.htm?3/7/3184\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/27,30\">",
"       27,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Granulomas &ndash; Endotracheal intubation can induce laryngeal granuloma formation (",
"      <a class=\"graphic graphic_picture graphicRef50901 \" href=\"UTD.htm?32/59/33712\">",
"       picture 3",
"      </a>",
"      ). The duration of intubation and severity of initial laryngeal injury do not appear to predict granuloma formation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/32\">",
"       32",
"      </a>",
"      ]. Hoarseness that persists longer than 7 to 10 days following extubation may indicate the presence of a laryngeal granuloma and should prompt fiberoptic laryngoscopy. Laryngeal granulomas often require surgical removal.",
"     </li>",
"     <li>",
"      Vocal cord paralysis &ndash; Unilateral vocal cord paralysis typically manifests as hoarseness immediately after extubation and resolves over days to months. It is generally caused by compression of the anterior branch of the recurrent laryngeal nerve between the ETT cuff and the thyroid cartilage in the subglottic larynx [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/33\">",
"       33",
"      </a>",
"      ]. The injury prevents abduction (opening) of the ipsilateral vocal cord, which becomes fixed in the adducted (closed) position. Bilateral vocal cord injury is less common, but its clinical manifestations are more severe (eg, extubation failure). The risk of recurrent laryngeal nerve injury may be diminished by avoiding the following: an oversized ETT, an overinflated ETT cuff, and excessive ETT movement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laryngeal injury can cause extubation failure. In a case series of 136 patients, 12 percent of the patients exhibited extubation failure within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/27\">",
"     27",
"    </a>",
"    ]. Among these patients, 47 percent had stridor. However, only half of the patients with stridor required reintubation.",
"   </p>",
"   <p>",
"    Vocal cord edema that causes vocal cord immobility and granulation tissue are among the common types of laryngeal injury that lead to extubation failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/27\">",
"     27",
"    </a>",
"    ]. More rarely, extubation failure can be caused by the presence of an obstructive fibrinous tracheal pseudomembrane [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/34\">",
"     34",
"    </a>",
"    ]. In such cases, fiberoptic bronchoscopy reveals a thick, circular, rubber-like membrane adhering to the tracheal wall at the site of the endotracheal tube cuff (",
"    <a class=\"graphic graphic_picture graphicRef65016 \" href=\"UTD.htm?43/44/44751\">",
"     picture 4",
"    </a>",
"    ). Rigid bronchoscopy is usually required for the removal of the pseudomembrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Swallowing impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swallowing is abnormal following extubation in approximately half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], although clinically significant aspiration is much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/35\">",
"     35",
"    </a>",
"    ]. This was illustrated by a series of 254 patients who were intubated endotracheally for &gt;48 hours following cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/36\">",
"     36",
"    </a>",
"    ]. Fifty-one percent of the patients exhibited post-extubation dysphagia. Risk factors for post-extubation dysphagia included a prolonged duration of endotracheal intubation, perioperative cerebrovascular events, and perioperative sepsis. The cause of impaired swallowing following extubation is not well understood, but it usually resolves without intervention.",
"   </p>",
"   <p>",
"    Many clinicians do not allow patients who have been intubated for a prolonged duration to eat for approximately 24 hours following extubation. Others request a swallowing evaluation before allowing the patient to eat. There is little moderate or high quality evidence to support either practice. In one case series, only around a quarter of patients received adequate nutrition (defined as at least 75 percent of their predicted daily requirement) during the first week following extubation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/38\">",
"     38",
"    </a>",
"    ]. We believe that these findings are probably typical and that clinicians should be as concerned about adequate nutrition as they are the potential for aspiration in the post-extubation patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tracheal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal stenosis is caused by high ETT cuff pressure (",
"    <a class=\"graphic graphic_picture graphicRef62003 \" href=\"UTD.htm?36/45/37599\">",
"     picture 5",
"    </a>",
"    ). When the ETT cuff pressure exceeds the mean capillary pressure in the tracheal mucosa (approximately 20 cm H2O), obstruction of capillary blood flow causes inflammation and erosion of the mucosa. This leads to necrosis, destruction of the tracheal architecture, and scarring.",
"   </p>",
"   <p>",
"    Tracheal stenosis usually becomes symptomatic (eg, dyspnea) within five weeks after extubation. Pulmonary function testing may demonstrate upper airway obstruction. Definitive diagnosis requires bronchoscopy or laryngoscopy, although emerging data suggests that spiral computed tomography (CT) with virtual bronchoscopy may be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tracheal stenosis may require surgical resection, stenting, or an alternative intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tracheoesophageal fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formation of a tracheoesophageal fistula in an intubated patient is rare, but the consequences can be devastating (",
"    <a class=\"graphic graphic_picture graphicRef65016 \" href=\"UTD.htm?43/44/44751\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. As an example, patients may develop recurrent aspiration pneumonia, prolonging the duration of mechanical ventilation. High ETT cuff pressure is the dominant risk factor. Other risk factors include high airway pressures, excessive motion of the ETT, and prolonged duration of mechanical ventilation.",
"   </p>",
"   <p>",
"    Evaluation of a possible tracheoesophageal fistula generally involves an esophagram using water-soluble contrast, esophagoscopy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoscopy. Conservative care is indicated until the patient is stable enough to undergo surgical correction. This consists of positioning the ETT cuff distal to the fistula, elevating the head of the bed, and frequent suctioning. Insertion of a jejunostomy tube for feeding plus a gastrostomy tube to suction gastric contents may help reduce gastroesophageal reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ETT can impair sinus drainage, leading to collections of uninfected fluid within the sinuses. The appearance of these collections on most radiographic studies is described as sinus opacification. Infection of these sinus collections causes nosocomial sinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among all patients admitted to an intensive care unit (ICU), the cumulative incidence of nosocomial sinusitis appears to be approximately 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/42\">",
"     42",
"    </a>",
"    ]. The incidence is substantially higher among patients who are mechanically ventilated and have sinus opacification detected by computed tomography (CT). As many as 70 percent of such patients may develop nosocomial sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of nosocomial sinusitis is similar among patients who are nasotracheally intubated and those who are orotracheally intubated, although nasotracheally intubated patients are more susceptible to noninfectious sinus opacification [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The natural history of noninfectious sinus collections is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for nosocomial sinusitis include endotracheal intubation, nasal colonization with Gram negative organisms, and enteral feeding via a nasogastric tube (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/42\">",
"     42",
"    </a>",
"    ]. Sedation and a Glasgow coma score less than 7 may be additional risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nasal alpha-adrenergic agonist plus a nasal glucocorticoid may decrease the incidence of nosocomial sinusitis. In a clinical trial, 79 patients who were mechanically ventilated because of multiple traumas were randomly assigned to receive placebo or a nasal alpha-adrenergic agonist (xylometazoline) plus a nasal glucocorticoid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/45\">",
"     45",
"    </a>",
"    ]. The treatment group had a decrease in maxillary sinus opacification (54 versus 82 percent) and maxillary sinusitis (8 versus 20 percent). These differences were not statistically significant. However, they would be clinically significant if real, suggesting that the trial was underpowered. Larger controlled clinical trials are necessary before the approach is suggested for routine management of mechanically ventilated patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial sinusitis should be considered in all intubated patients who have a fever without an obvious source, especially if there is purulent nasal drainage. The evaluation begins with a radiographic evaluation looking for sinus opacification. CT is the preferred modality because it is more sensitive than plain radiographs, readily available, and easy to interpret [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sinus ultrasound can also detect sinus opacification, although expertise with this technique is not widespread. The sensitivity and specificity of sinus ultrasound for identifying sinus opacification is similar to CT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Sinus ultrasound has the advantage of being able to distinguish noninfectious sinus opacification from nosocomial sinusitis in some patients. In one observational study, 67 percent of patients whose posterior, internal, and external sinus walls could be visualized had nosocomial sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/47\">",
"     47",
"    </a>",
"    ]. Nosocomial sinusitis was less common among patients whose posterior sinus wall only could be visualized.",
"   </p>",
"   <p>",
"    Additional evaluation is indicated for patients who have sinus opacification. Culture of sinus fluid is the gold standard for diagnosing nosocomial sinusitis. Endoscopic-guided middle meatal aspiration is a well-tolerated method of obtaining sinus fluid, although other approaches exist (eg, maxillary aspiration). Secretions collected from the nares or oral cavity are unreliable.",
"   </p>",
"   <p>",
"    Quantitative culture of sinus fluid identifies a likely pathogen in 60 to 70 percent of patients who are strongly suspected of having nosocomial sinusitis (ie, have fever without an alternative cause, sinus opacification on CT, purulent nasal drainage) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/43,49,50\">",
"     43,49,50",
"    </a>",
"    ]. A common threshold used to declare a quantitative culture positive is 10(3) colony forming units",
"    <span class=\"nowrap\">",
"     (cfu)/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Diagnostic sampling is often bypassed and empiric therapy initiated instead. The rationale for empiric therapy is that sampling is invasive and inconvenient. However, this approach has several drawbacks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic therapy increases the likelihood that sinus cultures performed later will yield false negative results [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More than 30 percent of patients with radiographic sinus opacification have a noninfectious fluid collection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/43\">",
"       43",
"      </a>",
"      ]. Thus, many patients are subjected to inappropriate therapy and the unnecessary risk of side effects with this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the significant drawbacks of empiric therapy, diagnostic sampling is suggested for patients who have sinus opacification plus an unexplained fever despite conservative management. This includes removal of tubes from the nose (ie, replacing a nasogastric tube with an orogastric tube) and nasal decongestants.",
"   </p>",
"   <p>",
"    All patients with nosocomial sinusitis should be assessed for the concurrent ventilator-associated pneumonia (VAP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogens that cause nosocomial sinusitis are similar to those that cause VAP or hospital-acquired pneumonia: Staphylococcus aureus, Streptococcus species, Pseudomonas species, and other gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/42,44,51,52\">",
"     42,44,51,52",
"    </a>",
"    ]. Gram-negative bacilli may be responsible for approximately half of cases of nosocomial sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaerobic bacteria and yeast (especially Candida albicans) have also been cultured from sinus aspirates of patients with nosocomial sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/53\">",
"     53",
"    </a>",
"    ]. However, it is uncertain how often the anaerobic bacteria are pathogens rather than oral contaminants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nosocomial sinusitis caused by Staphylococcus aureus, Pseudomonas aeruginosa, or Acinetobacter baumannii appears more likely to progress to VAP, compared to nosocomial sinusitis caused by other pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy should target pathogens identified by the sinus fluid culture. When therapy is empiric or the culture data are ambiguous, initial antimicrobial therapy should target common nosocomial pathogens. This approach is virtually identical to choosing an initial antibiotic regimen for VAP, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Empiric treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial therapy may not be sufficient for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients who do not improve with antimicrobial therapy or who develop nosocomial sinusitis while receiving antimicrobial therapy may require sinus drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Biofilm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria enmeshed in an antibiotic-resistant biofilm can adhere to the inner surface of the ETT within hours of intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/23\">",
"     23",
"    </a>",
"    ]. This biofilm narrows the lumen of the ETT and may contribute to both VAP and ventilator-associated tracheobronchitis. Its potential role in the development of VAP and ventilator-associated tracheobronchitis is supported by several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identical organisms are isolated from the ETT biofilm and tracheal secretions more frequently in patients with VAP than in those without VAP [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Silver-coated endotracheal tubes decrease both biofilm development [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/57-59\">",
"       57-59",
"      </a>",
"      ] and the incidence of VAP. The latter was demonstrated by the North American Silver-Coated Endotracheal Tube (NASCENT) trial, which randomly assigned 2003 patients to undergo mechanical ventilation with either a silver-coated ETT or a standard ETT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/60\">",
"       60",
"      </a>",
"      ]. The rate of VAP was lower among those using the silver-coated ETT (4.8 versus 7.5 percent). The silver-coated ETT was also associated with delayed occurrence of VAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link&amp;anchor=H14#H14\">",
"       \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Silver-coated endotracheal tube'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tracheobronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilator-associated tracheobronchitis (VAT, also called nosocomial tracheobronchitis) may be an intermediate condition between lower respiratory tract colonization and ventilator-associated pneumonia. Although there is no consensus definition, VAT is generally considered present if the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (&gt;38&ordm;C)",
"     </li>",
"     <li>",
"      No other recognizable cause of fever",
"     </li>",
"     <li>",
"      New or increased sputum production",
"     </li>",
"     <li>",
"      Positive culture of tracheal aspirates",
"     </li>",
"     <li>",
"      No radiographic infiltrate or evidence of pneumonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The estimated incidence of VAT ranges from 1.4 to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. Commonly implicated bacteria include Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii. Multidrug resistant bacteria and polymicrobial infections also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical importance of VAT was illustrated by a prospective cohort study that included 1889 patients who were mechanically ventilated for more than 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/64\">",
"     64",
"    </a>",
"    ]. VAT developed in 11 percent of patients. It was associated with a longer duration of mechanical ventilation (24 versus 9 days) and an increased length of ICU stay (32 versus 13 days) when compared to cases without VAT. Mortality was increased among patients who developed VAT (36 versus 32), a difference that narrowly missed reaching statistical significance (p = 0.051). Patients with VAT did not have an increased risk of VAP.",
"   </p>",
"   <p>",
"    The clinical importance of VAT may be similar to VAP. This was suggested by a prospective cohort study of 28 patients with VAT and 83 patients with VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/65\">",
"     65",
"    </a>",
"    ]. When directly compared, the groups had a similar length of ICU stay and hospital stay, duration of mechanical ventilation, survival rate to discharge, need for tracheostomy, and need for antibiotics.",
"   </p>",
"   <p>",
"    Additional evidence that VAT is clinically important is the finding that treatment improves clinical outcomes. A trial randomly assigned 58 patients with VAT to receive intravenous antibiotics or placebo for eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/67\">",
"     67",
"    </a>",
"    ]. VAT was defined by the criteria described above, plus an endotracheal aspirate culture of &gt;1,000,000 colony forming units",
"    <span class=\"nowrap\">",
"     (cfu)/mL.",
"    </span>",
"    Serial endotracheal aspirates facilitated targeted antibiotic therapy. The patients who received antibiotic therapy had significantly fewer episodes of ventilator-associated pneumonia (13 versus 47 percent), reduced ICU mortality (18 versus 47 percent), and more ventilator-free days. There was no difference in the duration of mechanical ventilation or the length of ICU stay.",
"   </p>",
"   <p>",
"    Aerosolized antibiotics may expedite the resolution of clinical signs of VAT, according to one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15545/abstract/68\">",
"     68",
"    </a>",
"    ]. Despite these results, the value of aerosolized antibiotics is best considered unproven since most of the patients enrolled in the trial also had pneumonia.",
"   </p>",
"   <p>",
"    The management of VAT is virtually identical to the management of ventilator-associated pneumonia, which is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positioning the endotracheal tube (ETT) after intubation is a two-step process. Insertion of the ETT into the airway is confirmed immediately after intubation using an end-tidal carbon dioxide detector or an esophageal detection device. Then, a portable chest radiograph is performed to assess the location of the distal tip of the ETT. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the position of the ETT is optimized, it should be evaluated periodically because the ETT can migrate over time. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest as-needed chest radiographs, rather than routine daily chest radiographs, for most patients in the ICU (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As a general guideline, cuff pressure should be maintained above 18 mmHg to prevent an air leak (air escaping around the ETT cuff) and reduce aspiration around the cuff. However, the cuff pressure should not exceed 25 mmHg or there may be increased risk of pressure necrosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cuff pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be suctioned using sterile technique, including a sealed system that minimizes nosocomial contamination. The optimal frequency of suctioning depends on the quantity of secretions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Suctioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications are common during mechanical ventilation. Adverse events that are directly attributable to the ETT include laryngeal injury (eg, laryngeal edema, vocal cord dysfunction), swallowing impairment, tracheal stenosis, tracheoesophageal fistula, sinusitis, and biofilm formation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/1\">",
"      Martin LD, Mhyre JM, Shanks AM, et al. 3,423 emergency tracheal intubations at a university hospital: airway outcomes and complications. Anesthesiology 2011; 114:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/2\">",
"      Jaber S, Jung B, Corne P, et al. An intervention to decrease complications related to endotracheal intubation in the intensive care unit: a prospective, multiple-center study. Intensive Care Med 2010; 36:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/3\">",
"      Esteban A, Anzueto A, Al&iacute;a I, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 2000; 161:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/4\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/5\">",
"      Gray P, Sullivan G, Ostryzniuk P, et al. Value of postprocedural chest radiographs in the adult intensive care unit. Crit Care Med 1992; 20:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/6\">",
"      Lotano R, Gerber D, Aseron C, et al. Utility of postintubation chest radiographs in the intensive care unit. Crit Care 2000; 4:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/7\">",
"      Sitzwohl C, Langheinrich A, Schober A, et al. Endobronchial intubation detected by insertion depth of endotracheal tube, bilateral auscultation, or observation of chest movements: randomised trial. BMJ 2010; 341:c5943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/8\">",
"      Krivopal M, Shlobin OA, Schwartzstein RM. Utility of daily routine portable chest radiographs in mechanically ventilated patients in the medical ICU. Chest 2003; 123:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/9\">",
"      Hejblum G, Chalumeau-Lemoine L, Ioos V, et al. Comparison of routine and on-demand prescription of chest radiographs in mechanically ventilated adults: a multicentre, cluster-randomised, two-period crossover study. Lancet 2009; 374:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/10\">",
"      Olufolabi AJ, Charlton GA, Spargo PM. Effect of head posture on tracheal tube position in children. Anaesthesia 2004; 59:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/11\">",
"      Hartrey R, Kestin IG. Movement of oral and nasal tracheal tubes as a result of changes in head and neck position. Anaesthesia 1995; 50:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/12\">",
"      Yap SJ, Morris RW, Pybus DA. Alterations in endotracheal tube position during general anaesthesia. Anaesth Intensive Care 1994; 22:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/13\">",
"      Kearl RA, Hooper RG. Massive airway leaks: an analysis of the role of endotracheal tubes. Crit Care Med 1993; 21:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/14\">",
"      Rello J, So&ntilde;ora R, Jubert P, et al. Pneumonia in intubated patients: role of respiratory airway care. Am J Respir Crit Care Med 1996; 154:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/15\">",
"      Guyton DC, Barlow MR, Besselievre TR. Influence of airway pressure on minimum occlusive endotracheal tube cuff pressure. Crit Care Med 1997; 25:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/16\">",
"      Henning J, Sharley P, Young R. Pressures within air-filled tracheal cuffs at altitude--an in vivo study. Anaesthesia 2004; 59:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/17\">",
"      Efrati S, Leonov Y, Oron A, et al. Optimization of endotracheal tube cuff filling by continuous upper airway carbon dioxide monitoring. Anesth Analg 2005; 101:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/18\">",
"      Valencia M, Ferrer M, Farre R, et al. Automatic control of tracheal tube cuff pressure in ventilated patients in semirecumbent position: a randomized trial. Crit Care Med 2007; 35:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/19\">",
"      Lorente L, Lecuona M, Jim&eacute;nez A, et al. Influence of an endotracheal tube with polyurethane cuff and subglottic secretion drainage on pneumonia. Am J Respir Crit Care Med 2007; 176:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/20\">",
"      Bouza E, P&eacute;rez MJ, Mu&ntilde;oz P, et al. Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. Chest 2008; 134:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/21\">",
"      Young PJ, Pakeerathan S, Blunt MC, Subramanya S. A low-volume, low-pressure tracheal tube cuff reduces pulmonary aspiration. Crit Care Med 2006; 34:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/22\">",
"      Combes P, Fauvage B, Oleyer C. Nosocomial pneumonia in mechanically ventilated patients, a prospective randomised evaluation of the Stericath closed suctioning system. Intensive Care Med 2000; 26:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/23\">",
"      Shah C, Kollef MH. Endotracheal tube intraluminal volume loss among mechanically ventilated patients. Crit Care Med 2004; 32:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/24\">",
"      Glass C, Grap MJ, Sessler CN. Endotracheal tube narrowing after closed-system suctioning: prevalence and risk factors. Am J Crit Care 1999; 8:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/25\">",
"      Friedman M, Baim H, Shelton V, et al. Laryngeal injuries secondary to nasogastric tubes. Ann Otol Rhinol Laryngol 1981; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/26\">",
"      Santos PM, Afrassiabi A, Weymuller EA Jr. Risk factors associated with prolonged intubation and laryngeal injury. Otolaryngol Head Neck Surg 1994; 111:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/27\">",
"      Tadi&eacute; JM, Behm E, Lecuyer L, et al. Post-intubation laryngeal injuries and extubation failure: a fiberoptic endoscopic study. Intensive Care Med 2010; 36:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/28\">",
"      Colton House J, Noordzij JP, Murgia B, Langmore S. Laryngeal injury from prolonged intubation: a prospective analysis of contributing factors. Laryngoscope 2011; 121:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/29\">",
"      Stone DJ, Bogdonoff DL. Airway considerations in the management of patients requiring long-term endotracheal intubation. Anesth Analg 1992; 74:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/30\">",
"      Colice GL, Stukel TA, Dain B. Laryngeal complications of prolonged intubation. Chest 1989; 96:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/31\">",
"      Darmon JY, Rauss A, Dreyfuss D, et al. Evaluation of risk factors for laryngeal edema after tracheal extubation in adults and its prevention by dexamethasone. A placebo-controlled, double-blind, multicenter study. Anesthesiology 1992; 77:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/32\">",
"      Colice GL. Resolution of laryngeal injury following translaryngeal intubation. Am Rev Respir Dis 1992; 145:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/33\">",
"      Weber S. Traumatic complications of airway management. Anesthesiol Clin North America 2002; 20:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/34\">",
"      Lins M, Dobbeleir I, Germonpr&eacute; P, et al. Postextubation obstructive pseudomembranes: a case series and review of a rare complication after endotracheal intubation. Lung 2011; 189:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/35\">",
"      Barquist E, Brown M, Cohn S, et al. Postextubation fiberoptic endoscopic evaluation of swallowing after prolonged endotracheal intubation: a randomized, prospective trial. Crit Care Med 2001; 29:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/36\">",
"      Barker J, Martino R, Reichardt B, et al. Incidence and impact of dysphagia in patients receiving prolonged endotracheal intubation after cardiac surgery. Can J Surg 2009; 52:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/37\">",
"      Skoretz SA, Flowers HL, Martino R. The incidence of dysphagia following endotracheal intubation: a systematic review. Chest 2010; 137:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/38\">",
"      Peterson SJ, Tsai AA, Scala CM, et al. Adequacy of oral intake in critically ill patients 1 week after extubation. J Am Diet Assoc 2010; 110:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/39\">",
"      Taha MS, Mostafa BE, Fahmy M, et al. Spiral CT virtual bronchoscopy with multiplanar reformatting in the evaluation of post-intubation tracheal stenosis: comparison between endoscopic, radiological and surgical findings. Eur Arch Otorhinolaryngol 2009; 266:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/40\">",
"      Payne DK, Anderson WM, Romero MD, et al. Tracheoesophageal fistula formation in intubated patients. Risk factors and treatment with high-frequency jet ventilation. Chest 1990; 98:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/41\">",
"      Harley HR. Ulcerative tracheo-oesophageal fistula during treatment by tracheostomy and intermittent positive pressure ventilation. Thorax 1972; 27:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/42\">",
"      George DL, Falk PS, Umberto Meduri G, et al. Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study. Clin Infect Dis 1998; 27:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/43\">",
"      Holzapfel L, Chevret S, Madinier G, et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. Crit Care Med 1993; 21:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/44\">",
"      Rouby JJ, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med 1994; 150:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/45\">",
"      Pneumatikos I, Konstantonis D, Tsagaris I, et al. Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. Intensive Care Med 2006; 32:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/46\">",
"      Heffner JE. Nosocomial sinusitis. Den of multiresistant thieves? Am J Respir Crit Care Med 1994; 150:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/47\">",
"      Vargas F, Bui HN, Boyer A, et al. Transnasal puncture based on echographic sinusitis evidence in mechanically ventilated patients with suspicion of nosocomial maxillary sinusitis. Intensive Care Med 2006; 32:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/48\">",
"      Hilbert G, Vargas F, Valentino R, et al. Comparison of B-mode ultrasound and computed tomography in the diagnosis of maxillary sinusitis in mechanically ventilated patients. Crit Care Med 2001; 29:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/49\">",
"      Souweine B, Mom T, Traore O, et al. Ventilator-associated sinusitis: microbiological results of sinus aspirates in patients on antibiotics. Anesthesiology 2000; 93:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/50\">",
"      Casiano RR, Cohn S, Villasuso E 3rd, et al. Comparison of antral tap with endoscopically directed nasal culture. Laryngoscope 2001; 111:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/51\">",
"      Talmor M, Li P, Barie PS. Acute paranasal sinusitis in critically ill patients: guidelines for prevention, diagnosis, and treatment. Clin Infect Dis 1997; 25:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/52\">",
"      Westergren V, Lundblad L, Hellquist HB, Forsum U. Ventilator-associated sinusitis: a review. Clin Infect Dis 1998; 27:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/53\">",
"      Le Moal G, Lemerre D, Grollier G, et al. Nosocomial sinusitis with isolation of anaerobic bacteria in ICU patients. Intensive Care Med 1999; 25:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/54\">",
"      Geiss HK. Nosocomial sinusitis. Intensive Care Med 1999; 25:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/55\">",
"      Bert F, Lambert-Zechovsky N. Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/56\">",
"      Adair CG, Gorman SP, Feron BM, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 1999; 25:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/57\">",
"      Olson ME, Harmon BG, Kollef MH. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest 2002; 121:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/58\">",
"      Berra L, De Marchi L, Yu ZX, et al. Endotracheal tubes coated with antiseptics decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology 2004; 100:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/59\">",
"      Rello J, Kollef M, Diaz E, et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med 2006; 34:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/60\">",
"      Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008; 300:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/61\">",
"      Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/62\">",
"      Kampf G, Wischnewski N, Schulgen G, et al. Prevalence and risk factors for nosocomial lower respiratory tract infections in German hospitals. J Clin Epidemiol 1998; 51:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/63\">",
"      Rello J, Ausina V, Castella J, et al. Nosocomial respiratory tract infections in multiple trauma patients. Influence of level of consciousness with implications for therapy. Chest 1992; 102:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/64\">",
"      Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002; 20:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/65\">",
"      Dallas J, Skrupky L, Abebe N, et al. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011; 139:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/66\">",
"      Nseir S, Di Pompeo C, Soubrier S, et al. Outcomes of ventilated COPD patients with nosocomial tracheobronchitis: a case-control study. Infection 2004; 32:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/67\">",
"      Nseir S, Favory R, Jozefowicz E, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 2008; 12:R62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15545/abstract/68\">",
"      Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008; 36:2008.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1644 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-8B005171DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15545=[""].join("\n");
var outline_f15_11_15545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30183736\">",
"      COMPLICATIONS OF INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CUFF PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      High volume, low pressure cuff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Low volume, low pressure cuff",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUCTIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laryngeal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Swallowing impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tracheal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Biofilm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tracheobronchitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1644|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/36/2626\" title=\"figure 1\">",
"      Modified Mallampati airway classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/53/30559\" title=\"figure 2\">",
"      Endotracheal tube positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/23/17776\" title=\"figure 3\">",
"      Endotrach tube neck movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/7/3184\" title=\"figure 4\">",
"      Vocal cord injury intubation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1644|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/31/34303\" title=\"picture 1\">",
"      Vocal cord edema Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/2/37935\" title=\"picture 2\">",
"      Ischemic ulceration Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/59/33712\" title=\"picture 3\">",
"      Airway granulomas Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/44/44751\" title=\"picture 4\">",
"      TE fistula Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/45/37599\" title=\"picture 5\">",
"      Tracheal stenosis Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=related_link\">",
"      Extubation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_11_15546="Intracytoplasmic sperm injection";
var content_f15_11_15546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracytoplasmic sperm injection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15546/contributors\">",
"     Kathleen Miller, BCTS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15546/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/11/15546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/11/15546/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/11/15546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracytoplasmic sperm injection (ICSI) refers to a technique in which a single sperm is injected directly into the cytoplasm of a mature oocyte. This procedure is performed as part of an in vitro fertilization (IVF) cycle, and provides an effective method for assisting fertilization in men with suboptimal semen parameters or who experienced no or low fertilization rates after conventional IVF.",
"   </p>",
"   <p>",
"    Initial strategies for assisting fertilization in vitro attempted to reduce fertilization barriers by circumventing the zona pellucida. Partial zona dissection (PZD) was the first of these micromanipulation techniques; the procedure involved breaking the zona pellucida mechanically or chemically and then exposing the manipulated oocyte to conventional in vitro insemination protocols. Subzonal insertion (SUZI) improved upon the basics of PZD, whereby 3 to 20 motile spermatozoa were injected through the zona pellucida directly into the perivitelline space of the oocyte. However, results with both PZD and SUZI were disappointing; fertilization rates were low and associated with oocyte damage and high polyspermia rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICSI was first applied to human gametes in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/4\">",
"     4",
"    </a>",
"    ]; the first pregnancies were reported in Belgium in 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/5\">",
"     5",
"    </a>",
"    ]. This technique has consistently demonstrated higher fertilization rates than PZD and SUZI, and produced more embryos with higher implantation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. The capacity of ICSI to permit almost any type of spermatozoa to fertilize oocytes has made it the most successful treatment for male factor infertility. In 2008, IVF with ICSI comprised 64.3 percent of ART procedures in the United States, IVF without ICSI comprised 35.5 percent; GIFT, ZIFT, or a combination of procedures accounted for the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of ICSI in the United States has increased dramatically since 1995, without a proportionate increase in diagnosis of male-factor infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/9\">",
"     9",
"    </a>",
"    ]. The use of ICSI for male factor infertility increased from 84 percent in 2003 to 87 percent in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/10\">",
"     10",
"    </a>",
"    ]. Worldwide, there is geographic variation in the use of ICSI with IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICSI was first used in cases of fertilization failure after standard IVF or when few sperm cells were available. The indications for use of ICSI in conjunction with IVF have been extended to couples with obstructive and non-obstructive azoospermia in whom immature spermatozoa are surgically retrieved from epididymis or testis, IVF cycles in which preimplantation genetic diagnosis is performed, and HIV discordant couples in order to minimize oocyte exposure to multiple spermatozoa. Fertilization rates of up to 80 percent and clinical pregnancy rates of up to 45 percent are observed with ICSI, thus reducing the use of adoption or donor sperm insemination in couples with male infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other treatments for male infertility are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough evaluation of the male patient, including semen analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], sperm morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/15\">",
"     15",
"    </a>",
"    ], and urology consultation is warranted. Although controversial, some authorities also utilize additional tests such as sperm antibody testing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/16\">",
"     16",
"    </a>",
"    ], and a wide spectrum of spermatozoa function tests ranging from, but not limited to, hamster-spermatozoa penetration assay, hemi-zona assay, mannose binding assay, hypo-osmotic swelling test, and acrosome reaction assay [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/17-22\">",
"     17-22",
"    </a>",
"    ] for identifying couples at risk for reduced or no fertilization with conventional IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/15,23-27\">",
"     15,23-27",
"    </a>",
"    ]. In males with severe oligospermia or azoospermia, additional testing may be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common genetic factors associated with male infertility are cystic fibrosis gene mutations (associated with congenital absence of the vas deferens), structural chromosomal abnormalities (eg, aneuploidy, inversion, translocation) associated with impaired testicular function, and Y chromosome microdeletions (associated with impaired spermatogenesis). Cystic fibrosis is associated with a mutation of the cystic fibrosis transmembrane conductance regulator gene. Men who carry this gene may not have the classic clinical manifestations of cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link&amp;anchor=H37#H37\">",
"     \"Causes of male infertility\", section on 'Abnormalities of the vas deferens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Structural chromosomal abnormalities in peripheral lymphocytes are observed in 10 to 15 percent of azoospermic men, 5 percent of oligospermic men, and less than 1 percent of normospermic men [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/28\">",
"     28",
"    </a>",
"    ]. The partners of these men are at increased risk of miscarriage and progeny are at increased risk of congenital anomalies.",
"   </p>",
"   <p>",
"    Detectable microdeletions of the Y chromosome are found by polymerase chain reaction in 10 to 15 percent of men with azoospermia or severe oligospermia. This is probably an underestimate since microdeletions that are nondetectable by current techniques likely exist. Sons of men with microdeletions will inherit the microdeletion and thus be at risk for infertility. The genetics of male infertility is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link&amp;anchor=H17#H17\">",
"     \"Causes of male infertility\", section on 'Autosomal and X chromosome defects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link&amp;anchor=H18#H18\">",
"     \"Causes of male infertility\", section on 'Y chromosome and related defects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some guidelines recommend systematically screening men with azoospermia or severe oligozoospermia for chromosomal abnormalities, including Y chromosome microdeletions, which may be present in lymphocytes or detected only in sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/29\">",
"     29",
"    </a>",
"    ]. Affected men are counseled about the risk of inherited spermatogenesis failure in male offspring and options such as sex selection and preimplantation genetic diagnosis. The American Society of Reproductive Medicine (ASRM) recommends that karyotyping be offered to men who have nonobstructive azoospermia or severe oligozoospermia (defined as less than 5 to 10 million",
"    <span class=\"nowrap\">",
"     sperm/mL)",
"    </span>",
"    prior to performing ICSI with their sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/28\">",
"     28",
"    </a>",
"    ]. Neither the definition of severe oligozoospermia nor the recommendation for screening severely oligozoospermic men is consistent worldwide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICSI is indicated for treatment of male factor infertility and selected types of female infertility, such as some morphologic anomalies of oocytes, limited quantities of oocytes, and anomalies of the zona pellucida [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/30\">",
"     30",
"    </a>",
"    ]. It is also used in couples with previous poor fertilization or polyspermy during an IVF cycle, or previous failed IVF cycles, and if preimplantation genetic diagnosis is planned for single gene defects.",
"   </p>",
"   <p>",
"    ICSI is indicated for male factor infertility when success with standard IVF regimens is considered unlikely because of [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/13,26,30-32\">",
"     13,26,30-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 2 million motile spermatozoa per ejaculate",
"     </li>",
"     <li>",
"      Antisperm antibodies thought to be causing infertility",
"     </li>",
"     <li>",
"      Prior or repeated fertilization failure with standard IVF protocols",
"     </li>",
"     <li>",
"      Frozen sperm limited in number and quality",
"     </li>",
"     <li>",
"      Obstruction of the male reproductive tract not amenable to repair",
"     </li>",
"     <li>",
"      Abnormal sperm morphology greater than 95 percent",
"     </li>",
"     <li>",
"      Specific spermatozoa defects impairing spermatozoa-oocyte interaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ICSI has also been successful in men with nonmosaic Klinefelter syndrome or long-standing azoospermia after chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/33\">",
"     33",
"    </a>",
"    ]; in these cases, spermatozoa are obtained from testicular biopsies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential indications for ICSI include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV discordant couples (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39865?source=see_link\">",
"       \"Use of assisted reproduction in HIV and hepatitis infected couples\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IVF involving preimplantation genetic diagnosis, in vitro matured oocytes, or previously cryopreserved oocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4279802\">",
"    <span class=\"h2\">",
"     ICSI versus standard IVF for treatment of infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review including only one trial comparing ICSI with IVF in couples",
"    <strong>",
"     without",
"    </strong>",
"    male infertility factors found no significant difference in pregnancy rates for these treatment approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/34\">",
"     34",
"    </a>",
"    ]. A similar systematic review in couples",
"    <strong>",
"     with",
"    </strong>",
"    moderate male infertility found that the overall fertilization rate was significantly higher after ICSI than after standard IVF (RR 1.9, 95% CI 1.4 to 2.5; nine trials), but suggested that similar fertilization rates could be achieved if high insemination concentration IVF were used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/35\">",
"     35",
"    </a>",
"    ]. Pregnancy rates were not reported. Thus, high insemination IVF appears to be a reasonable option in patients with moderate (not severe) male factor infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87588284\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICSI is unlikely to improve clinical pregnancy rates in couples with unexplained infertility or low oocyte yield and advanced maternal age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPERM RETRIEVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm are typically retrieved from ejaculated semen. Surgical retrieval of spermatozoa from the testicles or reproductive tract in combination with ICSI is an effective treatment for men with obstructive or nonobstructive azoospermia, ejaculatory dysfunction, or complications from cancer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/36\">",
"     36",
"    </a>",
"    ]. Limited microsurgical skills are needed to retrieve epididymal sperm microsurgically (microsurgical epididymal sperm aspiration [MESA]) or percutaneously (PESA), or to obtain testicular sperm from biopsy (testicular sperm extraction [TESE]) or fine-needle aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. TESE has been successful in obtaining sperm in over 50 percent of patients with nonobstructive azoospermia, including patients with Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Sperm retrieval rates are higher in Klinefelter syndrome patients with serum testosterone near the reference range (&gt;250",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient evidence to recommend any one sperm retrieval technique over another [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/42\">",
"     42",
"    </a>",
"    ]. In terms of sperm source, the fertilization, pregnancy, and live birth rates are equivalent with testicular or epididymal sperm retrieval in men with obstructive azoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/43\">",
"     43",
"    </a>",
"    ]; however, epididymal aspiration is preferred, when possible, because of a lower risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sperm can be obtained from testicular tissue even in cases of spermatogenic arrest or Sertoli cells only syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/37\">",
"     37",
"    </a>",
"    ]. Repeated surgical retrieval of spermatozoa can be avoided by standard cryopreservation if sufficient numbers of spermatozoa are obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/36,45\">",
"     36,45",
"    </a>",
"    ], or by cryopreservation in an empty human zona pellucida if only very few or even single spermatozoon are available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/46\">",
"     46",
"    </a>",
"    ]. Although live births of healthy newborns have been achieved, there are important genetic implications of these procedures. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Pregnancy and Pediatric Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The fertilization rate after ICSI with testicular spermatozoa in nonobstructive azoospermia is significantly lower than in obstructive azoospermia, but pregnancy and embryo implantation rates appear to be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. The clinical pregnancy rate of the partners of vasectomized men who have undergone TESE followed by ICSI appears to be reduced relative to men with obstructive azoospermia from other etiologies (9 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/50\">",
"     50",
"    </a>",
"    ]. This reduction in pregnancy rate was observed when the vasectomy occurred &ge;10 years prior to sperm retrieval and may be related to poorer sperm quality remote from vasectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The quality of post-vasectomy sperm may be compromised such that they are less capable of achieving a pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPERMATOZOA SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spermatozoa preparation skills and the ability to select a normal viable spermatozoa for injection are important factors in the success of ICSI. They play a key role because the direct injection of spermatozoa into the oocyte bypasses natural selection, thus it could inadvertently introduce a defective paternal genome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/53\">",
"     53",
"    </a>",
"    ]. If the spermatozoa used for ICSI have outwardly normal morphology and motility, the probability of fertilization and subsequent embryo development is almost guaranteed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Motility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired motility is the semen parameter most associated with a reduction in ICSI fertilization rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Since the human embryo derives its centriolar apparatus and mitotic potential from the spermatozoa, the use of spermatozoa with a damaged or abnormal centriole could result in embryos with severe cleavage arrest or irregular cleavage patterns. Immotile spermatozoa and poorly motile spermatozoa with no forward progression are more likely to have defective centrosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of spermatozoa from density gradients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/60\">",
"     60",
"    </a>",
"    ] and treatment with 2-deoxyadenosine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    to stimulate spermatozoa motility have been used to identify live spermatozoa in semen with variable motility [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/6,61\">",
"     6,61",
"    </a>",
"    ]. If spermatozoa remain immotile after treatment and processing, Eosin-Nigrosin staining is beneficial in determining viability of the spermatozoa preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/13\">",
"     13",
"    </a>",
"    ] and the hypo-osmotic swelling test can be used as a means to select viable spermatozoa from an immobile population at the time of ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sperm DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developing methods to identify, select, and isolate sperm with undamaged DNA is important since high levels of DNA damage in spermatozoa are associated with fertilization impairment and failure of embryo development after ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Selecting spermatozoa based on fine morphological assessments (eg, normal nuclear material) may enhance embryo survival and pregnancy outcome in couples with male infertility for whom ICSI with unselected sperm injection has failed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Zona pellucida binding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of sperm for ICSI by the hyaluronic acid binding method is based on the relationship between sperm receptors for zona pellucida and hyaluronic acid and the ability of competent mature sperm to attach themselves to hyaluronic acid through specific receptors found on the sperm plasma membrane. Sperm with diminished-maturity, increased levels of chromosomal aberrations, or failed spermatogenetic membrane remodeling, will not bind to hyaluronic acid. Embryologists select sperm by choosing the most morphologically normal looking sperm by eye or by nuclear features detected by specialized microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/67\">",
"     67",
"    </a>",
"    ]. The selection of sperm bound to hyaluronic acid for ICSI may facilitate the selection of individual mature sperm with low levels of chromosomal aneuploidies and thus lower rates of miscarriage after ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique for ICSI involves the use of sophisticated instruments and requires a trained embryologist [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/70\">",
"     70",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Policies/procedures",
"    </span>",
"    should protect gametes from temperature and pH variations and fluctuations, which may disrupt spindles and contribute to abnormal chromosome distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Microscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inverted microscope with high quality optics (eg, Nomarski or Hoffman) should be used for the most accurate visualization of gametes and microtools, thereby decreasing oocyte damage while optimizing fertilization rates. A sophisticated heated optical system, such as polarization microscopy, can be used to monitor spindle position during injection and reduce spindle damage during the ICSI procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. The inverted microscope should be located on an antivibration table in a quiet area of the lab and be fitted with at least a stage warmer, high precision micromanipulators, and microsyringe injection systems operated hydraulically by air or oil [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Micromanipulators offer the capability to manipulate gametes with precise movements at microscopic levels. Fabrication of microtools requires a microforge, pipette puller and microgrinder, although most laboratories purchase high quality precision ready-made microtools from different manufacturers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Oocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oocytes are obtained from the female partner in the same manner as in conventional IVF procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .) Several studies have suggested that factors such as maternal age and oocyte quality and quantity have a greater impact upon ICSI success than the severity of semen abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/56,77,78\">",
"     56,77,78",
"    </a>",
"    ]. Oocytes derived from poor quality stimulations (poor responders, hyperresponders) or exhibiting cytoplasmic abnormalities demonstrate higher degeneration rates, abnormal fertilization rates, and pregnancy loss rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oocytes are denuded of cumulus-coronal cells by exposure to hyaluronidase, and residual cells are gently aspirated with a finely pulled pipette. Excessive exposure to hyaluronidase or aggressive manipulation of oocytes to remove cells may parthenogenetically activate oocytes or reposition the first polar body [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. The oocytes are graded morphologically and only oocytes at metaphase II exhibiting a distinct extruded first polar body are used for injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An injection pipette containing an immobilized spermatozoon is gently pushed through the zona pellucida and through the oolemma into the center of the oocyte. The spermatozoa should be delivered with the smallest possible amount of medium. Negative pressure is then used to break the oolemma, followed by gentle aspiration of the cytoplasm. The effects of different methods of depositing sperm, breaking the oolemma, and aspirating cytoplasm for oocyte activation on fertilization and embryo development rates are an active area of investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. Laser-assisted ICSI is an innovative approach that has been used in patients with a history of poor ICSI outcome and with limited metaphase II oocytes. This technique is less traumatic to the oocytes during the ICSI procedure and has resulted in improved fertilization rates and embryo quality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new ICSI injection technology using piezo-driven pipettes has been successfully applied in a number of mammalian species [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/89\">",
"     89",
"    </a>",
"    ]. Damage to the oocyte is greatly reduced because the injector uses ultrasonic cutting forces, rather than piercing forces, to penetrate the oolemma, thus there is almost no deformation of the oocyte during the injection. This technique results in comparably high survival and success rates.",
"   </p>",
"   <p>",
"    After injection, the oocytes are cultured according to standard laboratory protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FERTILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fertilization rate following ICSI is approximately 50 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/6,31\">",
"     6,31",
"    </a>",
"    ]. Although ICSI does not guarantee fertilization, the incidence of complete fertilization failure is low and usually occurs in cycles with low oocyte yield [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure of fertilization is typically not due to nonplacement or ejection of the spermatozoa from the oocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/86,87,90,91\">",
"     86,87,90,91",
"    </a>",
"    ]. It may be caused by the failure of the oocytes to undergo activation, which is usually related to poor oocyte quality or sperm nonviability. Cytoplasmic maturation and fertilization rates can be enhanced by extending the oocyte preincubation time after retrieval and prior to ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/92\">",
"     92",
"    </a>",
"    ], by assisted oocyte activation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/93-95\">",
"     93-95",
"    </a>",
"    ], and by avoiding use of fresh ejaculates with globozoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/96\">",
"     96",
"    </a>",
"    ] or no motility [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/54\">",
"     54",
"    </a>",
"    ], and testicular sperm with no or partial motility. The fertilization procedure can cause oocyte damage and degeneration in 8 to 20 percent of procedures; each laboratory should analyze their rate to determine if technical or stimulation problems exist [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/79-81,87\">",
"     79-81,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICSI outcomes are also highly dependent upon the technical expertise of the embryologist [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pronucleus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of pronuclear formation after ICSI is necessary to distinguish and separate abnormally fertilized oocytes from normally fertilized oocytes, which possess two pronuclei, male and female, and extruded first and second polar bodies. Timing of pronuclear assessment may need to be altered since pronuclear formation may be advanced in ICSI fertilized oocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Polyspermia should not be an issue since only one spermatozoon is introduced into the oocyte during injection.",
"   </p>",
"   <p>",
"    Monospermic digynic (tripronuclear) and single pronucleate oocytes may occur more frequently with ICSI. For this reason, verification of the number of polar bodies at the time of fertilization assessment is essential. Tripronuclear oocytes with one polar body result from the nonextrusion of the second polar body and may be a consequence of damage or disruption to the spindle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/72,84,99,100\">",
"     72,84,99,100",
"    </a>",
"    ]. Pronuclear oocytes are not the result of asynchronous pronuclear development, but rather a failure of sperm to decondense fully and form the male pronucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any abnormally fertilized oocyte derived from ICSI should be discarded and not considered for embryo transfer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EMBRYO QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When embryo gross morphology and grades were assessed after ICSI, precompaction embryo quality did not seem to be adversely affected by the injection procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. However, precompaction embryonic implantation rates for ICSI-derived embryos are lower than embryos derived from conventional in vitro insemination, which suggests ICSI-derived embryos have a diminished implantation potential [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/83,104\">",
"     83,104",
"    </a>",
"    ]. This diminished potential may be due to paternal factors or the invasive nature of the ICSI technique. It does not typically manifest until late cleavage, compaction, or blastocyst stage of development [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/53,71-73,84,104\">",
"     53,71-73,84,104",
"    </a>",
"    ]. Therefore, blastocyst rather than cleavage-stage transfer may enhance embryo selection.",
"   </p>",
"   <p>",
"    Male factor infertility significantly reduces blastocyst production; it is not clear whether this is caused by the paternal genome or the ICSI technique [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/104-109\">",
"     104-109",
"    </a>",
"    ]. In one study, the insemination method had no impact on blastocyst production, indicating that the ICSI technique was not responsible for the decreased blastocyst production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/108\">",
"     108",
"    </a>",
"    ]. Data from several other studies have shown that blastocyst formation was significantly decreased in embryos derived from ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/104,110\">",
"     104,110",
"    </a>",
"    ]. Although production of blastocysts appears to be negatively affected by paternal or ICSI factors, most studies demonstrated equivalent pregnancy and implantation rates between blastocysts derived from ICSI and those from conventional insemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CRYOPRESERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies suggested a negative impact of ICSI upon cryosurvival, implantation, and ongoing pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/111-114\">",
"     111-114",
"    </a>",
"    ]; however, subsequent data from well-established programs have shown cryopreserved embryo survival (greater than 70 percent) and implantation potential (greater than 10 percent) can be highly successful regardless of the origin of sperm, method of insemination, or cryopreservation stage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/115-118\">",
"     115-118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the impact of ICSI upon cryosurvival and implantation potential of blastocysts derived from ICSI insemination. Due to the high fertilization rates and number of supernumerary embryos generated by ICSI, close attention needs to be paid to the efficacy of cryopreserving ICSI-derived embryos.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258813\">",
"    <span class=\"h1\">",
"     PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study offered chorionic villus sampling (CVS) or amniocentesis to all pregnancies after ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/119\">",
"     119",
"    </a>",
"    ]. ICSI patients had a significantly higher rate of inherited structural karyotype anomalies (1.4 versus 0.3 to 0.4 percent in prenatal tests in the general population; P &lt;0.001), which appeared to be related to a higher rate of l chromosomal anomalies in the fathers. There was no evidence of a higher risk of post-zygotic events leading to a higher proportion of chromosomal mosaicism from the ICSI procedure. Given these findings, couples should be informed of the risk of an abnormal fetal karyotype due to paternally inherited chromosomal abnormalities, the relatively benign phenotype of some of these chromosomal anomalies, and the risks associated with invasive prenatal diagnostic procedures so that they may make an informed choice about prenatal testing.",
"   </p>",
"   <p>",
"    Alternatively, if pretreatment genetic screening was performed to identify men with chromosomal abnormalities, then affected men could be counseled about the risks in their offspring and unaffected men could be reassured. Abnormalities of the Y chromosome would only affect male offspring; these couples could be offered options such as sex selection, preimplantation genetic diagnosis, or prenatal diagnosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H27\">",
"     'Chromosomal abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As discussed above, sons of men with microdeletions will inherit the microdeletion and thus be at risk for infertility. Patients should be counseled about this risk. Microdeletions are not identified on routine assessment of fetal karyotype. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREGNANCY AND PEDIATRIC OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICSI outcome can be viewed in terms of pregnancy rate and complications, neonatal status, and long-term physical and developmental issues. Potential risks accrue from iatrogenic, rather than natural, selection of the oocyte and sperm and technical concerns relating to the procedure itself (eg, injection of contaminants, disruption of the ooplasm, dysregulation of normal genetic processes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pregnancy and delivery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pregnancy rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In well-established centers, 30 percent of ICSI cycles result in a live birth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/31\">",
"     31",
"    </a>",
"    ], irrespective of sperm origin or count [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/34,120\">",
"     34,120",
"    </a>",
"    ]. ICSI outcomes do not differ substantially from those of conventional IVF cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. However, in all maternal age groups, the rate of live birth per egg retrieval appears to be slightly higher for IVF without ICSI (retrievals that resulted in live births 2007: IVF 33.3 percent versus 32.5 percent with ICSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10309766\">",
"    <span class=\"h3\">",
"     Monochorionic twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICSI appears to increase the risk of monochorionic placentation, particularly when combined with blastocyst transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/124-126\">",
"     124-126",
"    </a>",
"    ]. Moreover, there are two case reports of dizygotic twins with monochorionic placentation; both involved ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. The mechanism has not been explained, but may have been related to the procedure. The splitting of the inner cell mass caused by the artificial opening induced by the ICSI procedure has been proposed as a mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1771738384\">",
"    <span class=\"h3\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An in-depth discussion of the outcome of pregnancies conceived through IVF with or without ICSI can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .) Selected issues specific to ICSI are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pediatric issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Overall outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children conceived via ICSI have been followed for up to age 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Psychological outcomes, pubertal staging, neurological examination, and rates of",
"    <span class=\"nowrap\">",
"     surgery/hospitalization/remedial",
"    </span>",
"    therapy were similar for ICSI children and those conceived spontaneously. Physical and developmental health at age 5.5 years of age appear to be comparable to that of naturally conceived children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Congenital malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no more than a small increase in risk of major malformations in ICSI conceived children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/120,129,133,134\">",
"     120,129,133,134",
"    </a>",
"    ]. The best documented concern is for an increased risk of hypospadias and imprinting disorders, but the evidence is still inadequate to conclude that such a relationship exists. More reliable data are needed. Both study and control children should be examined in the same way and at the same age by blinded examiners using the same definitions of",
"    <span class=\"nowrap\">",
"     major/minor",
"    </span>",
"    birth defects and the data should be corrected for confounders, such as maternal age, plurality, and chromosomal abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link&amp;anchor=H17#H17\">",
"     \"Pregnancy outcome after assisted reproductive technology\", section on 'Congenital anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258644\">",
"    <span class=\"h3\">",
"     Imprinting disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a possibility that ICSI interferes with genomic imprinting during germ cell development and preimplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. In reports describing three cases of Angelman syndrome after ICSI, epigenetic defects were detected with loss of methylation of the maternal allele [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. However, the baseline risk of an imprinting disorder such as Angelman syndrome is low (less than",
"    <span class=\"nowrap\">",
"     1/100,000),",
"    </span>",
"    so any small increase in risk still results in only rare occurrences of the disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link&amp;anchor=H20#H20\">",
"     \"Pregnancy outcome after assisted reproductive technology\", section on 'Imprinting disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Chromosomal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the ICSI procedure itself or using sperm from subfertile men may increase the potential to transmit genetic or chromosomal abnormalities to offspring created from ICSI technology [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/135,140-142\">",
"     135,140-142",
"    </a>",
"    ]. These concerns have been validated as both de novo sex and autosomal chromosome aberrations appear to increase after ICSI.",
"   </p>",
"   <p>",
"    Subfertile men (and women) are more likely than fertile men to have chromosomal abnormalities (eg, aneuploidies, structural abnormalities, gene mutations, microdeletions) that may contribute to their subfertility and may be passed to their offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/29,143-146\">",
"     29,143-146",
"    </a>",
"    ]. These abnormalities may be confined to the sperm, or they may be autosomal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/147\">",
"     147",
"    </a>",
"    ]. One large series described 25 de-novo chromosomal abnormalities (10 of the sex chromosome, 15 autosomal) and 22 inherited chromosomal abnormalities among 1586 fetuses who underwent prenatal diagnosis (mean maternal age was 33.5 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/119\">",
"     119",
"    </a>",
"    ]. This represented a significantly increased rate of de-novo chromosomal anomalies in ICSI offspring (1.6 versus 0.5 percent in controls), and was related mainly to a higher number of sex chromosomal anomalies and partly to a higher number of autosomal structural anomalies. In addition, 17 of the 22 inherited chromosomal anomalies were paternally derived [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/148\">",
"     148",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"     \"Causes of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cystic fibrosis mutations are consistently associated with congenital absence of the vas deferens",
"    <span class=\"nowrap\">",
"     (&Delta;F508,",
"    </span>",
"    R1 17H, 5Tvar, 7Tvar). If ICSI is performed because of azoospermia due to congenital bilateral absence or atrophy of the vas deferens, the couple should be offered genetic counseling to discuss testing for cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/142\">",
"     142",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=see_link\">",
"     \"Cystic fibrosis: Prenatal genetic screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1771738481\">",
"    <span class=\"h3\">",
"     Sex ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The male-to-female ratio appears to be about 10 percent higher after IVF than after ICSI, but this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link&amp;anchor=H1750985980#H1750985980\">",
"     \"Pregnancy outcome after assisted reproductive technology\", section on 'Sex ratio at birth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether ICSI performed with nonejaculated sperm affects the sex of offspring. In two series, there was no significant difference in the ratio of male:female offspring when children from the total ICSI population were compared to children from ICSI pregnancies resulting from nonejaculated sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. In another series, the male:female ratio was significantly lower for children born after use of nonejaculated sperm (0.89) compared with conventional IVF (1.11), but did not differ significantly when compared with ICSI with ejaculated sperm (0.94) and natural conception (1.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/11/15546/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracytoplasmic sperm injection (ICSI) is indicated for treatment of male factor infertility and selected types of female infertility. It is also used in couples with previous poor fertilization or polyspermy during a conventional in vitro fertilization (IVF) cycle, or previous failed IVF cycles and if preimplantation genetic diagnosis is used to ensure absence of extraneous DNA from other sperm. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest offering men with azoospermia or severe oligozoospermia screening for chromosomal abnormalities, including Y chromosome microdeletions. If ICSI is performed because of azoospermia due to congenital bilateral absence or atrophy of the vas deferens, the couple should be offered genetic counseling to discuss testing for cystic fibrosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In well-established centers, 30 percent of ICSI cycles result in a live birth, irrespective of sperm origin or count. ICSI outcomes do not differ substantially from those of conventional IVF cycles. However, in all maternal age groups, the rate of live birth per egg retrieval appears to be slightly higher for IVF without ICSI. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pregnancy and Pediatric Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ICSI appears to increase the risk of monochorionic placentation and may lower the male-to-female sex ratio. ICSI may also interfere with genomic imprinting during germ cell development and preimplantation. (See",
"      <a class=\"local\" href=\"#H10309766\">",
"       'Monochorionic twins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H258644\">",
"       'Imprinting disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1771738481\">",
"       'Sex ratio'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/1\">",
"      Cohen J, Alikani M, Malter HE, et al. Partial zona dissection or subzonal sperm insertion: microsurgical fertilization alternatives based on evaluation of sperm and embryo morphology. Fertil Steril 1991; 56:696.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen J. A review of clinical microsurgical fertilization. In: Micromanipulation of Human Gametes and Embryos, Cohen J, Malter HE, Talansky BF (Eds), Raven Press, New York 1992. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/3\">",
"      Cohen, J, Adler, A, Alikani, M, et al. Assisted fertilization and abnormal sperm function. Semin Reprod Endocrinol 1993; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/4\">",
"      Lanzendorf SE, Maloney MK, Veeck LL, et al. A preclinical evaluation of pronuclear formation by microinjection of human spermatozoa into human oocytes. Fertil Steril 1988; 49:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/5\">",
"      Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992; 340:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/6\">",
"      Wada I, Macnamee M, Brinsden P. Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993; 8:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/7\">",
"      Van Steirteghem AC, Liu J, Joris H, et al. Higher success rate by intracytoplasmic sperm injection than by subzonal insemination. Report of a second series of 300 consecutive treatment cycles. Hum Reprod 1993; 8:1055.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/art/ART2008/PDF/ART_2008_Full.pdf (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/9\">",
"      Jain T, Gupta RS. Trends in the use of intracytoplasmic sperm injection in the United States. N Engl J Med 2007; 357:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/10\">",
"      Shridharani A, Sandlow JI. Vasectomy reversal versus IVF with sperm retrieval: which is better? Curr Opin Urol 2010; 20:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/11\">",
"      Nyboe Andersen A, Carlsen E, Loft A. Trends in the use of intracytoplasmatic sperm injection marked variability between countries. Hum Reprod Update 2008; 14:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/12\">",
"      Palermo GD, Neri QV, Takeuchi T, Rosenwaks Z. ICSI: where we have been and where we are going. Semin Reprod Med 2009; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, WHO Laboratory Manual for Examination of Human Semen and Semen-Cervical Mucus Interaction, Cambridge University Press, Cambridge 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/14\">",
"      Menkveld R, Wong WY, Lombard CJ, et al. Semen parameters, including WHO and strict criteria morphology, in a fertile and subfertile population: an effort towards standardization of in-vivo thresholds. Hum Reprod 2001; 16:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/15\">",
"      Kruger TF, Acosta AA, Simmons KF, et al. Predictive value of abnormal sperm morphology in in vitro fertilization. Fertil Steril 1988; 49:112.",
"     </a>",
"    </li>",
"    <li>",
"     Clarke, GN. Detection of antisperm antibodies using Immunobeads, In: Handbook of the Laboratory Diagnosis and Treatment of Infertility, Keel, BA, Webster, BW (Eds), CRC, Boca Raton, Florida 1990. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/17\">",
"      Overstreet JW, Yanagimachi R, Katz DF, et al. Penetration of human spermatozoa into the human zona pellucida and the zona-free hamster egg: a study of fertile donors and infertile patients. Fertil Steril 1980; 33:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/18\">",
"      Oehninger S, Coddington CC, Scott R, et al. Hemizona assay: assessment of sperm dysfunction and prediction of in vitro fertilization outcome. Fertil Steril 1989; 51:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/19\">",
"      Benoff S, Cooper GW, Hurley I, et al. Human sperm fertilizing potential in vitro is correlated with differential expression of a head-specific mannose-ligand receptor. Fertil Steril 1993; 59:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/20\">",
"      Barratt CL, Osborn JC, Harrison PE, et al. The hypo-osmotic swelling test and the sperm mucus penetration test in determining fertilization of the human oocyte. Hum Reprod 1989; 4:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/21\">",
"      Liu DY, Baker HW. Acrosome status and morphology of human spermatozoa bound to the zona pellucida and oolemma determined using oocytes that failed to fertilize in vitro. Hum Reprod 1994; 9:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/22\">",
"      Freeman MR, Archibong AE, Mrotek JJ, et al. Male partner screening before in vitro fertilization: preselecting patients who require intracytoplasmic sperm injection with the sperm penetration assay. Fertil Steril 2001; 76:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/23\">",
"      Jeulin C, Feneux D, Serres C, et al. Sperm factors related to failure of human in-vitro fertilization. J Reprod Fertil 1986; 76:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/24\">",
"      Liu DY, Baker HW. Tests of human sperm function and fertilization in vitro. Fertil Steril 1992; 58:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/25\">",
"      Mortimer D. The essential partnership between diagnostic andrology and modern assisted reproductive technologies. Hum Reprod 1994; 9:1209.",
"     </a>",
"    </li>",
"    <li>",
"     Baker, G, Lui, DY, Bourne, H. Assessment of the male and preparation of sperm for ARTs. In: Handbook of in vitro Fertilization, 2nd ed, Trounson, AO, Gardner, DK (Eds), CRC Press 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/27\">",
"      Liu DY, Garrett C, Baker HW. Clinical application of sperm-oocyte interaction tests in in vitro fertilization--embryo transfer and intracytoplasmic sperm injection programs. Fertil Steril 2004; 82:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/28\">",
"      Male Infertility Best Practice Policy Committee of the American Urological Association, Practice Committee of the American Society for Reproductive Medicine. Report on optimal evaluation of the infertile male. Fertil Steril 2006; 86:S202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/29\">",
"      Kurinczuk JJ. Safety issues in assisted reproduction technology. From theory to reality--just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? Hum Reprod 2003; 18:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/30\">",
"      Practice Committee of American Society for Reproductive Medicine. Intracytoplasmic sperm injection (ICSI). Fertil Steril 2008; 90:S187.",
"     </a>",
"    </li>",
"    <li>",
"     American Society for Reproductive Medicine., Intracystoplasmic sperm injection. (www.asrm.org/Patients/FactSheets/ICSI-Fact.pdf (Accessed 3/7/05)).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/32\">",
"      Practice Committees of the American Society for Reproductive Medicine and Society for Assisted Reproductive Technology. Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion. Fertil Steril 2012; 98:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/33\">",
"      Damani MN, Master V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol 2002; 20:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/34\">",
"      van Rumste MM, Evers JL, Farquhar CM. Intra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in patients with non-male subfertility. Cochrane Database Syst Rev 2003; :CD001301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/35\">",
"      Tournaye H, Verheyen G, Albano C, et al. Intracytoplasmic sperm injection versus in vitro fertilization: a randomized controlled trial and a meta-analysis of the literature. Fertil Steril 2002; 78:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/36\">",
"      Silber SJ, Van Steirteghem AC, Liu J, et al. High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy. Hum Reprod 1995; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/37\">",
"      Silber SJ, Nagy Z, Liu J, et al. The use of epididymal and testicular spermatozoa for intracytoplasmic sperm injection: the genetic implications for male infertility. Hum Reprod 1995; 10:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/38\">",
"      Watkins W, Nieto F, Bourne H, et al. Testicular and epididymal sperm in a microinjection program: methods of retrieval and results. Fertil Steril 1997; 67:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/39\">",
"      Schiff JD, Palermo GD, Veeck LL, et al. Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab 2005; 90:6263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/40\">",
"      Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med 2009; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/41\">",
"      Ramasamy R, Ricci JA, Palermo GD, et al. Successful fertility treatment for Klinefelter's syndrome. J Urol 2009; 182:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/42\">",
"      Van Perperstraten AM, Proctor ML, Phillipson G, Johnson NP. Techniques for surgical retrieval of sperm prior to ICSI for azoospermia. Cochrane Database Syst Rev 2001; :CD002807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/43\">",
"      Nicopoullos JD, Gilling-Smith C, Almeida PA, et al. Use of surgical sperm retrieval in azoospermic men: a meta-analysis. Fertil Steril 2004; 82:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/44\">",
"      Manning M, J&uuml;nemann KP, Alken P. Decrease in testosterone blood concentrations after testicular sperm extraction for intracytoplasmic sperm injection in azoospermic men. Lancet 1998; 352:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/45\">",
"      Fischer R, Baukloh V, Naether OG, et al. Pregnancy after intracytoplasmic sperm injection of spermatozoa extracted from frozen-thawed testicular biopsy. Hum Reprod 1996; 11:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/46\">",
"      Cohen J, Garrisi GJ, Congedo-Ferrara TA, et al. Cryopreservation of single human spermatozoa. Hum Reprod 1997; 12:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/47\">",
"      De Croo I, Van der Elst J, Everaert K, et al. Fertilization, pregnancy and embryo implantation rates after ICSI in cases of obstructive and non-obstructive azoospermia. Hum Reprod 2000; 15:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/48\">",
"      Vernaeve V, Tournaye H, Osmanagaoglu K, et al. Intracytoplasmic sperm injection with testicular spermatozoa is less successful in men with nonobstructive azoospermia than in men with obstructive azoospermia. Fertil Steril 2003; 79:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/49\">",
"      Serkiz IaI, Kovtun TV, Riabova EZ, Chebotarev EE. [Chemoluminescence of the blood plasma alpha-and beta-lipoproteins in rats irradiated with fast neutrons]. Radiobiologiia 1977; 17:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/50\">",
"      McVicar CM, O'Neill DA, McClure N, et al. Effects of vasectomy on spermatogenesis and fertility outcome after testicular sperm extraction combined with ICSI. Hum Reprod 2005; 20:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/51\">",
"      Abdelmassih V, Balmaceda JP, Tesarik J, et al. Relationship between time period after vasectomy and the reproductive capacity of sperm obtained by epididymal aspiration. Hum Reprod 2002; 17:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/52\">",
"      Borges J&uacute;nior E, Rossi-Ferragut LM, Pasqualotto FF, et al. Different intervals between vasectomy and sperm retrieval interfere in the reproductive capacity from vasectomized men. J Assist Reprod Genet 2003; 20:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/53\">",
"      Sakkas, AD, Manicardi, G, Bizarro, D, Bianchi, PG. Possible consequences of performing ICSI with sperm possessing nuclear DNA damage. Hum Fertil 2000; 26:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/54\">",
"      Nagy ZP, Liu J, Joris H, et al. The result of intracytoplasmic sperm injection is not related to any of the three basic sperm parameters. Hum Reprod 1995; 10:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/55\">",
"      Liu J, Nagy Z, Joris H, et al. Analysis of 76 total fertilization failure cycles out of 2732 intracytoplasmic sperm injection cycles. Hum Reprod 1995; 10:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/56\">",
"      Sherins RJ, Thorsell LP, Dorfmann A, et al. Intracytoplasmic sperm injection facilitates fertilization even in the most severe forms of male infertility: pregnancy outcome correlates with maternal age and number of eggs available. Fertil Steril 1995; 64:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/57\">",
"      Nagy ZP, Verheyen G, Tournaye H, Van Steirteghem AC. Special applications of intracytoplasmic sperm injection: the influence of sperm count, motility, morphology, source and sperm antibody on the outcome of ICSI. Hum Reprod 1998; 13 Suppl 1:143.",
"     </a>",
"    </li>",
"    <li>",
"     Sathananthan, AH. The paternal centrosome: its role in human embryonic development and infertility (a recent discovery), in Current Issues in Obstetrics and Gynaecology, Arulkumaran S and Ng SC, Eds, Oxford University Press, Singapore 1996. p.101.",
"    </li>",
"    <li>",
"     Sathananthan, AH, Trounson, A. Ultrastructure of ICSI. In: Handbook of in vitro Fertilization, 2nd ed, Trounson, AO, Gardner, DK, (Eds), CRC Press 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/60\">",
"      Ord T, Patrizio P, Marello E, et al. Mini-Percoll: a new method of semen preparation for IVF in severe male factor infertility. Hum Reprod 1990; 5:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/61\">",
"      Tournaye H, Janssens R, Verheyen G, et al. In vitro fertilization in couples with previous fertilization failure using sperm incubated with pentoxifylline and 2-deoxyadenosine. Fertil Steril 1994; 62:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/62\">",
"      Liu J, Tsai YL, Katz E, et al. High fertilization rate obtained after intracytoplasmic sperm injection with 100% nonmotile spermatozoa selected by using a simple modified hypo-osmotic swelling test. Fertil Steril 1997; 68:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/63\">",
"      El-Nour AM, Al Mayman HA, Jaroudi KA, Coskun S. Effects of the hypo-osmotic swelling test on the outcome of intracytoplasmic sperm injection for patients with only nonmotile spermatozoa available for injection: a prospective randomized trial. Fertil Steril 2001; 75:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/64\">",
"      Morris ID, Ilott S, Dixon L, Brison DR. The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development. Hum Reprod 2002; 17:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/65\">",
"      Sakkas D, Manicardi GC, Tomlinson M, et al. The use of two density gradient centrifugation techniques and the swim-up method to separate spermatozoa with chromatin and nuclear DNA anomalies. Hum Reprod 2000; 15:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/66\">",
"      Muriel L, Garrido N, Fern&aacute;ndez JL, et al. Value of the sperm deoxyribonucleic acid fragmentation level, as measured by the sperm chromatin dispersion test, in the outcome of in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2006; 85:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/67\">",
"      Bartoov B, Berkovitz A, Eltes F. Selection of spermatozoa with normal nuclei to improve the pregnancy rate with intracytoplasmic sperm injection. N Engl J Med 2001; 345:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/68\">",
"      Nicopoullos JD, Gilling-Smith C, Almeida PA, et al. The role of sperm aneuploidy as a predictor of the success of intracytoplasmic sperm injection? Hum Reprod 2008; 23:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/69\">",
"      Jakab A, Sakkas D, Delpiano E, et al. Intracytoplasmic sperm injection: a novel selection method for sperm with normal frequency of chromosomal aneuploidies. Fertil Steril 2005; 84:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/70\">",
"      Katz E, Watts LD, Wright KE, et al. Effect of incremental time experience on the results of in vitro fertilization with intracytoplasmic sperm injection (ICSI). J Assist Reprod Genet 1996; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/71\">",
"      Wang WH, Meng L, Hackett RJ, et al. Limited recovery of meiotic spindles in living human oocytes after cooling-rewarming observed using polarized light microscopy. Hum Reprod 2001; 16:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/72\">",
"      Wang WH, Meng L, Hackett RJ, et al. The spindle observation and its relationship with fertilization after intracytoplasmic sperm injection in living human oocytes. Fertil Steril 2001; 75:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/73\">",
"      Wang WH, Meng L, Hackett RJ, et al. Rigorous thermal control during intracytoplasmic sperm injection stabilizes the meiotic spindle and improves fertilization and pregnancy rates. Fertil Steril 2002; 77:1274.",
"     </a>",
"    </li>",
"    <li>",
"     Malter, HE. Tools and techniques for embryological manipulation. In: Micromanipulation of Human Gametes and Embryos, Cohen, J, Malter, HE, Talansky, BE, et al (Eds), Raven Press, New York 1992. p.250.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/75\">",
"      Schiewe MC. An effective, simplified, and practical approach to intracytoplasmic sperm injection at multiple IVF centers. J Assist Reprod Genet 1996; 13:238.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, CA, Boldt, J. Assisted Reproduction: Laboratory Consideration. In: Infertility and Reproductive Medicine Clinics of North America, Vol 9, Diamond, MP, DeCherney, AH (Eds), 1998. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/77\">",
"      Oehninger S, Veeck L, Lanzendorf S, et al. Intracytoplasmic sperm injection: achievement of high pregnancy rates in couples with severe male factor infertility is dependent primarily upon female and not male factors. Fertil Steril 1995; 64:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/78\">",
"      Devroey P, Godoy H, Smitz J, et al. Female age predicts embryonic implantation after ICSI: a case-controlled study. Hum Reprod 1996; 11:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/79\">",
"      Alikani M, Palermo G, Adler A, et al. Intracytoplasmic sperm injection in dysmorphic human oocytes. Zygote 1995; 3:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/80\">",
"      Greenblatt EM, Meriano JS, Casper RF. Type of stimulation protocol affects oocyte maturity, fertilization rate, and cleavage rate after intracytoplasmic sperm injection. Fertil Steril 1995; 64:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/81\">",
"      Palermo GD, Alikani M, Bertoli M, et al. Oolemma characteristics in relation to survival and fertilization patterns of oocytes treated by intracytoplasmic sperm injection. Hum Reprod 1996; 11:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/82\">",
"      Graham CF. Parthenogenetic mouse blastocysts. Nature 1970; 226:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/83\">",
"      Palermo G, Joris H, Derde MP, et al. Sperm characteristics and outcome of human assisted fertilization by subzonal insemination and intracytoplasmic sperm injection. Fertil Steril 1993; 59:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/84\">",
"      Blake M, Garrisi J, Tomkin G, Cohen J. Sperm deposition site during ICSI affects fertilization and development. Fertil Steril 2000; 73:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/85\">",
"      Nagy ZP, Liu J, Joris H, et al. The influence of the site of sperm deposition and mode of oolemma breakage at intracytoplasmic sperm injection on fertilization and embryo development rates. Hum Reprod 1995; 10:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/86\">",
"      Tesarik J, Sousa M. Key elements of a highly efficient intracytoplasmic sperm injection technique: Ca2+ fluxes and oocyte cytoplasmic dislocation. Fertil Steril 1995; 64:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/87\">",
"      Dumoulin JM, Coonen E, Bras M, et al. Embryo development and chromosomal anomalies after ICSI: effect of the injection procedure. Hum Reprod 2001; 16:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/88\">",
"      Demirol A, Benkhalifa M, Sari T, Gurgan T. Use of laser-assisted intracytoplasmic sperm injection (ICSI) in patients with a history of poor ICSI outcome and limited metaphase II oocytes. Fertil Steril 2006; 86:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/89\">",
"      Huang H, Mills JK, Lu C, Sun D. A universal piezo-driven ultrasonic cell microinjection system. Biomed Microdevices 2011; 13:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/90\">",
"      Dozortsev D, De Sutter P, Dhont M. Behaviour of spermatozoa in human oocytes displaying no or one pronucleus after intracytoplasmic sperm injection. Hum Reprod 1994; 9:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/91\">",
"      Schmiady H, Tandler-Schneider A, Kentenich H. Premature chromosome condensation of the sperm nucleus after intracytoplasmic sperm injection. Hum Reprod 1996; 11:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/92\">",
"      Rienzi L, Ubaldi F, Anniballo R, et al. Preincubation of human oocytes may improve fertilization and embryo quality after intracytoplasmic sperm injection. Hum Reprod 1998; 13:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/93\">",
"      Ebner T, Moser M, Sommergruber M, et al. Complete oocyte activation failure after ICSI can be overcome by a modified injection technique. Hum Reprod 2004; 19:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/94\">",
"      Heindryckx B, Van der Elst J, De Sutter P, Dhont M. Treatment option for sperm- or oocyte-related fertilization failure: assisted oocyte activation following diagnostic heterologous ICSI. Hum Reprod 2005; 20:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/95\">",
"      Swain JE, Pool TB. ART failure: oocyte contributions to unsuccessful fertilization. Hum Reprod Update 2008; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/96\">",
"      Liu J, Nagy Z, Joris H, et al. Successful fertilization and establishment of pregnancies after intracytoplasmic sperm injection in patients with globozoospermia. Hum Reprod 1995; 10:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/97\">",
"      Nagy ZP, Liu J, Joris H, et al. Time-course of oocyte activation, pronucleus formation and cleavage in human oocytes fertilized by intracytoplasmic sperm injection. Hum Reprod 1994; 9:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/98\">",
"      Nagy ZP, Janssenswillen C, Janssens R, et al. Timing of oocyte activation, pronucleus formation and cleavage in humans after intracytoplasmic sperm injection (ICSI) with testicular spermatozoa and after ICSI or in-vitro fertilization on sibling oocytes with ejaculated spermatozoa. Hum Reprod 1998; 13:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/99\">",
"      Palermo G, Munn&eacute; S, Cohen J. The human zygote inherits its mitotic potential from the male gamete. Hum Reprod 1994; 9:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/100\">",
"      Flaherty SP, Payne D, Swann NJ, Mattews CD. Aetiology of failed and abnormal fertilization after intracytoplasmic sperm injection. Hum Reprod 1995; 10:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/101\">",
"      Sultan KM, Munn&eacute; S, Palermo GD, et al. Chromosomal status of uni-pronuclear human zygotes following in-vitro fertilization and intracytoplasmic sperm injection. Hum Reprod 1995; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/102\">",
"      Oehninger S, Kruger TF, Simon T, et al. A comparative analysis of embryo implantation potential in patients with severe teratozoospermia undergoing in-vitro fertilization with a high insemination concentration or intracytoplasmic sperm injection. Hum Reprod 1996; 11:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/103\">",
"      Yang D, Shahata MA, al-Bader M, et al. Intracytoplasmic sperm injection improving embryo quality: comparison of the sibling oocytes of non-male-factor couples. J Assist Reprod Genet 1996; 13:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/104\">",
"      Griffiths TA, Murdoch AP, Herbert M. Embryonic development in vitro is compromised by the ICSI procedure. Hum Reprod 2000; 15:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/105\">",
"      Shoukir Y, Chardonnens D, Campana A, Sakkas D. Blastocyst development from supernumerary embryos after intracytoplasmic sperm injection: a paternal influence? Hum Reprod 1998; 13:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/106\">",
"      Dumoulin JC, Coonen E, Bras M, et al. Comparison of in-vitro development of embryos originating from either conventional in-vitro fertilization or intracytoplasmic sperm injection. Hum Reprod 2000; 15:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/107\">",
"      Janny L, Menezo YJ. Evidence for a strong paternal effect on human preimplantation embryo development and blastocyst formation. Mol Reprod Dev 1994; 38:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/108\">",
"      Jones GM, Trounson AO, Lolatgis N, Wood C. Factors affecting the success of human blastocyst development and pregnancy following in vitro fertilization and embryo transfer. Fertil Steril 1998; 70:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/109\">",
"      Miller JE, Smith TT. The effect of intracytoplasmic sperm injection and semen parameters on blastocyst development in vitro. Hum Reprod 2001; 16:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/110\">",
"      Schoolcraft WB, Gardner DK, Lane M, et al. Blastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization programs. Fertil Steril 1999; 72:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/111\">",
"      Cohen J, Simons RS, Fehilly CB, Edwards RG. Factors affecting survival and implantation of cryopreserved human embryos. J In Vitro Fert Embryo Transf 1986; 3:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/112\">",
"      Schnorr J, Brown S, Oehninger S, et al. Impact of intracytoplasmic sperm injection on embryo cryopreservation and clinical outcome. Fertil Steril 2001; 75:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/113\">",
"      Macas E, Imthurn B, Borsos M, et al. Impairment of the developmental potential of frozen-thawed human zygotes obtained after intracytoplasmic sperm injection. Fertil Steril 1998; 69:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/114\">",
"      Van Steirteghem AC, Van der Elst J, Van den Abbeel E, et al. Cryopreservation of supernumerary multicellular human embryos obtained after intracytoplasmic sperm injection. Fertil Steril 1994; 62:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/115\">",
"      Damario MA, Hammitt DG, Galanits TM, et al. Pronuclear stage cryopreservation after intracytoplasmic sperm injection and conventional IVF: implications for timing of the freeze. Fertil Steril 1999; 72:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/116\">",
"      Kowalik A, Palermo GD, Barmat L, et al. Comparison of clinical outcome after cryopreservation of embryos obtained from intracytoplasmic sperm injection and in-vitro fertilization. Hum Reprod 1998; 13:2848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/117\">",
"      Belva F, Henriet S, Van den Abbeel E, et al. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod 2008; 23:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/118\">",
"      de C&aacute;ssia Savio Figueira R, Madaschi C, Nichi M, et al. A comparison of post-thaw results between embryos arising from intracytoplasmic sperm injection using surgically retrieved or ejaculated spermatozoa. Fertil Steril 2009; 91:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/119\">",
"      Bonduelle M, Van Assche E, Joris H, et al. Prenatal testing in ICSI pregnancies: incidence of chromosomal anomalies in 1586 karyotypes and relation to sperm parameters. Hum Reprod 2002; 17:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/120\">",
"      Bonduelle M, Wennerholm UB, Loft A, et al. A multi-centre cohort study of the physical health of 5-year-old children conceived after intracytoplasmic sperm injection, in vitro fertilization and natural conception. Hum Reprod 2005; 20:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/121\">",
"      Society for Assisted Reproductive Technology, American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry. Fertil Steril 2007; 87:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/122\">",
"      Bonduelle M, Legein J, Buysse A, et al. Prospective follow-up study of 423 children born after intracytoplasmic sperm injection. Hum Reprod 1996; 11:1558.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov. (accessed April 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/124\">",
"      Abusheikha N, Salha O, Sharma V, et al. Monozygotic twinning and IVF/ICSI treatment: a report of 11 cases and review of literature. Hum Reprod Update 2000; 6:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/125\">",
"      Tarlatzis BC, Qublan HS, Sanopoulou T, et al. Increase in the monozygotic twinning rate after intracytoplasmic sperm injection and blastocyst stage embryo transfer. Fertil Steril 2002; 77:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/126\">",
"      Skiadas CC, Missmer SA, Benson CB, et al. Risk factors associated with pregnancies containing a monochorionic pair following assisted reproductive technologies. Hum Reprod 2008; 23:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/127\">",
"      Yoon G, Beischel LS, Johnson JP, Jones MC. Dizygotic twin pregnancy conceived with assisted reproductive technology associated with chromosomal anomaly, imprinting disorder, and monochorionic placentation. J Pediatr 2005; 146:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/128\">",
"      Souter VL, Kapur RP, Nyholt DR, et al. A report of dizygous monochorionic twins. N Engl J Med 2003; 349:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/129\">",
"      Belva F, Henriet S, Liebaers I, et al. Medical outcome of 8-year-old singleton ICSI children (born &gt;or=32 weeks' gestation) and a spontaneously conceived comparison group. Hum Reprod 2007; 22:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/130\">",
"      Leunens L, Celestin-Westreich S, Bonduelle M, et al. Follow-up of cognitive and motor development of 10-year-old singleton children born after ICSI compared with spontaneously conceived children. Hum Reprod 2008; 23:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/131\">",
"      Ludwig AK, Katalinic A, Thyen U, et al. Physical health at 5.5 years of age of term-born singletons after intracytoplasmic sperm injection: results of a prospective, controlled, single-blinded study. Fertil Steril 2009; 91:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/132\">",
"      Ludwig A, Katalinic A, Thyen U, et al. Neuromotor development and mental health at 5.5 years of age of singletons born at term after intracytoplasmatic sperm injection ICSI: results of a prospective controlled single-blinded study in Germany. Fertil Steril 2009; 91:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/133\">",
"      Katalinic A, R&ouml;sch C, Ludwig M, German ICSI Follow-Up Study Group. Pregnancy course and outcome after intracytoplasmic sperm injection: a controlled, prospective cohort study. Fertil Steril 2004; 81:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/134\">",
"      Fedder J, Loft A, Parner ET, et al. Neonatal outcome and congenital malformations in children born after ICSI with testicular or epididymal sperm: a controlled national cohort study. Hum Reprod 2013; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/135\">",
"      Practice Committee of American Society for Reproductive Medicine, Practice Committee of Society for Assisted Reproductive Technology. Genetic considerations related to intracytoplasmic sperm injection (ICSI). Fertil Steril 2008; 90:S182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/136\">",
"      Gosden R, Trasler J, Lucifero D, Faddy M. Rare congenital disorders, imprinted genes, and assisted reproductive technology. Lancet 2003; 361:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/137\">",
"      Nikolettos N, Asimakopoulos B, Papastefanou IS. Intracytoplasmic sperm injection--an assisted reproduction technique that should make us cautious about imprinting deregulation. J Soc Gynecol Investig 2006; 13:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/138\">",
"      &Oslash;rstavik KH, Eiklid K, van der Hagen CB, et al. Another case of imprinting defect in a girl with Angelman syndrome who was conceived by intracytoplasmic semen injection. Am J Hum Genet 2003; 72:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/139\">",
"      Cox GF, B&uuml;rger J, Lip V, et al. Intracytoplasmic sperm injection may increase the risk of imprinting defects. Am J Hum Genet 2002; 71:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/140\">",
"      Chang PL, Sauer MV, Brown S. Y chromosome microdeletion in a father and his four infertile sons. Hum Reprod 1999; 14:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/141\">",
"      Wennerholm UB, Bergh C, Hamberger L, et al. Incidence of congenital malformations in children born after ICSI. Hum Reprod 2000; 15:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/142\">",
"      ACOG Committee on Obstetric Practice, ACOG Committee on Gynecologic Practice, ACOG Committee on Genetics. ACOG Committee Opinion #324: Perinatal risks associated with assisted reproductive technology. Obstet Gynecol 2005; 106:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/143\">",
"      Gekas J, Thepot F, Turleau C, et al. Chromosomal factors of infertility in candidate couples for ICSI: an equal risk of constitutional aberrations in women and men. Hum Reprod 2001; 16:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/144\">",
"      Foresta C, Garolla A, Bartoloni L, et al. Genetic abnormalities among severely oligospermic men who are candidates for intracytoplasmic sperm injection. J Clin Endocrinol Metab 2005; 90:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/145\">",
"      Woldringh GH, Janssen IM, Hehir-Kwa JY, et al. Constitutional DNA copy number changes in ICSI children. Hum Reprod 2009; 24:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/146\">",
"      Martin RH. Cytogenetic determinants of male fertility. Hum Reprod Update 2008; 14:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/147\">",
"      Ohashi Y, Miharu N, Honda H, et al. High frequency of XY disomy in spermatozoa of severe oligozoospermic men. Hum Reprod 2001; 16:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/148\">",
"      Pang MG, Kim YJ, Lee SH, Kim CK. The high incidence of meiotic errors increases with decreased sperm count in severe male factor infertilities. Hum Reprod 2005; 20:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/149\">",
"      Bonduelle M, Liebaers I, Deketelaere V, et al. Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999). Hum Reprod 2002; 17:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/11/15546/abstract/150\">",
"      Belva F, De Schrijver F, Tournaye H, et al. Neonatal outcome of 724 children born after ICSI using non-ejaculated sperm. Hum Reprod 2011; 26:1752.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3261 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15546=[""].join("\n");
var outline_f15_11_15546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4279802\">",
"      ICSI versus standard IVF for treatment of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87588284\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPERM RETRIEVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPERMATOZOA SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sperm DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Zona pellucida binding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Microscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Oocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FERTILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pronucleus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EMBRYO QUALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CRYOPRESERVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258813\">",
"      PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREGNANCY AND PEDIATRIC OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pregnancy and delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pregnancy rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10309766\">",
"      - Monochorionic twins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1771738384\">",
"      - Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pediatric issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Overall outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H258644\">",
"      - Imprinting disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Chromosomal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1771738481\">",
"      - Sex ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39865?source=related_link\">",
"      Use of assisted reproduction in HIV and hepatitis infected couples",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_11_15547="Granulomatous liver dz causes";
var content_f15_11_15547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Miscellaneous causes of granulomatous liver disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Primary biliary cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Hodgkin's lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berylliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipogranulomas (from ingestion of mineral oil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Talc or other particulate matter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After jejunoileal bypass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhalation of copper sulfate (vineyard workers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ingestion of \"Green juice\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravesical administration of bacillus Calmette-Guerin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15547=[""].join("\n");
var outline_f15_11_15547=null;
var title_f15_11_15548="ACC AHA ETT risk assess CHD";
var content_f15_11_15548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Exercise testing for risk assessment and prognosis in patients with an intermediate or high probability of coronary heart disease (CHD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that exercise testing for risk assessment and prognosis in patients at intermediate or high probability of CHD is indicated in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; As part of the initial evaluation in the absence of the exceptions listed in class IIb and class III.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; After a significant change in cardiac symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The usefulness or efficacy is less well established for exercise testing for risk assessment and prognosis in patients at intermediate or high probability of CHD in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; The following ECG abnormalities:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Preexcitation (Wolff-Parkinson-White) syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Electronically paced ventricular rhythm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. More than 1 mm of ST depression at rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Complete left bundle branch block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; After cardiac catheterization to identify ischemia in the distribution of a coronary lesion of borderline severity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; After revascularization in patients with a significant change in anginal pattern that is suggestive of ischemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that exercise testing for risk assessment and prognosis in patients at intermediate or high probability of CHD is not useful in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; In the presence of severe comorbidity that is likely to limit life expectancy or prevent revascularization.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons, RJ, Abrams, J, Chatterjee, K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15548=[""].join("\n");
var outline_f15_11_15548=null;
var title_f15_11_15549="Clinical and laboratory findings in pemphigus";
var content_f15_11_15549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key clinical and laboratory findings in pemphigus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Autoantigens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histopathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Direct immunofluorescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indirect immunofluorescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        ELISA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Variants",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Pemphigus vulgaris",
"        </strong>",
"       </td>",
"       <td>",
"        Primarily middle-aged adults",
"       </td>",
"       <td>",
"        Desmoglein 1 and desmoglein 3, others",
"       </td>",
"       <td>",
"        Mucosal erosions; flaccid bullae and erosions on skin",
"       </td>",
"       <td>",
"        Suprabasal acantholysis; \"row of tombstones\" pattern of basal keratinocytes",
"       </td>",
"       <td>",
"        Intercellular deposition of IgG",
"       </td>",
"       <td>",
"        Intercellular deposition of IgG; monkey esophagus is preferred substrate",
"       </td>",
"       <td>",
"        Desmoglein 3 or both desmoglein 1 and desmoglein 3 autoantibodies",
"       </td>",
"       <td>",
"        Pemphigus vegetans and pemphigus herpetiformis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Pemphigus foliaceus",
"        </strong>",
"       </td>",
"       <td>",
"        Primarily middle-aged adults; endemic form most common in children and young adults",
"       </td>",
"       <td>",
"        Desmoglein 1",
"       </td>",
"       <td>",
"        Fragile blisters, shallow erosions, erythematous patches, crusts; mucosal involvement absent",
"       </td>",
"       <td>",
"        Subcorneal or granular layer acantholysis",
"       </td>",
"       <td>",
"        Intercellular deposition of IgG",
"       </td>",
"       <td>",
"        Intercellular deposition of IgG; normal human skin or monkey esophagus is preferred substrate",
"       </td>",
"       <td>",
"        Desmoglein 1 autoantibodies",
"       </td>",
"       <td>",
"        Endemic pemphigus foliaceus (fogo sevalgem), pemphigus erythematosus, and pemphigus herpetiformis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Paraneoplastic pemphigus",
"        </strong>",
"       </td>",
"       <td>",
"        Primarily adults, but may occur at any age",
"       </td>",
"       <td>",
"        Envoplakin, periplakin, others",
"       </td>",
"       <td>",
"        Severe stomatitis, variable cutaneous findings (eg, blisters, erosions, lichenoid lesions), bronchiolitis obliterans",
"       </td>",
"       <td>",
"        Variable findings; suprabasal acantholysis, keratinocyte necrosis, and lichenoid interface dermatitis are most common",
"       </td>",
"       <td>",
"        Intercellular and/or basement membrane zone deposition of IgG and/or C3",
"       </td>",
"       <td>",
"        Intercellular deposition of IgG; rat bladder is preferred substrate",
"       </td>",
"       <td>",
"        Envoplakin and periplakin autoantibodies",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        IgA pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subcorneal pustular dermatosis-type IgA pemphigus",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Desmocollin 1",
"       </td>",
"       <td>",
"        Vesicles, pustules, crusts on skin; annular, circinate, or herpetiform morphology; mucosal involvement usually absent",
"       </td>",
"       <td>",
"        Subcorneal clefts and pustules; minimal acantholysis; mixed infiltrate in dermis",
"       </td>",
"       <td>",
"        Intercellular deposition of IgA",
"       </td>",
"       <td>",
"        Intercellular deposits of IgA on monkey esophagus*",
"       </td>",
"       <td>",
"        Desmocollin 1 autoantibodies",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraepidermal neutrophilic dermatosis",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Poorly defined",
"       </td>",
"       <td>",
"        Vesicles, pustules, crusts on skin; annular, circinate, or herpetiform morphology; mucosal involvement usually absent",
"       </td>",
"       <td>",
"        Intraepidermal pustules; minimal acantholysis; mixed infiltrate in dermis",
"       </td>",
"       <td>",
"        Intercellular deposition of IgA",
"       </td>",
"       <td>",
"        Intercellular deposits of IgA on monkey esophagus*",
"       </td>",
"       <td>",
"        Desmoglein 1 and 3 autoantibodies have been reported in some patients",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Indirect immunofluorescence is negative in around 50 percent of patients with IgA pemphigus.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Test availability restricted to specialized laboratories.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15549=[""].join("\n");
var outline_f15_11_15549=null;
var title_f15_11_15550="Abx for infect conjunctivitis";
var content_f15_11_15550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Effect of antibiotics on cure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the rates of cure in children with acute infectious conjunctivitis treated with chloramphenicol eye drops or placebo drops. Data are reported on intention-to-treat analysis and children lost to follow-up are included in the denominator in calculating percentages. Children clinically cured after 7 days were censored from the study. With exclusion of children lost to follow-up, the cumulative cure rate at 7 days was 86 percent in the chloramphenicol group and 83 percent in the placebo group. Day zero is the day of recruitment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rose, P, Harnden, A, Brueggemann, A, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomized double-blind placebo-controlled trial. Lancet 2005; 366:41. Copyright &copy; Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15550=[""].join("\n");
var outline_f15_11_15550=null;
var title_f15_11_15551="Carpometacarpal compression";
var content_f15_11_15551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Compression of the carpometacarpal (CMC) joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is placed in a neutral position with the radial side up. The examiner grasps the base of the thumb just beyond the anatomical snuff box. The synovial lining and the base of the metacarpal are squeezed together using the thumb and finger. The compression can be enhanced by circumducting the thumb while continually holding pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_11_15551=[""].join("\n");
var outline_f15_11_15551=null;
